Feasibility studies for development of specific re-loadable binding sites for drug delivery systems immobilized onto implant surfaces by Al-Dubai, Haifa
 1 
 
 
 
DISSERTATION 
Feasibility Studies for Development  
of Specific Re-loadable Binding Sites for Drug 
Delivery Systems Immobilized onto Implant Surfaces  
Verfasserin  
Mag. Haifa Al-Dubai 
angestrebter akademischer Grad 
Doktor/in der Naturwissenschaften (Dr. rer.nat.) 
Wien, 2010  
Studienkennzahl: A 091 441 
Dissertationsgebiet: Genetik - Mikrobiologie 
Betreuer: Univ.Prof. Dr. Fritz Pittner 
 
 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     All art is 
autobiographical, 
the pearl is the 
oyster’s 
autobiograpy 
 
Federico Fellini 
 
 3 
 
 
 
 
 
 
 
 
 
 
 
 
I dedicate this work to people who through their presence 
gave me strength and hope during the ups and downs of 
this work 
Kamal, Roua, Raniem 
Gisi & Fritz  
 
 
 
 
 
 
 
 
 
 
 
 
 4 
Acknowledgments 
I wish to thank everyone who has in one way or another, helped 
me through life. In particular I wish to thank the following 
people: 
 
Firstly wish to express my best appreciation to my husband Dr. 
Kamal Al-Abdi who has always been at my side and whose love 
and support knows no limits 
 
I also wish to thank my parents, and siblings who provided me 
with a wonderful family and good education.  
 
I am grateful to my daughters, Roua and Raniem, who have been 
extremely sympathetic and helpful while I was working towards 
completion of my PhD.  
 
My special thanks and admiration goes to Prof. Fritz Pittner, my 
supervisor and admirable teacher who tought me the patience 
and passion for science and life. 
His patience and help encouraged us to face the challenges of 
experimental science. I will always remember him saying: 
“Nothing is perfect, even the sun has spots”. 
 
I wish to thank Mag. Gisela Pittner who, lovingly supported me in 
every step of this work with her problem solving and creative mind   
 
I wish to thank Prof. Franz Gabor (Department of Pharmaceutical 
Technology and Biopharmaceutics, Faculty of Life Sciences, 
University of Vienna, Austria), who with his generous support 
enabled me to continue my work when it seemed impossible. 
 5 
 
My warm appreciation goes to my colleagues and collaborators  
Martina Strobl, Helmut Hinterwirth and Georg Oberhofer for their 
friendly team work. Alma, Irene, Verena, Natascha, Nadira, 
Margit, Mirza, Ulrich  and many more for their company and 
creating a pleasurable atmosphere in the lab.  
 
Prof. Irene Lichtscheidl (Institute of Cell Imaging and 
Ultrastructure Research, Vienna, Austria) for helpful advice and 
giving me the chance to do microscopy in her lab. 
 
Prof. Marcela Hermann (Medical university of Wien, Max F. Perutz 
Laboratories, Department for medical Biochemistry) for 
invaluable help with immunization experiments  
 
Dr. Francisco M. Goycoolea in Valencia (University Santiago de 
Compostela, Spain) who provided us with precise protocols on 
preparation of Chitosan nanoparticles  
 
Dr. Albert Missbichler for his financial support for immunization 
experiments  
 
I also wish to thank my best friend Dr. Pantea Lotfian and her 
husband Dr. Bernhard Strauss for their support and 
encouragement throughout this work.  
Contents 
 6 
Abbreviations .............................................................................................................. 8 
Abstract .....................................................................................................................13 
Zusammenfassung ....................................................................................................15 
Introduction ................................................................................................................18 
1 Background ........................................................................................................18 
1.1 Re-stenosis after coronary stent implantation ............................................ 18 
1.1.1 Neointimal hyperplasia ........................................................................ 19 
1.1.2 Drug eluting stents (DES) ................................................................... 20 
1.1.3 Long coronary lesions ......................................................................... 20 
1.1.4 Saphenous vein graft stenting ............................................................. 21 
1.1.5 Current limitations of drug loading ....................................................... 22 
2 Our approach: Design of reloadable implant materials in this study ...................22 
3 Specific aims ......................................................................................................24 
3.1 Specific aim 1 ............................................................................................. 25 
3.1.1 Passive coating ................................................................................... 25 
3.2 Specific aim 2 ............................................................................................. 27 
3.2.1 Bio-recognitive system for drug delivery system ................................. 27 
3.3 Specific aim 3 ............................................................................................. 28 
3.3.1 Drug-delivery and targeting-systems ................................................... 28 
3.3.2 Controlled drug release ....................................................................... 30 
3.3.2.1 Biodegradable PLGA-based nanoparticles .................................. 31 
3.3.2.2 Chitosan nanoparticles................................................................. 32 
3.4 Specific aim 4 ............................................................................................. 34 
3.4.1 Active coating ...................................................................................... 34 
4 Applications of the novel implant material developed in this study .....................35 
4.1 Reloadable drug delivery implant systems ................................................. 35 
4.2 PLGA antibodies in clinical and research imaging...................................... 37 
Part 1 .........................................................................................................................50 
Covalent binding of a biocompatible coating and development of analytical tests for 
proof of a successful set-up .......................................................................................50 
Chapter 1 .............................................................................................................. 50 
1. Analytical methods for detection of small amounts of aminogroups on solid 
surfaces – a survey ........................................................................................... 52 
2. Biocompatible coating of implant materials ................................................... 73 
Contents 
 7 
Chapter 2 .............................................................................................................. 79 
Cleaving of antibody using dihydrolipoamide and anchoring of antibody fragment 
onto biocompatible coated carrier ..................................................................... 81 
Part 2 .........................................................................................................................99 
Development of new analytical tools for demonstration of protein binding to solid 
surfaces and binding of PLGA-nanoparticles to the receptor on the implant surface 99 
Chapter 3 ............................................................................................................ 100 
A dot-blot test using gold colloid cluster technology as a miniaturizable 
alternative to ELISA and hapten inhibition tests .............................................. 100 
Chapter 4 ............................................................................................................ 113 
Immunosorbent assay using gold colloid cluster technology for determination of 
IgEs in patient sera .......................................................................................... 115 
Part 3: ......................................................................................................................133 
Proof of binding of nanoparticles serving as drug carriers to receptors onto the 
biocompatible-coated implant surfaces and long term test showing degradation of 
nanoparticles and reloadability ............................................................................ 133 
Chapter 5 ......................................................................................................... 134 
CLISA as a tool for detection of successful immunization of rabbit‟s in order to 
produce PLGA Abs and testing binding of PLGA NPs to the coated implant 
surface for reloadability studies. ...................................................................... 134 
Chapter 6 ............................................................................................................ 165 
Production of polyclonal antibodies against the biocompatible polymer PLGA 
using silica amino microspheres as a carrier ................................................... 167 
Chapter 7 ............................................................................................................ 186 
Development of biocompatible carrier coating with binding Sites for 
biodegradable drug delivery system allowing reloadability .............................. 188 
Summary and further work ......................................................................................207 
Appendix..................................................................................................................212 
Curriculum Vitae ......................................................................................................239 
 
 
Abbreviation 
 
 8 
Abbreviations 
 
Ab  Antibody 
ABS Absorbance 
Ag  Antigen 
AP Alkaline phosphatase 
APS Ammonium peroxodisulphate 
APTS  3-Aminopropyltriethoxysilane 
AU  Absorbance units 
BBB Blood brain barrier 
ß-LG Beta-lactoglobulin 
ßME 2-Mercaptoethanol 
ß-MEA 2-Mercaptaethanol amine 
BMS Bare metal stent 
BODIPY 
493/503 
(4,4-Difluoro-1,3,5,7,8-pentamethyl-  
 4-boro-3a,4a-diaza-s-indacene) 
BrdU 5-bromo-2-desoxyuridine 
BSA    Bovine serum albumin 
CaCo2 Human epithelial colorectal adeno carcinoma 
CBB-R250 Coomassine Billant-Blue-R250 
CH2Cl2 Dichloromethane 
CLISA Cluster-Linked Immunosorbent Assay 
c-m-PEG Carboxy-methoxy-polyethylene glycol 
CS  Chitosan 
CS-Ab Mouse monoclonal Anti-ß-O-linked N-Acetylglucosamine 
(O-GlcNAc) IgM isotype 
CS-NPs Chitosan-nanoparticles 
CV Coefficient of variation 
dd. H2O Double distilled water 
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DDDs Drug delivery systems 
DESs Drug eluting stents 
DIC  N,N`-Diisopropylcarbodiimide 
DIC Different interference contrast 
DMF   Dimethyformamide 
DMSO Dimethyl sulfoxide 
DSMZ  Deutsche Sammlung von Mikroorganismen und 
Zellkulturen GmbH, Germany 
DTNB 5,5´-Dithio-bis-(2-nitrobenzoic acid) 
ECP  Eosinophil cationic protein 
EDC  (1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide 
hydrochloride 
ELISA Enzyme-linked immunosorbent assay 
EtAc  Ethyl acetate  
FDA  Food and drug administration 
FeCl3 Ferric chloride 
GA Glutaraldehyde 
GCCs Gold colloidal clusters 
GlcN 4-linked D-glucosamine 
GlcNAC 1,4-linked N-acetyl-D-glucosamine 
H2SO4 Sulfuric acid 
HAc    Acetic acid 
HAUCl4 Tetrachloric acid 
HCl Hydrochloric acid 
HDL   High density lipoprotein 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HNO3 Nitric acid 
HRP   Horseradish peroxidase 
HSA   Human serum albumin 
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Ig   Immunoglobulin 
 IaIp Inter-alpha inhibitor protein  
KCN Potassium cyanide 
LDH  Lactat dehydrogenase 
Lipoic acid 6, 8-dithiooctanoic acid 
MACE Major adverse cardiac events 
mc-Ab Monoclonal antibody 
MgCl2 Magnesium chloride 
m-PEG Methoxy-PEG 
MPS Mononuclear phagocytic system 
MRI Magnetic resonance imaging 
MS  Massenspectrometry 
NaN3 Sodium azid 
Na2S2O4 Sodium hydrosulfite 
Na3PO4 Sodium phosphate 
NaCl Sodium chloride 
NaHCO3 Sodium hydrogencarbonate 
NaOAc Sodium acetate 
Na2SO4 Sodium sulfate 
NBT  Nitro blue tetrazolium chloride 
NC  Nitrocellulose 
NH2 -m-PEG Amino-methoxy- polyethylene glycol 
NH2-PEG-NH2 Bis-amino- polyethylene glycol 
NHS  N-hydroxysuccimide ester 
NP(s)   Nanoparticle(s) 
O-GlcNAc O-linked N-Acetylglucosamine 
OPA   o-Phthaldialdehyde 
PAGE Polyacrylamide gel electrophoresis 
Abbreviation 
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PES Paclitaxel-eluting stent 
PB Phosphate Buffer 
PBS Phosphate Buffered Saline 
pc-Ab  polyclonal antibody 
PEG  Polyethylene glycol 
PET Positron emission tomography 
PGI2 Prostacyclin 
pI Isoelectric point 
PLGA  Poly (D,L-lactide-co-glycolide) 
PLI Polydispersity index 
PLL-g-PEG Poly (L-lysine)-g-poly(ethylene glycol) 
p-NPP para- Nitro Phenyl Phosphate 
RG Resomer 
SAM Silica-amino-microspheres 
SDS   Sodium dodecyl sulphate 
SES Sirolimus-eluting stent 
SH-PEG (O-[2-(3-Mercaptopropionylamino)ethyl]-O´-methyl-
polyethyleneglycol 
SOCl2 Thionylchloride 
Sulfo-NHS  Sulfo-N-hydroxysulfosuccinimide 
Sulfo-SDTB Sulfosuccinimidyl-4-o-(4,4-dimethoxytrityl) butyrate 
Sulfo-SMCC Sulfosuccinimidyl 4-(N-maleimido-methyl) -cyclohexane-
1-carboxylate 
SVG Saphenous veingraft 
TBS TRIS buffer saline 
TE  Tris/EDTA buffer 
TEMED 
 
N,N,N´,N´-Tetramethylenediamine 
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 THF Tetrahydrofurane 
TMB   Tetramethylbenzidine 
TNB 5-thio-2-nitrobenzoic acid 
TNBS 2,4,6-Trinitrobenzenesulfonic acid solution  
TNP Trinitrophenol 
TPP Sodium tripolyphosphate   
Tris Tris (hydroxymethyl)aminomethane 
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ZrO2 Zirconia (ceramics) 
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Abstract  
The overall objective of this thesis is to develop novel, bio-compatible coatings 
for medical implant materials with binding sites for bio-degradable nanoparticles that 
may serve as drug carriers. The drugs are released gradually during decomposition 
and after particle degradation the binding sites can be reloaded with new drug 
delivering particles. 
To achieve this goal, we used stainless-steel and zirconia as test implant materials. 
To improve biocompatibility of these materials a so called “passive coating” 
procedure is used where biocompatible polymers such as polyethyleneglycol (PEG) 
act as a barrier. Furthermore a specific receptor system was introduced for binding 
drug containing biodegradable nano- or micro-particles to mediate local 
pharmacological activity, the so called active coating. For this purpose specific 
antibodies or antibody-fragments were generated and coupled to the implant material 
surface as capture molecules for the drug releasing particles. 
Poly (D,L-lactide-co-glycolide) (PLGA) and chitosan were used to produce these 
biodegradable nanoparticles. The particles are then degraded either by hydrolysis or 
by means of enzymes circulating in the bloodstream (mere hydrolysis for PLGA and 
lysozyme for chitosan) while releasing the drugs locally. After complete 
biodegradation the receptor system is then free again for reloading with new particles 
containing the respective drugs, making this a completely new mean of drug 
administration on medical implants. 
Such coatings can be the basis for a number of applications that require controlled, 
local drug delivery at the interface between an implant and healthy tissue. Upon the 
need for medication, drug-loaded nanoparticles can be injected into the bloodstream, 
bind to the particle-specific antibodies on the target implant and gradually release 
their drug content during degradation. As nanoparticles can be loaded with different 
drugs, this technology allows easy adjustment to patient-specific medication needs 
as well as the administration of compounds that are easily degradable or difficult to 
dose.  
Analytical proofs of principle on these materials have proved to be difficult, as the 
currently available optical methods for testing the successful chemical setup could 
not be applied because of quenching effects on metal surfaces and the rough surface 
of zirconia (ceramics). Therefore specific binding of the nanoparticles onto the 
Abstract 
 14 
implant surface was tested on glass substrates, coated similarly as the implant 
materials, by means of fluorescence microscopy. Furthermore for proof of the 
successful chemical setup and biorecognitive binding several new analytical test 
methods had to be developed and evaluated. 
One of the major challenges we had to overcome was to find suitable biorecognitive 
systems for binding of the drug containing particles, as these have to be 
biocompatible too. Special efforts were made to identify and generate specific 
antibodies against biocompatible materials. In case of chitosan, antibodies were 
commercially available, whereas for PLGA a very stringent immunisation protocol 
had to be developed for antibody production in rabbits, in addition to optimization of 
the purification and titer determination protocols.  
Using these tools, we were able to perform specific experiments that demonstrate a 
proof of concept for the possibility to generate a reloadable targeting device for local 
drug release and potential of our approach in targeted drug delivery and release. 
This new system provides the basis for a wide array of applications in regenerative 
medicine such as stents, implants of artificial bones and other artificial tissues, 
requiring local drug action at the interface between an implant and healthy tissue in a 
controlled manner. The delivery system protects the incorporated drugs from 
degradation prior to action e.g. growth factors and immunosuppressives, and 
facilitates the transport of poorly absorbable or insoluble drug candidates to the 
intended site of action. Due to the high local drug concentration, the absorption rate 
of poorly soluble drug molecules will be improved, which would significantly reduce 
undesired, adverse systemic effects. Furthermore after implantation also a change of 
drugs is possible, as with each reloading procedure appropriate drugs according to 
patients needs may be chosen. 
 
Zusammenfassung 
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Zusammenfassung 
Ziel dieser Dissertation war die Entwicklung eines neuartigen biokompatiblen 
Beschichtungssystems für medizinische Implantatmaterialien, die Bindungsstellen für 
bioabbaubare, mit Wirkstoffen beladene Nanopartikel (Drug Carriers) tragen. Diese  
Wirkstoffe werden während des Abbaus der Drug Carriers dort kontrolliert freigesetzt. 
Nach dem Abbau der Partikel sind diese Bindungsstellen wieder frei um mit neuen 
Drug-Carriers beladen zu werden. 
Zum Erreichen dieses Ziels wurden als Testsystem die Implantatmaterialien 
Edelstahl und Zirkon-Keramik verwendet. Zur Verbesserung der Biokompatibilität 
wurde ein sogenanntes Passivcoating mit Polymeren wie z.B. dem medizinisch 
zugelassenen Polyethylenglykol (PEG) aufgebracht, um eine Schutzschicht zu 
bilden. Außerdem wurde ein geeignetes Rezeptorsystem zu verankert, das in der 
Lage ist, biodegradable mit Wirkstoffen beladene Mikro- oder Nanopartikel (Drug 
Carriers)  zu binden, um eine lokale pharmakologische Wirkung zu erzielen (Aktives 
Coating). Zu diesem Zweck wurden spezielle Antikörper bzw. auch Antikörper-
Fragmente als Capture-Moleküle an die Oberfläche des Implantatmaterials 
gebunden.  
Zur Herstellung der Drug Carriers wurden sowohl ein Copolymer aus Milch- und 
Glycolsäure (PLGA) als auch Chitosan verwendet. Die Drug Carriers werden dann 
entweder durch Hydrolyse oder mit Hilfe von Enzymen im Blut (Hydrolyse für PLGA, 
Lysozym für Chitosan) abgebaut und setzten die in ihnen enthaltenen Wirkstoffe 
lokal frei. Nach dem vollständigen Bioabbau liegen die Capture-Moleküle wieder frei 
vor und können mit neuen Drug Carriers beladen werden, womit ein vollkommen 
neuartiges System für Wirkstoffabgabe von medizinischen Implantaten zur 
Verfügung steht. 
Solche Beschichtungen können die Basis für eine Vielzahl von Anwendungen sein, 
die eine gezielte Wirkstoffabgabe an der Grenzfläche zwischen Implantat und 
gesundem Gewebe erfordern. Bei Bedarf können die Drug Carriers in die Blutbahn 
injiziert werden, binden an das Rezeptorsystem auf der Implantatoberfläche und 
setzen im Zuge ihres Abbaus die Wirkstoffe frei. Da sie mit unterschiedlichen 
Wirkstoffen beladen werden können, ermöglichen sie eine patientenspezifische 
Anpassung der Medikation, aber auch die Gabe von Wirkstoffen, die sonst zu rasch 
abbaubar oder schwierig zu dosieren wären.  
Zusammenfassung 
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Der analytische Nachweis des erfolgreichen chemischen Setups mit Hilfe optischer 
Methoden erwies sich als schwierig auf Grund von Quenching Effekten im Fall von 
Metall bzw. wegen der rauen Oberfläche bei Zirkon (Keramik). Daher wurde die 
spezifische Bindung der Nanopartikel an der Implantatoberfläche an Glasoberflächen 
mit gleicher chemischer Beschichtung mit Hilfe von Fluoreszenzmikroskopie getestet. 
Außerdem mussten für den Nachweis des erfolgreichen chemischen Aufbaus und 
der biorecognitiven Bindung verschiedene neue analytische Tests entwickelt und 
evaluiert werden. 
Ein schwieriges Problem, das in dieser Arbeit gelöst werden musste, war das Finden 
eines brauchbaren Biorekognitionssystems für das Binden der biokompatiblen Drug 
Carrier Nanopartikel. Es braucht spezielle Lösungsansätze, um Antikörperbildung 
gegen biokompatible Materialien zu induzieren. Im Fall von Chitosan, waren 
Antikörper kommerziell erhältlich, während für PLGA ein sehr stringentes 
Immunisierungsprotokoll in Kaninchen entwickelt werden und auch Probleme 
hinsichtlich Reinigung und Titerbestimmung gelöst werden mussten. 
Durch die durchgeführten Experimente war es möglich ein „Proof of concept“ für ein 
wiederbeladbares Targeting-system zur lokalen Medikamentenfreisetzung an 
Oberflächen zu geben. Dieses neuartige System ist eine Basis für ein breites 
Anwendungsgebiet in der regenerativen Medizin wie z.B. Stents, artifizielle 
Knochenimplantate und andere künstliche Gewebe, die eine lokale und kontrollierte 
Medikamentenfreisetzung an der Grenzfläche zwischen Implantat und gesundem 
Gewebe benötigen. Das Drug-Delivery System schützt die eingeschlossenen 
Wirkstoffe vor vorzeitigem Abbau – wichtig z.B. bei Wachstumsfaktoren und 
Immunsuppressiva und erleichtert auch den Transport von schwer absorbierbaren 
oder schwer löslichen Wirkstoffen zum erwünschten Wirkort. Dank der hohen lokalen 
Wirkstoffkonzentration wird die Absorption schwerlöslicher Substanzen verbessert, 
wodurch unerwünschte systemische Nebenwirkungen vermindert werden können.  
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Introduction 
1 Background 
Advances in modern material sciences have brought many life saving products to 
the clinic, in particular to the operation theatre in the form of various implants. 
Optimal biocompatibility is of utmost importance when developing novel implant 
materials and a number of challenges still need to be addressed in this area. In 
addition, the implanted material needs to have specific mechanical properties (e.g. 
durability and resistance to the chemical stresses) within environment at the 
implanted site. Single compound materials rarely possess all the above-mentioned 
qualities. During the last decade, surface modification with biocompatible materials 
has emerged as one possible method to improve the biocompatibility of medical 
implants. Another goal that has become feasible recently is to design implant 
materials able to stimulate healing, and improve restoration of diverse tissue 
functions. For this purpose drug eluting implants have been developed. However the 
following problems are still the drawback of available drug eluting implants.  
 
1.1 Re-stenosis after coronary stent implantation 
Despite advances of modern intervention in coronary artery heart infarction, re-
stenosis continues to be the main problem after balloon angioplasty treatment (Liu M. 
et al. 1989). Compared to angioplasty alone, coronary stent implantation has been 
proven effective in the reduction of re-stenosis in native coronary vessels. 
Nevertheless, re-stenosis rates after bare-metal stent implantation are still as high as 
20% to 40% at 6 months post intervention (Scheller B. et al. 2004). The 
physiopathology of re-stenosis after balloon angioplasty and stent implantation 
suggests 5 major mechanisms: i) elastic recoil; ii) thrombus formation at the injury 
site; iii) inflammation; iv) proliferation of smooth muscle cells; v) neointimal 
hyperplasia. Thrombogenicity of the stents is associated predominantly with activated 
thrombocytes, which may be induced by shear forces and through contact with 
biomaterials (Courtney JM. et al. 1994). Furthermore, it has been suggested that 
metal ions can induce activation of blood platelets as well as other cell types 
(Ruygrok P. et al. 1996). Stented blood vessels show reactive inflammatory 
Introduction 
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infiltrates, composed of lymphocytes, histiocytes and eosinophiles, surrounding the 
stent struts (Karas SP. et al. 1992). It is assumed that this inflammatory reaction is a 
mixed response to both, vessel injury, and non-specific activation mediated through 
metal ions released from the alloy of the stent. More over eosinophils have been 
identified in post-mortem studies as important players of both restenosis and 
thrombosis after drug-eluting stent (DES) implantation. Further studies are warranted 
to establish whether ECP (eosinophil cationic protein, a marker of eosinophil 
activation) is a risk marker or plays a contributory pathogenetic role (Niccoli G. et al, 
2009). 
 
1.1.1 Neointimal hyperplasia 
The innermost cell layer, or intima, of a blood vessel is composed of a single layer of 
cells that are adapted to respond to mechanical stress in a highly specific manner, as 
they are constantly exposed to the shear forces generated by blood flow. Intimal 
hyperplasia after balloon injury is a complex process involving platelets, growth 
factors, endothelial cells, smooth muscle cells, mechanical injury, wall shear stress, 
and probably other unknown factors (Liu M. et al. 1989). Stent implantation often 
leads to intimal hyperplasia, perturbed tissue growth with characteristic inflammatory 
cells, proliferating smooth muscle cells and extracellular matrix, consisting of 
collagen, elastin and several types of glycoproteins (Strauss B. et al. 1994). However 
it has been assumed for a long time that excessive cell proliferation is the major 
mechanism of intimal hyperplasia (Schwartz RS. et al. 1992). Three major stent-
related factors influence the extent of intima proliferation: i) stent material; ii) stent 
design; and iii) extent of vascular injury.  
In order to reduce re-stenosis and stent-associated thrombosis, significant efforts 
have been devoted to improve the biocompatibility of the stent material (Ruygrok P. 
et al. 1996). Ideally the stent material should combine both, excellent mechanical 
properties and good biocompatibility. New stent designs, changes in the composition 
of the materials, and surface modifications such as coatings have been applied 
(Ruygrok P. et al. 1996). Recently, the use of drug-eluting stents, coated with anti-
proliferative substances has become a milestone in interventional cardiology.  
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1.1.2  Drug eluting stents (DES) 
Recently, drug-eluting stents have been introduced as a new and promising 
technique to reduce re-stenosis after stent implantation. There are three different 
approaches for binding pharmacologically active compounds onto coronary stents: 
 The drug is bound by a polymer onto the stent surface (Suzuki T. et al. 2001). 
 The drug is bound by an inorganic stent coating (Kataoka T. et al. 2001). 
 The drug is directly applied onto the stent surface without any coating (Kaluza 
GL. et al. 2002).  
Several substances with immunosuppressive, antiproliferative and cytostatic 
properties such as Sirolimus, Eveolimus, and Paclitaxel have been tested as active 
stent coatings and were shown to reduce re-stenosis in humans (Sousa J. et al. 
2001, Grube E. et al. 2004, Chieffo A. et al. 2002). Despite these advances, re-
stenosis rates still remain substantial in patients with high-risk for re-stenosis, such 
as patients with long coronary lesions, complex lesion morphologies or lesions at 
bifurcations of blood vessels (Park S. J. et al. 2008). Moreover, results from small 
selected patient groups showed potential risks when delivering anti-proliferative 
drugs from coronary stents. As these substances do not only inhibit smooth muscle 
proliferation, but also disturb re-endothelialization of stent struts, the risk of acute and 
sub-acute stent thrombosis might be increased. Another alarming observation was a 
significant increase of incomplete stent strut apposition with Sirolimus eluting stents 
(Moreno R. 2005, Anderson R. et al. 2005). Roiron C. et al. study shown that a trend 
to an increased risk of stent thrombosis after Paclitaxel eluting stent implantation was 
found, whereas the risk of stent thrombosis was similar with Sirolimus eluting stent 
and bare-metal stents (Roiron C. et al. 2006). Paclitaxel is cytotoxic, whereas 
sirolimus is cytostatic. In general drug-eluting stents may be associated with an 
increased rate of late stent thrombosis, myocardial infarction and death (David E. et 
al. 2009).  
 
1.1.3 Long coronary lesions 
A study by Faraasen S. et al. compared the efficacy of the Sirolimus-eluting stent 
(SES), the Paclitaxel-eluting stent (PES) and the bare metal stent (BMS) in patients 
with elongated coronary lesions. The two DES groups had longer stented segments 
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than the BMS group. After six months, angiographic follow-up showed lower in-
segment re-stenosis rates in the SES (9.3%) and PES (21%) groups than in that of 
the BMS group (42.5%). The rate of major adverse cardiac events (MACE) including 
death, myocardial infarction, and target lesion revascularization at 9 months was 
higher in the BMS group (26.6%) than in the SES (13.0%) and PES (15.7%) groups 
(Faraasen S. et al. 2003). In general SES showed significantly greater suppression of 
neointimal hyperplasia in complex coronary lesions compared to PES (Yun-Kyeong 
C. 2009). 
 
1.1.4 Saphenous vein graft stenting 
Saphenous vein graft (SVG) stenting is still a challenge for modern engineering, 
cardiology and basic research. In this approach, a part of the saphenous vein of the 
patient is implanted at the site of coronary lesion to fulfil stent-like function. However, 
SVGs tend to degenerate rather quickly and up to 50% of SVGs show significant re-
stenosis and nearly 40% are completely occluded after 10 years (Kim Y. et al. 2006, 
Firzgibbon G. et al. 1991). Furthermore SVG stenting is associated with re-stenosis 
rates as high as 50% at 6 months, and does not significantly improve the survival 
rate (Firzgibbon G. et al. 1996, Keeley E. et al. 2001). De Jaehere et al. DES 
implantation in SVG lesions appears safe (De Jaehere P. et al. 1996). However, 
patients were followed only for 6 months. Longer follow-up in SVG interventions is 
especially important because it is known that vein graft related complications 
continue to develop after 6 months. DES is effective in reducing target vessel 
revascularization at 9 months, although most of this advantage is lost at 2 years 
(Bruce R. et al. 2009). A study by Ge et al. compared the efficacy of SES with bare 
metal stents in patients who underwent SVG intervention within one year. SES is 
clinically safe and feasible, but is not associated with a decrease of clinical events up 
to one year compared with BMS. The most likely explanation is the small size of 
SESs due to the unavailability of larger stents. The small size of SESs allows only 
limited contact of the drug with the blood vessel wall in relation to the dimensions of 
the lesion (Ge L. et al. 2005).   
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1.1.5 Current limitations of drug loading 
Currently, drug-eluting implants, including stents, are prepared by incubating the 
implant in the pharmaceutical drug followed by drying. Drug release is then achieved 
either by passive diffusion or by degradation of the implant matrix (Wu P. et al. 2006). 
However, this approach allows only limited control of such important parameters as 
drug dosing, release kinetics, and release duration. Another study showed that 
increasing Rapamycin concentrations (0.5, 2,2%) can lead to reduced re-stenosis via 
a polymer-free on-site stent coating compared to BMS. Rapamycin acts analogous to 
sirolimus. In-segment restenosis was significantly reduced from 25.9% with BMS to 
18.9%, 17.2 and 14.7% with 0.5, 1.0 and 2.0% respectively (Chu W. et al. 2006). The 
main drawback of small drug eluting implants is their limited drug loading capacity. 
Furthermore, currently used methods allow only single drug loading onto the implant, 
and after implantation the drug cannot be changed according to varying patient 
needs throughout different stages of the healing process.  
Another approach is the use of nanoparticulate drug carriers specifically transfecting 
arterial walls. Here the problem arises that only very small particles of about 110 nm 
are suitable, whereas larger particles (> 300nm) show only very short residence time 
on the arterial wall surface and accumulate in liver and spleen and lung. (Brito L., 
Amici M. 2007). 
 
2 Our approach: Design of reloadable implant materials in 
this study 
The overall objective of my thesis is to investigate and develop possible solutions to 
these limitations for coronary stent implant materials with the hope of extending these 
solutions to other types of implants.  
The general design approach developed in this thesis is outlined in Figure 1. 
Implant materials were coated with a biocompatible layer that was covalently bound 
to the implant backbone. This biocompatible layer forms a passive protection layer to 
prevent rejection of the implant material. Additional binding sites were then anchored 
in this protective layer and were subsequently used to load biodegradable, drug 
containing nanoparticles onto the implant via specific bio-recognition sites. Use of 
these specific binding sites overcomes problems as outlined by Brito L. and Amici M. 
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2007 as the particles will act site directed on the implant material and unspecific 
accumulation in liver, lungs and spleen will be minimized. After implantation into the 
patient, such a structure will serve as a re-loadable drug delivery system. While the 
particles are degraded, either by hydrolysis or by enzymes in the surrounding body 
fluids, the drugs will be released gradually. At the end of this process the bio-
recognitive sites are regenerated and become free to bind newly injected drug 
containing particles again. The possibility of re-loading allows not only patient-
adequate dosage of drugs but also change of medication after implantation, i.e. using 
different drugs at different stages of the healing process.  
 
 
 
Figure 1. Principle of nanoparticle binding, drug release and reloading.  
 
A similar solution to the one proposed in this thesis was already described in a 
published Patent WO 02/067849, however the patented concept has many 
drawbacks and limitations.  Patent WO 02/067849 demonstrates in principle a novel 
biomedical device that potentially can overcome several of the abovementioned 
prior-art limitations by allowing targeted delivery and activation of therapeutic agents 
at a specific tissue site. To achieve this goal several general engineering methods 
were described to produce such a device. However, the practical realisation of such 
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a proposed device is still missing. The principal design concept of the biomedical 
implant described in this patent is similar to that developed in this thesis. However, 
the bio-recognitive principles illustrated in the patent were described in rather general 
terms as a listing of known biorecognitive interactions that consist of binding of one of 
the biorecognitive partners to the implant material and the other to a drug containing 
particle. The only recognitive principle mentioned explicitly in this patent was based 
on avidin-biotin interaction. The avidin-biotin system represents one of the strongest 
biorecognition reactions with respect to binding, and therefore cannot be the reaction 
of choice for a reloadable drug delivery implant system, as was claimed in the patent. 
Binding reaction systems for reloadable systems need to be strong enough to keep 
the drug releasing nanoparticles tightly bound for a certain period of time, but on the 
other hand weak enough to allow reloading after the gradual decomposition of the 
beads. Furthermore, avidin is immunogenic in humans, leading to inflammatory 
response, and this immunogenicity is increased after binding to a carrier-particle as 
was suggested in the patent. Moreover, the iso-electric point of avidin is 10. At 
physiological conditions in the human body avidin will be positively charged and 
adheres, non-specifically, to cell surfaces and other negatively charged structures. 
Furthermore, biotin (vitamin H) is endogenous in the human body, and therefore 
biotinlyated particles as described in this patent will compete with vitamin H for 
avidin-binding sites, thus not allowing an implant site specific application.   
 
3 Specific aims 
In order to realise the development of the drug delivery system for implant materials 
the following specific aims were pursued.   
 
Specific aim 1: To produce a covalently bound biocompatible coating for implant 
materials 
Specific aim 2: To introduce binding sites for degradable, drug loaded nanoparticles 
into the biocompatible coating 
Specific aim 3: To search and develop a biorecognitive reloadable binding system 
for drug delivery system e.g. nanoparticles  
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Specific aim 4: To provide a proof of principle testing of the interaction between the 
nanoparticles and their in biocompatible coating embedded binding 
site  
3.1 Specific aim 1  
To produce a covalently bound biocompatible coating for implant materials 
(Chapter 1)  
 
Implant Material Coating 
The implant materials selected for use in this study were stainless-steel L316, or 
ceramics (zirconium dioxide ZrO2), which were chemically activated for binding the 
passive coating layer and the bio-recognitive system. The passive coating of the 
implant materials with the partially functionalized polymer polyethyleneglycol (PEG) 
was intended to enhance the biocompatibility of stainless-steel L316 or ceramics. 
The biorecognitive system – in our approach receptor molecules capable of binding 
nanoparticles – was embedded into the PEG coating. This biorecognitive system had 
to be chosen very carefully to avoid any interactions with other components 
circulating in the blood. Furthermore, the binding between receptor molecules and 
nanoparticles had to be strong enough to keep the drug releasing nanoparticles 
tightly bound for a certain period of time, but on the other hand weak enough to allow 
reloading after the gradual decomposition of the particles. In our approach we used 
antibodies as receptors for the drug loaded nanoparticles. The nanoparticles used in 
this study were either made of PLGA (Poly (D,L-lactide-co-glycolide)) that is 
degradable by hydrolysis, or of chitosan that is degraded by the lysozyme circulating 
in human blood.  
 
3.1.1  Passive coating 
In general, passive coating with hydrophilic, protein-repellent polymers provides good 
biocompatibility as it acts as a barrier between the implant-material and the host 
defence mechanisms that initially rely on opsonisation by endogenous marker 
molecules. In this study the well-described polymer polyethyleneglycol (PEG) was 
used for passive implant-coating. PEG is water-soluble and non-ionic and approved 
by the FDA (food and drug administration) for many pharmaceutical and biomedical 
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applications. It can be chemically modified for attachment to other molecules and 
surfaces (Li J. et al. 2003). PEG is widely used in the food additives and cosmetics 
industries and has many biochemical, industrial, and pharmaceutical applications as 
a potent fusogenic agent (Bailey F. et at. 1976). In clinical practice, PEG is often 
employed to study the permeability of organs such as the gut (Parlesak A. et al. 
1994) and bile duct (Roma M. et at. 1991) under normal and pathological conditions. 
Several enzymes and proteins with therapeutic potential have been covalently 
modified with varying sizes of PEG in order to enhance their biological efficacy (Katre 
N. 1993). PEG conjugates of several clinically important proteins have been shown to 
exhibit increased circulatory lifetime as well as reduced antigenicity and 
immunogenicity (Katre N. 1993, Lang G. et al. 1992, Zimmerman R. et al. 1989, 
Meyers F. et al. 1991, Wada H. et al. 1990, Chaffee S. et al. 1992). PEGylated drugs 
such as PEG-interferon and PEG-asparaginase are already available on the market. 
In addition, PEG confers tolerogenic properties to a number of allergens (Holford-
Strevens V. et at. 1982). These observations have emphasized the potential 
usefulness of PEG in enhancing the therapeutic index of many biologically important 
molecules.  
 
The generation of protein resistant surfaces is a basic requirement in the design of 
many medical devices and implants that come in contact with blood, such as 
catheters or vascular stents. Protein resistant surfaces are necessary to avoid or 
reduce non-specific protein adsorption, platelet adhesion, and thrombus formation 
and thus prevent undesired reactions of the living system to the device or implant. 
Since implant materials, such as steel or titanium and its alloys, covered by their 
respective surface oxides (passive film), are often applied in blood-contacting 
devices, a reliable method for reducing protein adsorption on oxide surfaces in vivo 
would be highly desirable. Moreover, protein resistant surfaces are increasingly 
applied in bioaffinity sensing where the selectivity and sensitivity of the 
antigen/antibody assay is directly proportional to the suppression of non-specific 
adsorption. In other words, protein resistant surfaces are needed to reduce non-
specific adsorption in order to allow implant site-specific ligand recognition. 
Non-specific adsorption can be avoided by pre-coating the implant surface with a 
material resistant to protein adsorption. Such materials are typically non-ionic and 
very hydrophilic. For example, polyvinyl alcohol (Amanda A. et al. 2001), 
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polyacrylamide as e.g. poly HEMA (Park S. et al. 2000), hyaluronic acid (Matsuda T. 
et al. 1992), dextrane (Holland NB. et al. 1998), and PEG (Scott M. et al. 1998, 
Zalipsky S. et al. 1992, Kenausis G. et al. 2000, Huang NP. et al. 2001, Van de 
Vondele S. et al. 2003) have been used as coating materials for such purpose. PEG 
has also been used to sterically stabilize red blood cells from lectin-induced 
haemagglutination and fibroblasts from adhesion to fibronectin-coated surfaces 
(Elbert D. et al. 1998).  
 
In this thesis we set out to develop a biocompatible coating for the implant 
materials stainless-steel 316L and ceramics (zirconia, ZrO2-TZP-A BiO-HIP). 
The covalently bound polymer layer conveys biocompatibility by reducing 
protein adsorption. On the other hand, the polymer layer also contains 
functional groups that provide anchorage for a bio-recognition system that 
makes this layer a pharmacologically active coating. 
 
3.2 Specific aim 2 
To introduce binding sites for degradable, drug loaded nanoparticles into the 
biocompatible coating (Chapters 2, 7) 
 
3.2.1 Bio-recognitive system for drug delivery system 
A difficult issue to solve in this thesis was to find suitable biorecognitive systems for 
binding of the drug containing particles. The design of the receptor is of great 
importance as any bio- or chemorecognitive interactions with other components 
circulating in the blood should be avoided. Furthermore, the binding between the 
receptor and the nanoparticles has to be strong enough to keep them tightly bound 
during their lifetime, but on the other hand allow reloading after final degradation. 
Antibodies against the biocompatible nanoparticles were bound to the implant 
surface as biorecognitive site for reloading of the particles. 
 
In this thesis we chose an antibody which serves as a binding site for the bio-
recognitive system for drug containing nanoparticles. The immobilization of Ab 
molecule or its Fab´ fragment onto the biocompatible coated carriers is shown 
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using fluorescence microscopy. More over a newly optimized method to create 
two Fab` fragments using dihydrolipoamide was developed.  
 
3.3 Specific aim 3 
To search and develop a biorecognitive reloadable binding system for a drug 
delivery system e.g. nanoparticles (Chapters 3, 4, 5, 6). 
 
3.3.1 Drug-delivery and targeting-systems  
The method of drug delivery can have a significant effect on the efficacy of the drug. 
Most drugs have an optimum concentration range with a maximum benefit, and 
concentrations below this range produce minimal or no therapeutic benefit, whereas 
concentrations above this range may be toxic. On the other hand, the very slow 
progress in improving efficacy of treatments in severe diseases has suggested a 
growing need for specific delivery of therapeutics to targets tissues. The “magic 
bullet” concept, (Ehrlich P. 1913), brought drug targeting systems to the fore front of 
pharmaceutical research, however the practical implementation of these “magic 
bullets” continues to be a challenge. Since then new concepts for controlling the 
pharmacodynamics, pharmacokinetics, immunogenicity, biorecognition, non-specific 
toxicity, and efficacy of drugs have been developed. These drug delivery systems 
(DDSs) are based on interdisciplinary approaches combining pharmaceutical 
research, polymer sciences, molecular biology and bio-conjugate chemistry. Other 
approaches to drug delivery are focused on crossing particular physical barriers, 
such as e.g. the blood brain barrier (BBB), in order to improve targeting of the drug 
and also improve its effectiveness. This approach is an alternative and acceptable 
way for delivery of protein drugs as opposed to delivery via the gastro-intestinal tract, 
where degradation can occur very rapidly. Other challenges for DDS are related to 
the properties of the carrier that needs to maintain the drug in a stable and active 
form while it is travelling through the body to its specific target site. Non-specific 
interactions need to be avoided during this time. Various DDSs and drug targeting 
systems are currently under development to minimize drug loss and degradation, to 
prevent harmful side-effects, and to increase drug bioavailability at the target site.  
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Among such drug carriers are micro- or nano-particles made of biodegradable 
natural and synthetic polymers, lipoproteins, liposomes and micelles. According to a 
number of studies, nanoparticles show better performance than other drug carriers 
(Kaparissides C. et al. 2006). Nanoparticles have a solid structure with good physical 
stability and can be designed using a wide range of materials to control release of the 
encapsulated drug. Drugs can be bound to nanoparticles in various forms such as a 
solid solution, dispersed or adsorbed onto the surface, or chemically bound. To 
prolong the circulation of nanoparticles in the blood their surface can be modified, 
coated or attached with targeting ligands to achieve site-specific drug delivery 
(Saeed Arayne M. et al. 2007).  
In biological systems nanoparticles show different properties depending on their 
surfaces (Figure 2). The bio-distribution of nanoparticles is largely determined by 
their physical and biochemical properties, such as the nature of the polymer and 
drug, particle size and biochemical surface properties (Cheng J. et al. 2007). The 
polymeric matrices of "conventional structures” (Figure 2) tend to be hydrophobic and 
are slightly coated by serum proteins that act as opsonins. However, opsonisation of 
the particles can be reduced by coating nanoparticles with flexible hydrophilic 
polymers, particularly polymers containing polyethylene glycol (PEG), which allows 
them to remain in the circulation for extended periods of time (Garnett M. et al. 2006). 
PEG as a polymer for "nonfouling" surfaces can resist the adsorption of proteins 
and/or cells. The matrix of polymeric nanoparticles can be modified with cell-specific 
ligands (e.g. antibodies) for "target-orientation". Such target-oriented nanoparticles 
are commonly used in chemotherapy. However, phagocytic cells, such as 
macrophages, may recognize injected particulate drug carriers as foreign materials 
and remove them via nonspecific phagocytosis via the mononuclear phagocytic 
system (MPS) (Thomasin C. et al. 1996). In this case the MPS-clearance might be 
decreased by reducing the particle size to < 100 nm. These nanoparticles were also 
reported to resist opsonisation. 
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Figure 2. Surface variations of nanoparticle drug carriers.  
 
3.3.2 Controlled drug release  
The mode of drug delivery can make the difference between a drug‟s success and 
failure. Moreover the choice of drug is often influenced by the way it is administered. 
Drugs can be released at a controlled rate (continuous release), by diffusion, or by 
degradation of the polymer over time. Pulsed release, which closely mimics the way 
of natural hormone release, such as insulin, is often the preferred method of drug 
delivery. It is achieved by using drug-carrying polymers that respond to specific 
stimuli such as changes in pH, temperature or ultrasonication (Chouhan R. and 
Bajpai AK. 2009; Husseini G.  and Pitt W. 2009).  
Controlled drug release and the subsequent bio-degradation of the nanoparticle 
polymer are important aspects in the development of successful formulations. The 
rate of bio-degradation of nanoparticles can be controlled via the 
hydrophobic/hydrophilic ratio. Release rates depend on: 
 Diffusion through the NP-matrix 
 Diffusion (in case of nanocapsules) through the polymer wall 
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 Desorption of the surface-bound/adsorbed drug 
 Erosion of nanoparticle-matrix  
 A combination of erosion and diffusion  
 
3.3.2.1 Biodegradable PLGA-based nanoparticles 
PLGA {poly (D, L-lactide-co-glycolide)] is a random copolymer of glycolic acid and 
lactic acid, it is insoluble in water and soluble in organic solvents, such as ethyl 
acetate, chloroform, dichloromethane, tetrahydrofurane, DMSO, dioxane, toluene, 
acetone, ethanol or petroleum ether. The ratio of glycolic acid to lactic acid 
determines the rate of degradation, generally considered as hydrolysis. The 
hydrophilicity of PLGA increases with decreasing percentage of glycolic acid. 
Degradation of PLGA yields lactic acid and glycolic acid, both also products of the 
endogenous metabolism. A large number of in vivo and in vitro studies have shown 
the full biocompatibility and biodegradability of PLGA nanoparticles and their 
degradation product (Athanasiou K. et al. 1996, Anderson J. 1997, Tracy M. 1999). 
 
In clinical applications, PLGA nanoparticles can be administered parenterally, 
vascularly or orally for site-specific delivery. However, the nonspecific adsorption of 
plasma proteins on PLGA micro- and nanospheres remains one of the main 
limitations of drug targeting (Müller M. et al. 2003).  Müller et al. (2003) demonstrated 
a strong decrease of protein adsorption on poly (L-lysine)-g-poly(ethylene glycol) 
(PLL-g-PEG)-coated PLGA microspheres for the tested proteins HSA (human serum 
albumin), Fibronectin, Fibrinogen, and IgG as representatives for abundant human 
blood proteins. The choice of PLGA as a polymer for nanoparticles originated from 
their use in the medical device industry to make bioabsorbable sutures. However, 
their unique properties, including versatile degradation kinetics, established safety 
and biocompatibility, made them appear ideal for drug delivery applications. 
Moreover, PLGA nanoparticles not only modify the pharmacokinetics of encapsulated 
drugs, but they also protect the occluded drugs from enzymatic attack. 
Currently, a number of FDA-approved products on the market utilize PLGA as 
excipients to achieve sustained release of the active ingredient, such as e.g. 
Neutropin Depot, Sandostatin LAR or Trelstar Depot. PLGA nanoparticles are 
used also as a carrier for AI-700 that is used for stress echo cardiological evaluation. 
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The efficiency of PLGA nanoparticles as a local drug delivery system (for example 
dexamethasone) to decrease neointimal proliferation, without having significant 
systemic effects was already shown in the rat carotid injury model after ballon injury 
(Andweson J. and Shive M. et al. 1997). 
 
3.3.2.2 Chitosan nanoparticles 
Chitosan (CS) is a linear aminopolysaccharide composed of approximately 20% 1,4-
linked N-acetyl-D-glucosamine (GlcNAc) and approximately 80% β1, 4-linked D-
glucosamine (GlcN) produced by partial deacetylation of chitin in hot alkali. As 
described in Yan W. 2005, CS has shown favourable biocompatibility characteristics 
(Knapczyk J. et al. 1989; Hirano S. et al. 1989, 1990) as well as the ability to 
increase membrane permeability, both in vitro (Aspden F. et al. 1997; Lehr C. et al. 
1992; Dumitriu S. and Chornet E. 1998) and in vivo (Takeuchi H. et al. 1996). It is 
degradable by lysozyme, which circulates in the bloodstream, thus making it a 
suitable material for drug containing nanoparticles. Moreover the low toxicity (Aspden 
et al. 1995), ease chemical modification and excellent capacity for the protein-
entrapment of CS make it a suitable candidate for use in gene- and drug-delivery 
systems (Calvo P. et al. 1997b, De la Fuente M. et al. 2008). CS has received 
increasing attention in the design and engineering of novel nanoparticulate drug 
delivery systems. Desirable properties of CS include biocompatibility, 
biodegradability, bio-and mucoadhesivity, as well as hydrophilic characteristics that 
facilitate administration and increase the bioavailability of poorly absorbable drugs 
across various epithelial barriers, such as corneal, nasal and intestinal mucosa 
(Alonso M. J. et al. 2007). An additional advantage of a CS based system is that it 
can be produced under aqueous and fairly mild conditions, thus being especially 
suitable to preserve the bioactive conformation of delicate macromolecules (e.g. 
proteins, hormones, antigens, pDNA, siRNA, growth factors, heparin, etc.) that 
otherwise would be prone to enzymatic degradation and hydrolysis (Janes K. et at. 
2001; Csaba N. et al. 2006). The physicochemical, biomedical and pharmaceutical 
properties of chitosan have been described in detail in several articles (Skaugrud O. 
et al. 1999; Agnihotri S. et al. 2004; Ravi Kumar M. et al. 2004; George M. and 
Abraham T. 2006; Rinaudeo M. 2006, 2008). Drug delivery systems including 
chitosan-beta-cyclodextrin nanoparticles and nanocore-coated type capsules were 
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described in Alonso et al. (Alonso M. J. et al. 2007). Thus, Chitosan has been widely 
utilized in the development of potentially innovative drug delivery systems, tissue 
engineering and wound dressing systems over the last decade. Alonso M.J. and 
Goycolea F.M 2008 mentioned that over 50% of the total number of filed patents in 
2006 that claim the use of this biopolymer as a substantial part of the invention are 
related to drug delivery, tissue engineering and wound healing (Higuera-Ciapara I. et 
al. 2007).  
From a biopharmaceutical point of view, CS has the potential of serving as an 
absorption enhancer across intestinal epithelia, because of its mucoadhesive and 
permeability enhancing property (Janes K. et al. 2001). It has been shown that CS 
could enhance insulin absorption across human intestinal epithelial (Caco-2) cells 
without injuring them (Artursson P. et al. 1994; Schipper N. et al. 1996, 1997, 1999; 
Thanou M. et al. 2001). CS has been used in preparing films, beads, intragastric 
floating tablets, microspheres, and nanoparticles in the pharmaceutical field (Berthold 
et al. 1996; Felt O. et al. 1998; Giunchedi P. et al. 1998; Calvo P. et al. 1997a; Illum 
L. 1998; Wu et al. 2003). Previous results have also emphasized the importance of 
particle size and have demonstrated the advantages of nanoparticles (>1µm) over 
microspheres (Meclean S. et al. 1998). Their small size facilitates distribution via 
blood circulation throughout the body. Hydrophilic nanoparticles have in general a 
longer life time in the blood stream (Allemann E. et al. 1993).  
In this thesis a very stringent immunisation protocol was developed for the 
production of polyclonal antibodies against a biocompatible and biodegradable 
polymer, such as PLGA (Chapter 6). A number of technical problems were 
solved regarding purification and testing of the titer, which proved difficult due 
to the rapid degradation of PLGA in the injected rabbits. The determination of 
PLGA Abs in immune sera was carried out using ELISA and Cluster Linked 
Immunosorbent Assay (CLISA). By direct purification of PLGA antibodies from 
immune rabbit sera, using affinity chromatography, a protein was isolated 
which interacts with PLGA. Analysis of this protein by means of native gel 
electrophoresis and mass spectrometry showed that this protein has a 
homology to albumins. Therefore, we investigated also the effect of human 
serum albumin on PLGA, and could prove its binding to PLGA nanoparticles. 
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According to these results, it is recommended to coat PLGA-NPs before 
injecting them into the human body to avoid unspecific coating with serum 
albumin. 
Another drug delivery system based on chitosan nanoparticles was also 
studied in this thesis to show proof of principle for the novel developed 
implant material. 
 
3.4 Specific aim 4  
To provide a proof of principle testing of the interaction between the 
nanoparticles and their in biocompatible coating embedded binding site 
(Chapter 7)  
  
3.4.1  Active coating  
Active coating is based on the temporary binding of pharmacologically active 
substances onto implant material. Upon release, these substances can exert their 
intended pharmacological effect at the implant site. In this thesis we chose to use a 
drug delivery system was based on functionalized nanoparticles. These particles are 
capable of binding to molecular receptors embedded on the applied polymer coated 
implant material. Such a bio-recognitive system has to fulfill several requirements:  
1) Any bio- or chemorecognitive interaction with other components than target 
molecules should be prevented;  
2) The binding between receptor and particles has to be strong enough to keep the 
drug releasing nanoparticles locally and tightly bound;  
3) The biorecognitive interaction between the polymer of the particles and the 
receptor should be strong enough, but weak with the emerging monomers (lactic- 
and glycolic acid in case of PLGA nanoparticles or 1, 4-linked N-acetyl-D-
glucosamine (GlcNAc) and approximately 80% β1, 4-linked D-glucosamine (GlcN) in 
the case of chitosan nanoparticles) to allow reloading.  
To meet these criteria, antibodies recognizing PLGA or chitosan, the polymers 
forming the nanoparticles, need to be bound to the implant surface. As the epitope 
recognized by an antibody comprises a sequence of 6-8 amino acids, it is expected 
that the binding of any residual monomer to the paratope is weak, and the monomer 
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is easily displaced by the PLGA- or chitosan-polymer. This effect was shown by 
classic binding competition assays (Elvin A. et al. 1960).  
In this thesis the interaction between the nanoparticles and the implant was 
studied using fluorescently labeled particles visualized by fluorescence 
microscopy. It has been shown previously that different drugs can be 
embedded into biocompatible and biodegradable PLGA or chitosan 
nanoparticles. These nanoparticles then gradually release the drugs in a 
controllable manner. The release of encapsulated drugs can be tailored by 
modulating the molar ratio of the monomers, by the addition of auxiliary 
agents, and by the size of the particles (Ertl B. et al. 1999; Wolf M. et. al. 2003). 
This makes the nano-encapsulation of drugs in PLGA or chitosan 
nanoparticles an approved and safe technology for the long term delivery of 
therapeutics. 
 
4 Applications of the novel implant material developed in 
this study 
4.1 Reloadable drug delivery implant systems 
Our proposed strategy for coating and drug delivery can provide the basis for a 
number of applications that require controlled, local drug delivery at the interface 
between an implant and healthy tissue. Upon the need for medication, drug-loaded 
nanoparticles can be injected into the human body as e.g. in case of heart stents or 
directly into e.g. specially constructed joint implants. These will subsequently bind to 
the particle-specific antibodies on the target implant, and release the drug. As 
nanoparticles can be loaded with different drugs, this technology allows easy 
adjustment to patient-specific medication needs, as well as the administration of 
compounds that would either degrade quickly, or that are difficult to dose, if given 
orally or intravenously (e.g. growth factors, immunosuppressives, thrombolytic 
enzymes made biocompatible by chemical engineering). 
 
Bone implants: Depending on the application, nanoparticles can be loaded with 
various drugs to improve the recovery of the patient after implantation. For example, 
placement of an implant is always associated with the risk of microbial infection, and 
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the risk is considerably higher when used for fixing open-fractured bones 
(Tsukayama D. and Gustilo R. 1996) or in joint revision surgeries (Dunlop D. et al. 
2002). This necessitates effective antimicrobial therapy immediately after surgery. 
However, systemic therapies are not optimal as there is poor accessibility to the 
implant site due to impaired blood circulation. In addition, after attachment to the 
implant surface pathogens can develop resistance to drugs, so that higher 
concentration of antibiotics need to be administered, increasing systemic doses may 
have a limit, because of toxicity (Wu P. et al. 2006). It can be envisaged that many of 
these implant-associated complications may be addressed far more efficiently 
through local delivery of pharmaceuticals as proposed in this project. For bone, 
implant therapies that stimulate the bone to bridge the gap between healthy tissue 
and the implant and even render it resistant to erosion are highly desired for a longer 
implant lifetime. In addition, osteosynthetic devices and artificial joints often face 
bones with a certain extent of osteoporosis. Restoring the bone mass locally may 
improve both the implant itself and the structure of the repaired bone. Bone 
regeneration can be strongly enhanced by growth factors. They promote replication, 
differentiation, protein synthesis and/or migration of respective cell types. These 
effects increase the osteoblastic activity of the bone tissue and therefore stimulate 
bone regeneration (Lieberman J. et al. 2002; Solheim E. 1998). Simple dip-coating of 
implants with certain growth factors significantly accelerates bone formation and gap 
bridging (Sumner D. et al. 1995). However, the efficacy of such physisorbed 
molecules is not optimal; because they are released quickly, and eluted molecules 
may cause side effects such as uncontrolled ossification at other sites. A number of 
important issues remain to be resolved, before local delivery systems for growth 
factors can be successfully implemented in the clinic. These are above all 
optimisation of dosing, release kinetics and release duration.  
 
Cardiovascular stents: Drug delivering implants [e.g. drug eluting stents (DESs)] 
play already an important role in the treatment of cardiovascular diseases. These 
stents have been introduced as a new and promising technique to reduce restenosis 
after stent implantation. Several substances with immunosuppressive, 
antiproliferative and cytostatic activities have been tested as active stent coatings, 
and were shown to reduce restenosis in humans (Chieffo A. et al. 2002; Grube E. et 
al. 2004). Despite these advances, restenosis rates still remain substantial in patients 
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with high-risk for restenosis, such as patients with long lesions and complex lesion 
morphologies in bifurcations. The DESs currently in use contain only a certain 
amount of drugs, and restenosis may take place if this reservoir is used up. These 
limitations can be overcome through reloading the stent with drugs, as proposed in 
our study. Moreover nanoparticles can be loaded with different drugs that directly 
interfere with intima proliferation such as prostacyclin (PGI2) which prevents 
thrombosis.  
For patients with additional pathogenic problems, such as e.g. hypertension or 
diabetes additional appropriate drugs could be administered via nanoparticles. This 
would reduce discomfort for the patients by elimination the need for daily intake of 
pharmaceuticals and consequent reduction of their adverse side effects. The drug-
loaded nanoparticles can be injected as required. Moreover if stent thrombosis 
occurs shortly after implantation and there is no possibility for acute coronary 
angiography, it is necessary to apply thrombolytic drugs. Conventionally these are 
administered systemically, with the disadvantage of adverse effects on the whole 
body, whereas the proposed targeted nanoparticles act only in the vicinity of the 
stent. 
 
4.2  PLGA antibodies in clinical and research imaging 
Targeting is the ability to direct the drug-delivery system to the site of interest. Nano-
particles can be targeted actively, e.g. by conjugating them with specific antibodies 
against certain characteristic components of the tissue of interest. The preferential 
accumulation of chemotherapeutic agents in solid tumours as a result of the 
enhanced vascular permeability of tumour tissues, compared with healthy tissue, is 
an example of passive targeting. For active targeting PLGA antibodies can be used. 
A strategy for therapeutical and diagnostic applications is illustrated in Figures 3 and 
4. A spacer molecule is coupled on one end with ligands that are selectively 
recognized by receptors on the surface of the cells of interest. The other end of the 
spacer molecule can bind to PLGA antibodies which interact specifically with PLGA 
nanoparticles that contain drugs for therapeutical purposes or visualisation dyes for 
diagnostic purposes or, e.g. gadolinium for MRI (magnetic resonance imaging) or 
PET (positron emission tomography) live imaging. This could allow for a more 
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precise targeting to the site of interest (for example in solid tumors) since ligand–
receptor interactions can be highly selective. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Therapeutic and diagnostic applications of PLGA antibodies.  
 
 
 
 
Figure 4. Diagnostic application of PLGA antibodies for tracing of the localisation of PLGA 
nanoparticles in the body using PET or MRI. 
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1. Analytical methods for detection of small amounts of amino 
groups on solid surfaces – a survey 
  
This Chapter describes approaches developed for passive coating to reach the first 
specific aim in this thesis; to produce a covalently bound biocompatible coating 
for implant-materials.   
 
The implant materials used in this study were stainless-steel L316 and ceramics 
(ZrO2). Passive coating for enhancement of biocompatibility through the so called 
“Stealth effect” was achieved by the use of partially functionalized, biocompatible 
derivatives of polyethylene glycol (PEG). The effective binding of PEG derivatives to 
stainless-steel L316, and ceramics was illustrated using analytical methods for 
detection of amino groups. Their absence or presence during the different steps of 
binding procedures provides a useful proof of successful reaction procedures. As the 
amount of amino groups on the surface of implant materials turned out to be very 
low, very sensitive analytical methods had to be used. Fluorescent staining with OPA 
(o-phthaldialdehyde) proved difficult to demonstrate such an effective setup on metal 
because of quenching of optical signals, as well as on ceramics, because of its 
uneven surface. For these purposes, silicate glass material was used. Silicate glass 
has similar chemical properties to ceramics and provides additional advantages such 
as availability, low price, even surface and does not interfere with optical signals 
when using fluorescence microscopy. Furthermore, it can be derivatized using the 
same procedures as metal or ceramics. The effective binding of PEG derivatives to 
stainless-steel L316, and ceramics and in parallel to silicate glass was shown using 
an enzymatic assay [alkaline phosphatase (AP)] specifically developed for our 
purpose using. The final binding of fluorescent labeled nanoparticles to coated 
surfaces was then shown on silicate glass. Different analytical methods were 
performed or adapted for detection of small amounts of amino groups on solid 
surfaces. Next to the quantification of available amino groups, the area-wide coating 
should be visualized with regard to biocompatible coating of medical relevant 
materials. Thereby, photometric and fluorometric methods were used as well as an 
enzymatic assay was developed and all compared to each other. 
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Introduction 
For medical applications, the biocompatible coating of relevant materials is important 
for acceptance or rejection of the foreign material. The biocompatibility of a long-term 
implantable medical device refers to the ability of the device to perform its intended 
function, with the desired degree of incorporation in the host, without eliciting any 
undesirable local or systemic effects in that host (Williams D. et al. 2003). In the 
literature, Poly(ethylene glycol) (PEG) is one of the best described biocompatible 
polymers for non-fouling surfaces (Ratner B.D. et al. 2004). It is hydrophilic and 
therefore employed extensively in pharmaceutical and biomedical applications. For 
attachment of other compounds, it can be chemically modified.  
Tests of biocompatibility are performed in animal experiments with porcine coronary 
artery as the most commonly used animal model or in vitro with the help of cell or 
organ culture. Thereby, the chemical, physical and structural properties of the 
biomaterial and the tissue responses to it are critical factors. Thus, next to culture 
studies (data not shown) the area-wide coating with the biocompatible bisamino-PEG 
(NH2-(CH2-CH2-O)n-NH2) was evaluated in this study by comparison of different 
analytical methods for the detection of small amounts of amino groups on solid 
surfaces.  
 
Coating procedures 
As carriers, stainless steel 316L (12% Ni, 17% Cr, 2.2% Mo, 67% Fe, 1% Cu, 0.25% 
N) was used as standard of medical implant materials as well as glass slides for 
fluorescence microscope studies. For photometric methods with TNBS and the 
Kaiser test, controlled-pore glass powder or Gulsenit respectively were used. 
Gulsenit is an active magnesium silicate mineral having a particle size less than 10 
µm and a density of about 3.2 kg/l. The first step of coating was conducted by amino-
silanization with APTS (3-aminopropyltriethoxysilane), a popular organo-silane to 
create functional amino groups on inorganic surfaces (Scheme 1). The reaction can 
be performed either by aqueous or by organic solvent deposition. Heating to 110°C 
forms the siloxane bond resulting in a more stable coating. 
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Scheme 1 
 
For activation of 316L, the stainless steel was etched with 3% HNO3, 0.5M HCl or 6M 
HCl for 10 min and soaked for two days in double distilled water (dd. H2O) to obtain 
hydroxyl groups needed for the further amino-silanization as described before. The 
effective etching was verified by reaction of Fe3+ with NaSCN forming a red complex 
(Scheme 2).  
Fe2+ Fe3+
H2O2
Fe3+ 6 SCN- [Fe(SCN)6]
3-
(red)  
Scheme 2 
 
For coating with bisamino-PEG, different linkers were used. For linking with EDC (1-
ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride), the amino-silanized 
surface was reacted first with succinic anhydride to introduce carboxylate groups 
(Scheme 3).  
O OO
O Si (CH2)3
H
N C
O
(CH2)2 C
OH
O
= R
O
OH
O Si (CH2)3 NH3
aminopropyl silane
coated surface
succinic anhydride
 
Scheme 3 
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EDC is a zero-length cross-linker and an often used carbodiimide for coupling of 
carboxylates with amines. Adding additional sulfo-NHS (sulfo-N-
hydroxysulfosuccinimide) increases the yield of EDC-mediated reactions several 
times (Scheme 4) (Pittner F. 2002). 
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Scheme 4 
 
For direct cross-linking of two amino-groups p-chloro-anil for PEGylation (Scheme 5) 
and glutaraldehyde for coupling of alkaline phosphatase (AP) for the enzymatic 
assay (Scheme 6) were used. 
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Scheme 5 
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Analytical methods for detection and quantification of amino groups 
For detection of the amino groups of the amino-silanized or of the amino-PEGylated 
slides respectively, different analytical methods were compared. Thereby, the 
quantification of the amount of amino-groups available on the surface as well as the 
area-wide coating for optimal biocompatibility were studied. Here, the Kaiser-test, an 
enzymatic assay, assays employing TNBS (2,4,6-trinitrobenzenesulfonic acid 
solution) and sulfo-SDTP (sulfo-succinimidyl-4-O-(4-4´-dimethoxytrityl)-butyrate) and 
the fluorescent staining with OPA (o-phthaldialdehyde) are discussed. 
 
TNBS assay 
TNBS, a reagent introduced by Sateke in 1960 (Okuyama T. et al. 1960), reacts 
under relatively mild alkaline conditions with amines forming an unstable 
Meisenheimer complex – a highly chromogenic orange-colored derivative with an 
absorbance of 335nm. Subsequent acidification to pH 1 rapidly converts the orange 
unstable product to a yellow stable trinitrophenol (TNP) derivative (Scheme 7) 
(Palmer D. et al, 1969).  
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Scheme 7 
 
Kaiser test 
The ninhydrin reaction was developed by Moore and Stein in 1948 (Moore S. et al. 
1948) and adapted for the detection of amino groups on solid phases by Kaiser et al. 
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in 1970 (Kaiser E. et al. 1970). Ninhydrin reacts with primary amines on the surface 
forming Ruhemann‟s Blue (Scheme 8). As Ruhemann‟s blue is slightly soluble it can 
be found on the surface as well as in the solution, thus it is not useful for 
quantification. 
 
 
Scheme 8 
 
Enzymatic assay 
An enzymatic approach was developed to detect very small amounts of amino 
groups on solid surfaces. The free immobilized amino groups on the carriers are 
activated with glutaraldehyde followed by coupling of calf intestinal alkaline 
phosphatase (AP). AP catalyzes the hydrolysis of p- nitrophenyl phosphate- (p-NPP) 
cleaving a phosphomonoester with a strong yellow color detectable at 405nm 
(Scheme 9). 
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Scheme 9 
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The slope – using a calibration function with different amounts of AP at a constant 
amount of p-NPP - is proportional to the concentration of the coupled AP, which can 
be correlated to the number of amino groups on carriers. The amount of immobilized 
enzymes was calculated using a standard calibration curve.  
 
Sulfo-SDTP assay 
Sulfo-SDTB (sulfo-succinimidyl-4-O-(4,4´-dimethoxytrityl)-butyrate) is used for 
colorimetric assay and has a high sensitivity to amino groups on solid support (Gaur 
R. et al. 1989). Sulfo-SDTB reacts with amino groups in the presence of perchloric 
acid to release the 4.4´-dimethoxytrityl cation with a very high extinction coefficient 
(E498 = 70.000) (Scheme 10), which makes this method very sensitive (Alonzo C. et 
al. 1997). The released cation can be measured at a wavelength of 498nm.  
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Scheme 10 
 
OPA assay 
OPA (o-phthaldialdehyde) reacts with amino groups in presence of thiol-containing 
molecules like 2-mercaptoethanol generating a fluorescence product with an 
extinction wavelength of λexc = 360nm and an emission wavelength of λem = 455nm 
(Scheme 11). Detection limits for proteins in liquid are in the μg/ml range. 
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Results and Discussion 
TNBS assay 
Only slides after amino-silanization by organic solvent deposition show a faint yellow 
staining. However, this method - widely used for amino-group tests on controlled 
pore glass beads or other substrates with very large surfaces - was not sensitive 
enough to detect small amounts of amino groups on rather flat solid surfaces and 
thus, it was not used further. As the much simpler OPA assay showed better results 
for these purposes, it was preferred. 
 
Kaiser test 
The Kaiser test was efficient for detection of free amino groups on organic amino-
silanized Gulsenit, as this substrate is a porous silicate with high surface. However, 
this assay is not sensitive enough for detection of amino groups on most carriers and 
nonporous amino-silanized glass powder. 
 
 
Figure 1. Detection of free amino groups with the Kaiser test. The intensity of the blue color is 
generated by the reaction of ninhydrin with free amino groups. Amino-silanized Gulsenit provides the 
most intensive blue color due to the high amount of free amino groups. However, the Kaiser test was 
of limited value for detection of free amino groups on amino-silanized glass slides or glass beads. 
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Enzymatic assay 
Table 1 shows the results for amino-silanized carriers. Etching of 316L stainless steel 
with 0.5M HCl and 3% HNO3 increases the amount of AP that could be immobilized 
about four fold compared to 6M HCl. For the non-etched 316L stainless steel, no AP 
activity was measured which demonstrates the importance of previous etching of 
stainless steel for subsequent amino-silanization. Thus, etching with 0.5M HCl or 3% 
HNO3 was preferred for further immobilizations. The detected amount of amino 
groups on glass carriers is higher than 316L stainless steel despite the etching.  
 
Sample 
description 
Slope 
Amount of 
coupled AP 
(ng/carrier) 
Calculated 
amount of NH2 
[nmol/cm2] 
Appendix 
(1.2) 
Not etched 
316L 
8.00E-05 -0.1 
 
-1.929E-07 
 
Figure 2A 
316L etched 
with 0.5 M HCl 
0.0006 2.5 
 
4.823E-06 
 
Figure 2B 
316L  3% 
HNO3 
0.0005 2.0 
 
3.858E-06 
 
 
Figure 2C 
Amino-
silanized   
glass 
0.0007 3.0 
 
5.787E-06 
 
Figure 2D 
Table 1. Quantification of AP immobilized with glutaraldehyde onto amino-silanized carriers and the 
etching effect of stainless steel 316L (surface of the glass slides and 316L = 2.88 cm²). The amount of 
immobilized AP enzyme is calculated using a standard calibration curve (y = 0.0002x + 0.0001) as 
described in the section Experimental.  
 
Table 2 shows the results of the 316L stainless steel after amino-PEGylation using 
EDC as a cross-linker at pH 5 and 10. The different etching methods of the 316L 
stainless steel and the different pH conditions for cross-linking with EDC show 
virtually similar results. However, the amount of immobilized AP is approximately 
about four fold less in comparison to the amino-silanized 316L stainless steel; the 
detected free amino groups on PEGylated glass at pH 5 is five times higher than 
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316L stain less steel and 4 fold higher compared to PEGylated glass at pH 10. This 
might be due to the fact that the terminal free amino groups of bisamino-PEG (MW 
1500) are protonated and stretched better in acidic buffer than in alkaline buffer. 
Glass carriers showed the highest immobilization amount of amino groups. Therefore 
only glass carriers were used for detection of amino groups using sulfo-SDTB.  
 
Sample description Slope 
Amount of 
coupled AP 
(ng/carrier) 
Calculated 
amount of NH2 
[nmol/cm2] 
Appendix 
(1.3) 
316L etched with 0.5 M HCl, 
PEGylated at pH 5 
0.0002 0.5 
 
9.645E-07 
 
Figure 3, A 
316L etched with 3% HNO3, 
PEGylated at pH 5 
0.0002 0.5 
 
9.645E-07 
 
Figure 3, B 
316L  etched with 0.5 M 
HCl, PEGylated at pH 10 
0.0002 0.5 
 
9,645E-07 
 
Figure 3, C 
316 L etched with 3% 
HNO3, PEGylated at pH 10 
0.0002 0.5 
 
9.645E-07 
 
Figure 3, D 
Amino-silanized glass and 
amino-PEGylated at pH 5 
0.0007 3 
 
         5.787E-06 
 
Figure 3, E 
Amino-silanized glass and 
amino-PEGylated at pH 10 
0.0003 1 
 
1.929E-06 
 
Figure 3, F 
Table 2. Quantification of amino groups via glutaraldehyde immobilized AP onto etched amino-
silanized and amino-PEGylated carriers. See legend of Table 1 and section experimental methods 
describing the calculation of the detected amino groups.  
 
Sulfo SDTB 
The detected amounts of 4,4'-dimethoxytrityl cations after reaction of sulfo-SDTB with 
amino-silanized glass slides and amino-PEGylated glass slides - using the p-chloro-
anil coupling procedure at pH 10 - were similar. However, a higher amount of amino 
groups was detected by amino-PEGylation at pH 5 for both reagents EDC and p-
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chloro-anil. A similar amount of amino groups is detected after amino-PEGylation at 
pH 10 using EDC.  
 
  
     Amino-
PEGylated 
slides     by  
means of  
 
Amino-
silanized 
slides 
p-chloro-anil 
pH 5 
p-chloro-anil 
pH 10 
EDC/sulfo-
NHS, pH 5 
EDC/sulfo-
NHS, pH 10 
Absorption 
(498nm) 
0.651 1.019 0.72 1.045 0.903 
Concentration of 
sulfo-SDTB 
(µg /slide) 
21.2 37.3 24.2 38.4 32.1 
Calculated amount 
of NH2 [nmol/cm
2] 
15.45 27.24 16.93 28.07 24.90 
Table 3. Detected amount of amino groups on amino-silanized and amino-PEGylated slides by means 
of either EDC/sulfo-NHS or p-chloro-anil at pH 5 or 10 using the standard curve for sulfo-SDTB. All 
coating experiments were done triplicate, the results given are the average amounts of amino groups 
on the solid surface for different coupling methods. The concentration of sulfo-SDTB/slide is calculated 
using the calibration curve of sulfo-SDTB giving the equation for standard function (y = 22.814x + 
0.1685). The surface area of slides was 2.26 cm². 
 
OPA assay 
A very important advantage of OPA is the formation of a fluorescent reaction product 
on the surface of the tested materials. Thus, the OPA method is also applicable for 
visualization of the distribution of amino groups on surfaces. The efficiency of 
aqueous and organic amino-silanization appears similar by staining with OPA 
whereas the TNBS assay demonstrates that the organic solvent deposition method 
for amino-silanization showed higher amounts of amino groups. Thus, for all further 
coatings and experiments the organic solvent deposition method was preferred 
because it is a simpler and faster procedure. 
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A: Organic amino-silanization   B: Aqueous amino-silanization   C: Negative control 
            
Figure 2. Visualizations of the fluorecent molecule OPA after reaction with amino groups after amino-
silanization by A: organic solvent deposition, B: aqueous deposition, C: unsilanized slides (negative 
control). 
 
The introduction of carboxylate groups onto the surface of amino-silanized surfaces 
was tested under different pH conditions (pH 6 and pH 8.4). Several amino groups 
did not react with succinic anhydride at pH 6 and hence they can be detected by 
reaction with OPA, in contrast to pH 8.4, where almost all available amino groups 
have reacted. 
 
A: Succinic anhydride coupling at pH 6  B: Succinic anhydride coupling at pH 8.4  
         
Figure 3. Effect of pH on coupling of succinic anhydride to amino groups. A: pH 6, B: pH 8.4, which is 
preferred because of better reactivity. 
 
The immobilization of bis-amino-PEG or carboxyl-PEG (NH2-PEG-CH3) as negative 
controls was carried out with the cross-linker EDC and with EDC plus sulfo-NHS at 
pH 10. A positive signal can be seen with the bisamino-PEG coated carrier after 
reaction with OPA. Sulfo-NHS is important to increase the reaction efficiency by 
several folds. However, no signal is observable with the carboxyl-PEGylated carrier. 
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A: negative control                             B: EDC cross linker  C: EDC/sulfo-NHS           
          
Figure 4. Reaction of the fluorescent molecule OPA with A: carboxl-PEGylated carrier (negative 
control), B: amino-PEGylated carrier linked only with EDC C: amino-PEGylated carrier linked with EDC 
plus sulfo-NHS. 
 
Experimental Methods 
All used reagents were of analytical grade. The stainless steel was received from 
Goodfellow, Gulsenit from MAGINDAG and the glass powder was a controlled-pore 
glass from Sigma. 
 
Coating 
Etching of stainless steel 316L 
To clean the surface from fatty material, the carriers were washed with isopropanol 
and rinsed several times with dd. H2O. Etching occurs under mild conditions with 3% 
HNO3. After repeated washing with dd. H2O, the steel was soaked for two days in 
water. For successful etching of stainless steel 316L a spot test for Fe3+ was used. A 
Whatman® filter paper was moistened with 5% NaSCN and then dried at room 
temperature (rt). To 1 ml of the supernatant of the 3% HNO3 solution over steel 50 ml 
of 1% H2O2 were added. 5 µl of this solution were dotted onto the Whatman® filter 
paper. The color will turn to red in presence of Fe3+ ions (see supplementary 
materials Figure 5). 
 
Amino-silanization 
For amino-silanization by organic solvent or aqueous deposition, the glass slides 
were cleaned from fatty material with isopropanol and washed several times with dd. 
H2O.  
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Amino-silanization by organic solvent deposition 
The support materials (glass slides or stainless steel 316L) were shaken in a 5% 
(v/v) APTS (Fluka) solution in 95% EtOH at rt for 1h. After 3x of 5min washing with 
95% EtOH, they were incubated over night at 110°C. 
 
Amino-silanization by aqueous deposition 
The support materials were shaken in a 10% (v/v) APTS solution in dd. H2O at 75°C 
for 2h. After 3x of 5min washing with dd. H2O, they were incubated over night at 
110°C. 
 
Coupling of succinic anhydride as a linker 
1 g succinic anhydride (Merck) was suspended in 25 ml of phosphate buffered saline 
(PBS) pH6 (avoid buffers containing primary amino groups such as Tris) and the pH 
adjusted to either pH 6 or 8.4 with 1M NaOH. Even in buffered solutions, the pH 
should be monitored to prevent severe acidification of the reaction solution. This 
solution was added to the amino-silanized carriers and reacted at rt over night to 
assure complete blocking of all amino groups. After washing 3x 5min with buffer and 
3x with dd. H2O, the carrier can be activated with carbodiimides. 
 
EDC combined with sulfo-NHS 
400 mg EDC (Sigma) (0.1M) and sulfo-NHS (Pierce) (final concentration 5mM) were 
dissolved in 50 ml of dd. H2O and the pH was adjusted to 10 with 1M NaOH. The 
carboxylated carriers prepared with succinic anhydride were incubated in this 
solution for about 1 to 2 h (maximum) at rt under gentle shaking and thereafter 
washed several times with dd. H2O. 
 
p-Chloro-anil as a linker 
The amino-silanized carriers were washed 3x 5min with toluene under shaking and 
thereafter incubated in a 1% (w/v) solution of p-chloro-anil (Fluka) in toluene for 1h 
under gentle shaking. After washing 2x with toluene, acetone and dd. H2O the carrier 
is ready for amino-PEGylation. 
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(Amino-)PEGylation 
1 g O,O′-bis(3-aminopropyl)polyethylene glycol (bis-amino-PEG, MW ~1500) (Fluka) 
was dissolved in 50 ml carbonate-bicarbonate buffer, pH 10 or in 50 ml citric acid-
sodium citrate buffer, pH 5. The slides prepared with EDC plus sulfo-NHS or with p-
chloro-anil respectively were shaken in this solution over night and afterwards 
washed several times with dd. H2O. 
 
Analytical methods for detection and quantification of amino groups 
TNBS assay 
A 0.01% (w/v) TNBS–solution (Sigma) was prepared freshly by dilution of 20 µl 5% 
(w/v) stock solution (Sigma) with 0.1 M sodium bicarbonate buffer, pH 8.4. The 
(amino group containing) slides were shaken for 2 h at 37°C in this solution and 
afterwards 1 ml 10% SDS and 0.5 ml 1 M HCl added to each sample. 
 
Kaiser assay 
Solution A: Phenol (8 g) was dissolved in 2 ml EtOH. Solution B: KCN solution (10 
mM) in dd. H2O: 200 µl were diluted to a volume of 10 ml with pyridine. Solution C: 
50 mg ninhydrin (Merck) was diluted to 1 g with EtOH and dissolved. Then 500 µl of 
each solution was added to a test tube containing the sample and boiled for 5 min in 
a water bath. 
 
Enzymatic assay 
For immobilization of AP, the amino-silanized carriers were shaken gently in 3 ml 
2.5% glutaraldehyde (Fluka) solution in 0.05M PBS buffer pH 7 for 1h and washed 
several times with ice water. 40 µl of AP solution in 300 µl 0.05M PBS pH 7 were 
dissolved and 100 µl of this solution added to each carrier and incubated over night 
in a humid chamber at rt. After washing the carriers with buffer (3x 5 min), the AP-
activity can be measured as followes;  1) the carrier was placed in a disposal cuvette 
and filled up to 4 ml with 0.1M Tris buffered saline containing 0.15 M NaCl and 5 mM 
MgCl2, pH 9.5 (TBS);  The reaction was initiated by addition of 10 µl p-NPP (Koch 
Light LTD) solution (50 mg/ml dd. H2O) and the absorption measured against a blank 
at 405nm every 30 sec. The cuvette content was mixed with a pasteur pipette before 
every measurement. 
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For generation of a calibration curve, a stock solution of AP with a concentration of 
4.5 µg/ml in 0.1M TBS was prepared. Different aliquots (1.12, 2.24 and 4.49 µl) were 
added in a disposal cuvette and filled up to 4 ml with TBS and the reaction was 
initiated and mnoitored as described above.  
The calibration curve was calculated by measuring the extinction of several 
concentrations of AP. The definite concentration of each AP and its slopes are used 
to give the equation for standard function (y = 0.0002x + 0.0001). The slope is 
proportional to the concentration of the enzyme, which should be somewhat equal to 
the number of amino groups on the surface of the carrier. Using the standard 
equation and the slope of each sample, the amount of immobilized amino groups can 
be calculated. 
 
Sulfo-SDTP assay 
A 2.33 mg/ml sulfo-SDTB (Pierce) stock solution (42 mg SDTB dissolved in 2 ml 
DMF and 16 ml 50 mM sodium bicarbonate buffer) was prepared freshly. For 
calibration, the stock solution was diluted several times with 35% (v/v) perchloric acid 
to concentrations from 7 to 46.7 µg/ml and the absorbance was measured after 10 
min at 498 nm against a blank of 35% perchloric acid. For the detection of amino 
groups on solid surfaces, the carriers were soaked in 1 ml stock solution for 10 min, 
thereafter rinsed first with 1 ml dd. H2O, and then soaked in 10 ml dd. H2O to remove 
excess of sulfo-SDTB. 1 ml 35% perchloric acid was added to each carrier and 
reacted for 10 min. The observed orange color indicated the release of 4,4'-
dimethoxytrityl cations. The 1 ml solution was then transferred to a cuvette and the 
absorbance measured as described above. 
 
OPA Test 
A solution of 1 ml 50 mM borate buffer, pH 9.2, 250 µl OPA (Fluka) (20mg/ml) and 
250 µl 2-mercaptoethanol (Fluka) were added to the amino groups containing carrier 
and reacted for 1 h at rt. After washing several times with ethanol, the fluorescent 
marking of amines by OPA was observed under the fluorescence microscope 
Olympus BX41 using an extinction wavelength of 360 nm and an emission 
wavelength of 436 nm. The photos were taken by ColorView Soft Imaging System 
(Olympus Soft Imaging Solutions, Münster, Germany) with a magnification of 10x 
(N.A 0.25) and edited with the Cell^D life science documentation software. 
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Supplementary Materials and Protocols 
 
Etching of stainless steel 316L  
Chemical etching with acids was carried out to activate stainless steel 316L 
introducing hydroxyl groups for e.g. amino-silanization. Figure 5 illustrates the fast 
spot test for detection of iron ions in the acids (3% HNO3 and 0.5M HCl), which 
indicates successful etching of 316L stainless steel by showing  red color due to  [Fe 
(SCN)6]
3-. Dotting acid solution only (negative control), shows no color change. Since 
both acids show a positive reaction, etching with 3% HNO3 was used in further 
immobilization procedures. 
               3% HNO3     0.5 M HCl 
 
 
Figure 5. Spot test for the detection of iron ions after etching 316 L with 3% HNO3 or 0.5M HCl. No 
color is detected with the negative control.  
 
Quantification of amino groups on carriers 
The Kaiser-test is of limited value for the detection of amino groups on most carriers 
and amino-silanized glass powder (see publication). Therefore, other detection 
assays were tested such as the TNBS-test, an enzymatic assay, using AP, a test 
using OPA and sulfo-SDTB. 
. 
TNBS-Test 
The introduction of reactive chemical groups (amino-groups) onto carriers after 
amino-silanization was also tested using a TNBS-test. After addition of 1 ml 10% 
SDS and 0.5 ml 1 M HCl to organic and aqueous amino-silanized 316 L stainless 
steel and glass carriers, a light yellow color is observed only for the  organic amino-
silanized foil.  
Tested carriers:  
 Glass-slides after organic amino-silanization. 
 Glass-slides after aqueous amino-silanization.  
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 Aqueous and organic amino-silanized glass-slides after amino-PEGylation 
using EDC- crosslinker and carbonate-bicarbonate buffer, pH 10. 
 Aqueous and organic amino-silanized glass-slides after amino-PEGylation 
using EDC-crosslinker and citric acid-sodium citrate buffer, pH 5.  
A faint yellow color was observed only on the carriers after organic amino- 
silanization, thus indicating the higher efficiency of organic amino-silanization. 
Therefore, it was chosen for further immobilizations. For the detection of free amino 
groups after amino-PEGylation, the TNBS test is not sensitive enough. Therefore 
other sensitive alternative tests as e.g. the enzymatic assay with AP were developed 
and used. 
 
Enzymatic assay for the detection of amino groups, using AP 
An enzymatic assay for the detection of amino groups was developed. Alkaline 
phosphatase was coupled to the amino groups on the carriers by means of 
glutaraldehyde cross-linking under carefully controlled conditions. Higher amounts of 
amino groups result in also higher amounts of bound AP, which can be quantified 
with p-NPP as a substrate. Table 4 shows the results for amino-silanized and amino-
PEGylated ceramics (ZrO2) carriers.  
 
Sample 
description 
Slope 
Amount of 
coupled AP 
(ng/carrier) 
Calculated 
amount of NH2 
[nmol/cm
2
] 
Appendix 
(1.2) 
Amino- 
silanized 
ceramics 
0.0002 0.5 9.259E-06 Figure 2F 
Amino- 
PEGylated  
ceramics at pH 
10 
0.0002 0.5 9.259E-06 Figure 2H 
Amino- 
PEGylated  
ceramics at pH 
5 
0.0002 0.5 9.259E-06 Figure 2G 
Table 4.  Quantification of AP immobilized with glutaraldehyde onto amino-silanized and amino-
PEGylated ceramics (ZrO2) carriers (surface of the ceramics 0.3 cm². See legend of Table 1 
describing the calculation of the detected amino groups.  
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The results for 316 L stainless steel and glass are shown in Table 2 and for ceramics 
carriers (Table 4) after amino-PEGylation using EDC for crosslinking. The bis-amino-
PEG-polymer immobilized onto an amino-silanized carrier contains free terminal 
amino groups, which can be used to couple AP by using GA (glutaraldehyde). The 
amount of immobilized AP on amino-silanized and amino-PEGylated ceramics was 
similar, but higher than observed with glass and 316 L stainless steel.  
After immobilization of bis-amino PEG (NH2-PEG-NH2) at different pH (5 or 10) onto 
316 L stainless steel carriers which previously activated through different etching 
methods then amino-silanized give almost identical amount of detected amino-
groups.   
After amino-PEGylation, the amount of immobilized AP is 6 times less (0.5 ng) 
compared to AP immobilization onto mere amino-silanized carriers (2.5-3 ng) (Tables 
1, 2 and 4). However the free amino groups detected on PEGylated glass at pH 5 are 
five times higher than on 316L stainless steel and 4 fold higher compared to 
PEGylated glass at pH 10. This may be due to the fact that the conformation of 
immobilized polymers such as NH2-PEG-NH2 (MW 1500) is such that the terminal 
free amino group can be hidden. In acidic buffer the terminal free amino groups of 
NH2-PEG-NH2 (MW 1500) are protonated and point outward to the hydrophilic 
surrounding because of their electrical charge. Alternatively, both amino groups 
might react with the solid support. This effect should be reduced by using a large 
excess of NH2-PEG-NH2 for coupling.  
The enzymatic assay using AP shows a similar amount of amino groups after amino-
PEGylation on 316 L stainless steel at the different pH conditions (5 or 10). However 
in the case of glass carriers the enzymatic assay using AP was promising, we 
observed the highest amount of immobilized amino groups.  
 
Sulfo- SDTB 
The purpose of the sulfo-SDTB colorimetric assay was to measure quantitatively the 
available reactive amino groups on the surface of amino-silanized and amino-
PEGylated carriers. Amino-PEGylation was carried out by means of either 
EDC/sulfo-NHS or p-chloro-anil. The coupling of NH2-PEG-NH2 was carried out at 
pH 5 as well as pH 10. The amount of reactive amino groups can be determined by 
means of a standard curve of sulfo-SDTB (Figure 6). The amount of 4,4´-
dimethoxytrityl cations detected corresponds to the quantitative measurement of 
Chapter 1 
 72 
reactive amino groups. The detected amount of 4, 4´-dimethoxytrityl cations from 
amino-silanized slides and amino-PEGylated slides using p-chloro-anil at pH 10 was 
similar. However a higher amount of detectable amino groups was observed for 
PEGylated slides at pH 5 for both activators (EDC/sulfo-NHS or p-chloro-anil) and a 
similar result was shown for amino-PEGylation at pH 10 using EDC/sulfo-NHS 
activation (see publication Table 3).   
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Figure 6. Standard curve of sulfo-SDTB (mg/ml). 
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 2. Biocompatible coating of implant materials  
Binding of linkers suitable for coupling to PEG or proteins 
To achieve biocompatibility of implant materials they need to be coated with PEG. 
The choice of procedure to couple molecules to the amino-groups on the material 
surface depends on the functional groups of the PEG derivative. For immobilization 
of bi-functional bis-amino-PEG (NH2-PEG-NH2), succinic anhydride is coupled first to 
the aminosilane and thereafter activated with EDC (Scheme 11) or EDC/sulfo-NHS 
(Scheme 4). Another method is applied for p-chloro-anil linkers (Scheme 5). Several 
proteins such as alkaline phosphatase or lactate dehydrogenase can be immobilized 
onto amino-silanized carriers using glutaraldehyde (Scheme 6) as a crosslinker 
(Hardy P. et al. 1969).   
 
Activation of Carboxylate Groups via EDC  
The carbodiimide EDC ((1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
hydrochloride) is often used for coupling carboxylates to amines in bio conjugate 
procedures (Hoare D. and Koshland D. 1966; Chu B. et al. 1986; Ghosh S. et al. 
1990). Most biological substances are water soluble and so are EDC and its reaction 
by-products. There is no need to use organic solvents or complicated buffer systems. 
EDC reacts with carboxylate groups to a highly reactive O-acylisourea (Schema 11). 
This intermediate reacts further with amino groups of NH2-PEG-NH2 by forming an 
amide bond. However, oligomerisation occurs if the molecule to be activated contains 
both a carboxylate and an amino group. In such systems EDC should not be used, 
and buffers containing carboxylates or free amines such as Tris or glycine have to be 
avoided. The reaction should be performed in an aqueous buffer system, preferably 
at pH 5. But even at pH 10 positive results are obtained (Pittner F. 2000). 
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Scheme 11. The terminal carboxylate groups (created as shown in Scheme 3) react with EDC and 
form the highly reactive O-acylisourea. This intermediate reacts with primary amines of NH2-PEG-NH2 
by forming an amide bond.  
 
Procedure: 
400 mg EDC was dissolved in 50 ml dd. H2O and pH adjusted to 10 with 1M NaOH. 
The carboxylated carrier - prepared with succinic anhydride - was incubated in EDC 
solution for 1-2 h (not longer than 2h) at room temperature under gentle shaking. The 
activated carrier was washed several times with dd. H2O. The carrier can 
subsequently be reacted with NH2-PEG-NH2. 
 
Coupling of Glutaraldehyde as a linker  
Glutaraldehyde is a widely used homobifunctional cross-linker. The reactive aldehyde 
groups of glutaraldehyde form Schiff bases with proteins and other molecules 
containing amino groups (Hardy P. et al. 1969). Crosslinking via glutaraldehyde is 
difficult to reproduce due to variability between different glutaraldehyde solutions. 
Fresh glutaraldehyde often will not yield the same results as aged solutions (Pittner 
F. 2002). One problem stems from different degrees of “aging” by polymerization 
based on aldol condensation. Glutaraldehyde is an efficient crosslinker for proteins, 
but this is also the reason for its toxicity and fixative properties when incorporated 
into living cells. Reacting different amino groups in a predictable way is difficult, as 
both aldehyde groups of the same molecule can react with the first reagent, resulting 
in loop structures. This can be overcome by using a large excess of glutaraldehyde in 
the first reaction step. As in our case solid surfaces containing amino groups are 
reacted, the excess of the soluble glutaraldehyde can be rinsed off, increasing the 
possibility of binding another amino-group containing reagent (in our case AP) in the 
second step.  
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Scheme 12. Formation of Schiff bases through reaction of glutaraldehyde with primary amines. As is 
evident many byproducts may be formed. The reversible imine bonds may then be reduced selectively 
to the stable amines by means of borohydrides as sodium borohydride or sodium cyanoborohydride. 
 
The immobilization of proteins such as AP (alkaline phosphatase) etc. on amino-
silanized carriers is illustrated in Scheme 13.  
 
 
 
Scheme 13. Glutaraldehyde as a crosslinker for binding of proteins 
 
Procedure: 
The amino-silanized carriers were activated in a 2.5 % glutaraldehyde solution (in 
0.1M sodium phosphate, 0.15 M NaCl, pH 7.2) for one hour at room temperature 
under shaking. The carriers were washed with ice cold dd. H2O. The enzyme AP (9 
mg/ml) was diluted 1:10 in 0.1M sodium phosphate with 0.15M NaCl, pH 7.2 and 
100µl of diluted AP added to each activated carrier. The reaction was carried out 
over night at 4°C. The carriers were washed with 0.1 M PBS and stored in 0.05M 
saline solution at 4°C. 
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PEGylation  
Amino-PEGylation  
Amino-PEGylation using NH2-PEG-NH2 can be performed either under alkaline or 
acidic conditions. Both methods were tried and, two different buffer systems (0.1M 
carbonate-bicarbonate buffer, pH 10 and 0.1M citric acid-sodium citrate buffer, pH 5) 
were used respectively.  
 
 
 
Scheme 14. Amino-PEGylation via EDC activation of the succinylated carrier 
 
Procedure: 
1 g O,O′-bis (3-aminopropyl) polyethylene glycol (NH2-PEG-NH2, MW 1500) was 
dissolved in 50 ml of 0.1M carbonate-bicarbonate buffer, pH 10 or 0.1M citric acid-
sodium citrate buffer, pH 5 respectively. The activated carrier [either with EDC 
(Scheme 14), EDC/Sulfo-NHS (Scheme 4) or p-chloro-anil (Scheme 5)] was 
incubated over night in acidic or alkaline buffer solutions respectively. Each 
PEGylated carrier was washed 3 times for 5 min under shaking in the respective 
buffers (depending on used buffer for immobilization) to remove unreacted PEG, and 
subsequently washed several times with dd. H2O.  
 
Carboxyl-PEGylation 
Carboxyl-PEGylation using methoxy-carboxyl-PEG (MW 2000) is carried out on 
organic amino-silanized carriers using EDC at pH10. 0,887g Methoxy-carboxyl PEG, 
as synthesized according to Rumplayr K. 2006 (see appendix) was dissolved in 25 
ml 0.1M carbonate-bicarbonate buffer, pH 10. 400 mg EDC (2 mM) was added to 
dissolved methoxy-carboxyl PEG and stirred for 30 min at room temperature. This 
solution was added to organic amino-silanized slides and incubated under shaking 
over night. The carboxyl-PEGylated carrier was washed 3 times with 0.1M carbonate-
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bicarbonate buffer, pH 10 for 5 min under shaking to remove unreacted PEG, 
afterwards washed several times with dd. H2O. 
 
Detection of amino groups 
Analytical methods are available for amino group quantification, but sometimes 
problems arise for the detection of very small amounts of amino groups on solid 
supports. The Kaiser test was sufficient for the detection of amino groups on carriers 
such as Gulsenit, however it had limitations in sensitivity when used for other 
carriers, such as glass, stainless steel 316L, and ceramics, because of the much 
smaller –NH2 content. Other detection methods were investigated such as TNBS-
test, OPA, an enzymatic assay using AP as well as sulfo-SDTB.  The details of these 
methods were described in the publication above. 
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Cleavage of antibodies using immobilized dihydrolipoamide and 
anchoring of antibody fragments onto biocompatible-coated carrier 
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Specific Aim 2:  To introduce binding sites for degradable, drug loaded 
nanoparticles into the biocompatible coating.  
 
In the course of this work it was necessary to anchor a suitable receptor system to 
bind drug containing biodegradable nanoparticles to mediate local pharmacological 
activity, the so called active coating. One of the challenges we had to address in this 
thesis was to find suitable biorecognitive systems for binding of the drug containing 
particles. The design of the receptor is of great importance to avoid and/or eliminate 
any bio- or chemorecognitive interactions with other components circulating in the 
blood. Furthermore, the binding between the receptor and the nanoparticles has to 
be strong enough to keep them tightly bound during their lifetime, but on the other 
hand allow reloading after final degradation. Antibodies (Abs) against the 
biocompatible nanoparticles were bound to the implant surface as biorecognitive site 
for reloading of the particles. As Abs against the drug carriers are very expensive in 
case of chitosan nanoparticles (CS-NPs, see Chapter 7), or only available in 
extremely small amounts for PLGA nanoparticles, binding conditions were optimized 
with HRP-IgG. 
 
The Ab molecules were selectively cleaved with a reducing agent such as 2-MEA (2-
mercaptoethanolamine), or the newly optimized method developed during this thesis 
using dihydrolipoamide immobilized to amino-silanized Gulsenit to create two Fab` 
fragments. The determination of Fab´ fragments immobilized to amino-silanized or 
amino-PEGylated glass carriers was shown using fluorescent staining with OPA–
Test (o-phthaldialdehyde). This newly optimized method saves time, is economical 
and has additional advantages compared to the commonly used MEA method 
(described in Chapter 5): There is no need to remove the reducing agent from the 
sample solution, thus avoiding the time consuming gel filtration chromatography 
always prone to re-oxidation of sulfhydryls during this step. The reagent 
dihydrolipoamide can be easily removed from the sample solution via centrifugation 
and no contaminating by-products are produced. Furthermore, after regeneration of 
the immobilizate with Na2S2O4 the reaction can be repeated several times with the 
same immobilizate. 
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Cleaving of antibody using dihydrolipoamide and anchoring of 
antibody fragment onto biocompatible coated carrier 
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Abstract 
 This study demonstrates the possibility of anchoring from antibody fragment onto 
carrier surface with biocompatible coating. The antibody molecule is cleaved to two 
antibody fragment with immobilized dihydrolipoamide. The detection of the 
biocompatible coating and the immobilization of antibody fragment is shown using 
fluorescence microscopy. The biocompatibility coating of 316L stainless steel carrier 
is determined in cell culture with Caco-2 cells. This immobilization of antibody 
fragment can serve in further aspect as a suitable specific binding site for drug 
delivery systems.  
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Introduction 
The primary objective of this study is to develop carriers containing bio-compatible 
coatings and binding sites for bio-degradable nano- or micro-particles that may serve 
as reloadable drug delivery carriers by medical implant materials. Binding reaction 
/interactions for reloadable systems need to be sufficiently strong to keep the drug 
releasing nano- or micro-particles tightly bound for a certain period of time, but 
should also be weak enough to allow reloading after the gradual decomposition of 
the particles. In this study the specific binding site is chosen as an antibody fragment. 
As antibodies (Abs) against the drug carriers (biocompatible and biodegradable 
polymer) are not available, binding conditions were demonstrated with HRP-antibody 
(Ab). The cleavage of Abs to create Fab´ fragments was carried out using 
immobilized dihydrolipoamide. The method of reduction of disulfides with 
dihydrolipoamide immobilized onto a gel-material was used first by Gorecki and 
Patchornick in 1973. In our approach, lipoic acid (6, 8-dithiooctanoic acid) was 
immobilized to amino-silanized Gulsenit via the carboxylic acid group by means of 
the water soluble carbodiimide EDC. The efficiency of the immobilization was 
monitored using the Kaiser-test for free amino groups (Kaiser E. et al. 1970). 
Afterwards the cyclic disulfide of immobilized lipoic acid was reduced to thiols using 
sodium dithionite (Na2S2O4) as a reducing agent (Scheme 1) 
 
 
 
 
Scheme 1 
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These thiols are able to cleave disulfide bridges of Abs creating two Fab` fragments 
with free sulfhydryl groups. This method is time saving and economical. The reagent 
dihydrolipoamide can be easily removed from the sample solution via centrifugation 
and the Fab´ fragments are free of contaminating by-products. The efficiency of 
cleavage of Abs is shown by a positive Ellman‟s assay (Ellman C. et al. 1959). 
Furthermore, after regeneration of the immobilizate with Na2S2O4, the reaction can 
be repeated several times with the same immobilizate. 
Medical implant materials should be biocompatible. For this purpose a biocompatible 
coating or so called “passive coating” for medical implant materials is developed 
using polyethyleneglycol (PEG) derivatives. PEG is biocompatible, can act as a 
barrier and is widely used for this purpose due to its hydrophilic and also hydrophobic 
character (Ratner B.D. et al. 2004). In the course of this study, the previously cleaved 
antibody-fragments are anchored in the PEG-coating on the surface of the carrier 
material. The anchor of a suitable receptor system (Ab fragment against the polymer 
of biodegradable nano- or micro-particles) to bind drug containing biodegradable 
nano- or micro-particles can serve to mediate local pharmacological activity, the so 
called active coating. The nano- or micro-particles can be injected into patients after 
implantation. The nano- or micro-particles circulating in blood should bind specifically 
to their receptor (Ab fragment) on the biocompatibly coated implant surface. The 
particles can then be degraded either by hydrolysis or by means of enzymes 
circulating in the bloodstream while releasing the drugs. After complete 
biodegradation, the receptor system is then free again for reloading with new 
particles containing the respective drugs, making this a completely an attractive 
means of drug administration on medical implants. Such coatings can be the basis 
for a number of applications that require controlled, local drug delivery at the 
interface between an implant and healthy tissue. As nano- or micro-particles can be 
loaded with different drugs, this technology allows easy adjustment to patient-specific 
medication needs as well as the administration of unstable compounds or drugs that 
are difficult to dose. Several studies have already shown the possibility to load and 
release different drugs nano- or micro-particles consisting of biodegradable and 
biocompatible polymers (Wolf M. et al. 2003, Alonso J.M. et al. 2008, Liu Y. et al. 
2010).  
 
 
Chapter 2 
 84 
Results and Discussion 
The surface of the carriers (316L stainless steel, silica glass) needs to be previously 
activated via chemical etching followed by amino-silanization in order to immobilize 
the biocompatible NH2-PEG-NH2 polymer (amino-PEGylation). Amino-PEGylation 
was carried out using EDC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide) cross 
linker. For this purpose succinic anhydride is coupled first to the amino-silanized 
carrier and thereafter activated with EDC/sulfo-NHS (N-hydroxysulfosuccinimide) to 
immobilize NH2-PEG-NH2 (Scheme 2).  
 
 
Scheme 2 
 
Fab´ fragments of polyclonal anti-peroxidase-Ab are immobilized onto amino-
PEGylated carriers. The immobilization of Fab´ fragments onto amino-silanized and 
amino-PEGylated carriers is shown by OPA (o-phtaldialdehyde). OPA reacts with 
amino groups in the presence of thiol-containing molecules like ßME (ß-
mercaptoethanol) generating a fluorescent product with an excitation wavelength of 
360 nm and an emission wavelength of 455 nm (Scheme 3).  
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In this approach, OPA is used as a crosslinker between amino groups on the carrier 
and sulfhydryl groups on the Fab´ fragments. For this purpose Fab´ fragments are 
used instead of ßME which is used normally for detection of amino groups by means 
of OPA (Scheme 4), thus allowing simultaneous detection of positive Ab cleavage as 
well as its immobilization onto amino-silanized or amino-PEGylated slides.   
 
 
Scheme 4 
 
The chemical setup concerning biocompatible coating was shown in 316L stainless-
steel and zirconia (ceramics) as widely used medical implant materials. Analytical 
proofs of principle on these materials concerning Ab fragment immobilization are 
difficult, as currently available optical method (OPA assay) could not be applied 
because of quenching effects of steel and very uneven surface structure of used 
zirconia. Therefore specific binding of the antibody fragments to the carrier surface 
was tested by means of fluorescence microscopy on silicate glass precoated with the 
same chemical procedures as steel and zirconia. However, the biocompatibility of 
amino-PEGylated 316L stain-less steel is tested in vitro with Caco 2 cells.   
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Detection of amino-PEGylation and immobilization of Fab fragment by means 
of OPA-assay 
The cleavage of HRP-Abs was carried out by means of dihydrolipoamide immobilized 
on amino-silanized Gulsenit. The efficiency of lipoic acid immobilization onto organic 
amino-silanized Gulsenit is shown by means of the Kaiser-test for amino group 
detection. The intensity of the blue color is generated by reaction of ninhydrin with 
free amino groups. The efficiency of cleavage of Abs by means of immobilized 
dihydrolipoamide is observed by a positive Ellman‟s assay. A positive signal of 
Ellman's assay is observed in the presence of sulfhydryl groups of Fab´fragments 
and no signal is detected with amino-silanized Gulsenit including lipoamide due to 
the absence of free thiol groups. OPA is used to crosslink the sulfhydryl of cleaved 
Abs to amino groups of NH2-PEG-NH2 on the surface of slides. This approach is very 
efficient as it allows immobilization onto amino-PEGylated slides and at the same 
time the detection of successful Ab cleavage. Anti peroxidase-IgG was cleaved with 
immobilized dihydrolipoamide to create two Fab` fragments containing free sulfhydryl 
groups in the hinge region. OPA crosslinks these Fab` fragments with amino-groups 
on amino-PEGylated slides. The immobilization of cleaved Abs to amino-PEGylated 
carriers is shown in Figure 1. 
 
 
Figure 1. HRP-IgG Fab fragments immobilized by means of OPA onto silicate glass slides A: activated 
via EDC/sulfo-NHS and amino-PEGylated at pH 5, B: activated via EDC/sulfo-NHS (negative control).  
 
Biocompatibility test of amino-PEGylated 316 L stainless steel using Caco2 
cells 
The biocompatibility of the plain and amino-PEG coated stainless steel was 
evaluated by cell proliferation studies, two and three days post seeding. Proliferation 
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revealed that both amino-PEG coated surfaces displayed tremendous impact on the 
proliferative activity of Caco-2 cells as shown in Figure 2.  
 
 
 
Figure 2. Proliferative activity of Caco-2 cells on day 2 and 3 post seeding for bis-amino-PEGylated 
stainless steel coated at pH 5 and pH 10. Reference 1 refers to proliferation on uncoated glass slides 
and Reference 2 is proliferation on plain high grade steel as growth support (n=6, mean ± SD) 
 
A glass slide was used as reference substrate for cell proliferative activity and 
resulted a signal of 0.1881 AU (absorbance units) on day 2 and 0.3722 AU on day 3 
post seeding, respectively. Plain high grade steel presented itself as possible growth 
substrate, with no toxicity. However, generally it resulted in lower cell proliferation 
0.1516 AU on day 2 and 0.2179 AU and day 3 postseeding, which indicated a need 
for some improvements. These improvements were made by using amino-
PEGylation. Both amino-PEG coated substrates represented suitable growth 
supports for Caco-2 cells with 2-fold proliferation compared to glass as a reference 
on day 2 post seeding. On day 3, these results are slightly different, whereas amino-
PEG coating at pH 5 resulted in further constant cell growth, and 1.5-fold higher 
proliferation, the amino-PEG coating at pH 10 revealed lower (by two fold) 
proliferation then on day 2 compared to a glass reference on the same day. 
The BrdU proliferation assay provided insight into the biocompatibility of amino-
PEGylated high grade steel. Glass slides are commonly used as cell growth support 
(Mahelkova G. et al. 2009). On the second day, the initial adhesion and proliferation 
activity between glass and plain high grade steel is comparable. Coating with PEG is 
commonly known to reduce protein adsorption and cell adhesion (Johnson P.A. et al. 
2009). On the contrary, amino-PEGylated stainless steel showed improved cell 
growth. The initial cell adhesion is highe; the cells show a stable attachment and 
keep proliferating at the same rate as on glass slides. These results suggested 
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amino-PEGylation at pH 5 as the best combination for biocompatible coating. 
Furthermore, this study confirmed amino-PEGylated high grade steel as 
biocompatible substrate that induces stable cell attachment and provides confident 
further cell growth. 
 
Experimental Methods 
Organic amino-silanization of inorganic carriers 
The inorganic carriers amino-silanized in this study were stainless steel 316L 
(Goodfellow, Germany), silicate glass slides (Ø12 mm, Assistant, Austria), zirconia 
(ZrO2-TZP-A BiO-HIP, Z-Systems AG) and Gulsenit (MAGINDAG, Austria). Gulsenit 
is an active magnesium silicate mineral having a particle size less than 10 µm and a 
density of about 3.2 kg/l. Stainless steel 316L and silicate glass need to be 
chemically etched before amino-silanization to introduce hydroxyl groups necessary 
for amino-silanization. Gulsenit and zirconia were silanized directly. Stainless steel 
316L (12% Ni, 17% Cr, 2.2% Mo, 67% Fe, 1% Cu, and 0.25% N) was etched with 
3% HNO3 for 10 min. Silicate glass slides may be etched with 3% HNO3 for 10 min or 
1M NaOH for 30 min. The carriers were washed several times with dd. H2O and then 
soaked for at least two days in dd. H2O under gentle shaking. Replacement of dd. 
H2O is highly recommended several times to enhance hydroxyl group formation. The 
surface of carriers is then modified by amino-silanization with 3-aminopropyl 
triethoxysilane (Pittner F. 2000) in order to immobilize NH2-PEG-NH2. The used 
carriers were covered with freshly prepared 5% (v/v) (3-aminopropyl) triethoxysilane 
solution (APTS, Sigma, Austria) in 95% EtOH and reacted for one hour under gentle 
shaking at room temperature. The carrier was washed with 95% (v/v) EtOH 3 times 
for 5 min under gentle shaking and incubated at 110°C over night. 
 
Binding of succinic anhydride to the amino-silanized surface 
Succinic anhydride is applied to introduce carboxylate groups onto the surface of 
amino-silanized material: 1 g of succinic anhydride (Merck, Austria) was suspended 
in 25 ml PBS buffer pH 8.4. The pH was monitored and adjusted to 8.4 with 1M 
NaOH to prevent severe acidification of the reaction solution, which could also 
damage the molecule to be coupled in the further step. This solution was added to 
the amino-silanized carrier and reacted at room temperature over night to assure 
complete blocking of all amino groups (control the pH over the first few hours of the 
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reaction). The carrier was then washed 3 times for 5 min with buffer followed 3 times 
with dd. H2O. 
 
EDC combined with sulfo-NHS 
0.1mM EDC (Sigma, Austria) and Sulfo-NHS (Pierce, Switzerland) in a final 
concentration of 5 mM were dissolved in 50 ml dd. H2O and the pH adjusted to 10 
with 1M NaOH. The carboxylated carrier prepared with succinic anhydride was 
incubated in this solution for about 1 to 2 h (maximum) at room temperature under 
gentle shaking. The activated carrier was washed several times with dd. H2O. 
 
Amino-PEGylation 
1 g O,O′-bis (3-aminopropyl) polyethylene glycol (NH2-PEG-NH2, MW 1500, Fluka, 
Austria) was dissolved in 50 ml of 0.1M citric acid-sodium citrate buffer pH 5 or 50 ml 
of 0.1M carbonate-bicarbonate buffer pH 10 respectively.  The carrier, activated with 
EDC/Sulfo-NHS was incubated in the above prepared solutions separately at least 
overnight. Each amino-PEGylated carrier was washed 3 times for 5 min under 
shaking with the buffer to remove unreacted PEG and then washed several times 
with dd. H2O.  
 
Cleavage of disulfide bonds in the hinge region of antibodies with the help of 
immobilized dihydrolipoamide  
To immobilize lipoic acid onto Gulsenit, 40 mg lipoic acid (Sigma) was dissolved in 20 
ml EtOH and 50 mg EDC was dissolved in 10 ml EtOH. Dissolved lipoic acid and 
EDC were added to 5 g carrier (amino-silanized Gulsenit) and incubated overnight at 
room temperature under stirring. The carrier was rinsed 3 times with dd. H2O then 3 
times with EtOH; using a suction funnel, pore size 4 to remove solvent from carrier 
after every rinse. The Ellman‟s test was used to ensure that there wer no remaining 
free-SH groups. The efficiency of immobilization is determined with the Kaiser-test, 
which detected fewer amino groups in the immobilizate than with amino-silanized 
Gulsenit. The lipoamide bound to the carrier is reduced to dihydrolipoamide as 
following: 20 ml Na2S2O4-solution (0.16 g/ ml dd. H2O) was added to 5g of the carrier 
containing immobilized lipoic acid and reacted for 30 min at room temperature under 
shaking. The carrier was rinsed two times with dd. H2O followed by two times with 
EtOH using a suction funnel, pore size 4 to remove washing solutions from the 
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carrier after every rinse. The carrier was dried at room temperature. The successful 
reaction was detected by a positive Ellman's test for free –SH groups. The carrier 
was stored in a sealed vessel at room temperature. For cleavage of Abs with the help 
of immobilized dihydrolipoamide 1 ml 0.1M PBS, pH 8 was added to 0.5g 
dihydrolipoamide immobilizate followed by 2 µl Ab (e.g. pc anti-peroxidase Ab, 41mg/ 
ml). The splitting reaction of the Ab was performed for 30 min under shaking at room 
temperature. The supernatant containing split Abs was isolated from traces of carrier 
by short centrifugation. 50 µl of Ellman's reagent was added to 100 µl of the 
centrifuged supernatant. If the test is positive, the rest of supernatant were then used 
for further experiments. 50 µl of Ellman's reagent was added to about 60 mg carrier. 
The test should give no color change. For regeneration of the carrier it is reduced 
with Na2S2O4 (Sigma) as described above. 
 
Ellman’s test  
The proof of the immobilization of lipoic acid onto the carrier is given by Ellman's test. 
50 µl Ellman's reagent (DTNB (5, 5´-dithio-bis-(2-nitrobenzoic acid), Pierce) in a 
concentration of 4 mg/ml in 1 ml 0.1M PBS pH 8) was added to about 60 mg of 
carrier containing either immobilized lipoic acid or dihydrolipoamide (after reduction) 
respectively. Ellman's reagent and carrier were mixed gently using a yellow pipette-
tip avoiding air bubbles. It is recommended to carry out the test in white 
microtiterplates to facilitate visualization of color difference between samples and 
Ellman's reagent.  
 
Immobilization of cleaved antibody onto silanized or amino-PEGylaed carrier 
via OPA 
OPA (250 µl, 20 mg/ ml, Fluka) was added to 1 ml 50 mM borate buffer pH 9.2 and 
500 µl cleaved antibodies (via immobilized dihydrolipoamide). This mixture was 
added onto the carrier containing free amino groups and reacted for 1 h at room 
temperature then washed with EtOH. The fluorescent product on the carrier was 
visualized under the fluorescence microscope Olympus BX41 using an excitation 
wavelength of 360 nm and an emission wavelength of 436 nm. The pictures were 
taken by Color View [Soft Imaging System (Olympus Soft Imaging Solutions, 
Münster, Germany)] at 10x magnification and edited with the Cell^D life science 
documentation software. 
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Biocompatibility test of amino-PEGylated 316 L stainless steel using Caco2 
cells 
The BrdU cell proliferation ELISA test kit was obtained from Roche diagnostics 
GmbH, Vienna (Austria). All other chemicals were of analytical grade. 
 
Cell culture 
Caco-2 cells, human epithelial colorectal adeno carcinoma, were obtained from 
DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, 
Germany). The cells (passage number 37) were grown in RPMI-1640 cell culture 
medium containing 4 mmol L-glutamine,10% fetal calf serum and 150 µg/ml 
gentamycine in a humidified atmosphere of 5% CO2 and 95% air at 37°C. Cells were 
grown to 80 - 90% confluency and subcultured with TrypLE® select.  
 
Proliferation studies 
The proliferation rate was determined using BrdU cell proliferation ELISA test kit 
according to the manufacturer‟s instructions. The incorporation of 5-bromo-2-
desoxyuridine (BrdU) into DNA of proliferating cells was quantified at 450 nm using a 
microplate reader (Spectrafluor-reader, Tecan, Groedig, Austria). Cells were seeded 
on high grade steel supports coated with amino-PEG at pH 5 or 10. Cell proliferation 
on glass slide and plain high grade steel served as a reference. Prior to cell seeding 
Flexiperm®, plain stainless steel and glass slides were disinfected in 70 % ethanol 
for 30 min, and amino-PEG coated high grade steel for 1 min and left to dry. After 
forming wells by attachment of Flexiperm® the cells were seeded (17000 cells/well) 
and the BrdU proliferation test was performed two and three days post-seeding. 
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Supplementary Materials and Protocols 
Detection of SH-groups using the Ellman's assay 
Scheme 5 shows the reaction of Ellman's reagent [DTNB (5,5´-dithio-bis-(2-
nitrobenzoic acid)] with sulfhydryl containing molecules under slightly alkaline 
conditions to release the highly chromogenic compound TNB (5-thio-2-nitrobenzoic 
acid) (Ellman C. 1959; Riddles P. et at. 1979). The reagent contains a disulfide bond 
between two TNB groups and reacts with free sulfhydryls to create a mixed disulfide 
product. At pH 8, the release of one TNB group per available thiol provides a yellow 
colored product with an absorbance at 412 nm.  
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Scheme 5. The reaction of Ellman's reagent with a SH-group at pH 8 releases the yellow colored TNB 
anion with an absorbance at 412 nm. 
 
As is illustrated in Scheme 5, the release of TNB anions of Ellman's reagent per 
available thiol yields a yellow colored product at pH 8. A positive Ellman‟s assay 
reaction is observed with cleaved antibodies (2µl pc BSA-Ab/ml) prepared via 
immobilized dihydrolipoamide on Gulsenit, which is a better carrier than amino-
silanized glass powder (Figure 2). Untreated Glass beads and Gulsenit show no 
signal due to the absence of free thiol groups in immobilized lipoamide. 
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Figure 2. A positive signal of Ellman's assay is observed in the presence of sulfhydryl groups of 
Fab´fragments. Immobilized dihydrolipoamide on amino-silanized Gulsenit provides a darker yellow 
color than on amino-silanized glass powder. Ellman's assay shows no signal in the absence of 
sulfhydryl groups on Gulsenit or glass powder containing lipoamide. (-)= color of Ellman's reagent 
alone 
 
Detection of NH2-groups using the Kaiser test 
The Kaiser test was efficient for the detection of free amino groups on amino-silica 
beads used for immunization (Chapter 6) and amino-silanized Gulsenit. Figure 3 
shows the efficiency of lipoic acid immobilization onto organic amino-silanized 
Gulsenit. The intensity of the blue color decreased with increasing amounts of 
immobilized lipoic acid due to presence of only few free amino groups. As the 
immobilization of lipoic acid onto amino-silanized Gulsenit was more efficient than on 
amino-silanized glass beads, Gulsenit was chosen for immobilization of lipoic acid. 
However, the Kaiser-test is of limited value for the detection of amino groups on most 
carriers and on amino-silanized glass powder (see Chapter 1).  
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Figure 3. Detection of free amino groups by the Kaisertest. The intensity of the blue color is generated 
by reaction of ninhydrin with free amino groups. Amino-silanized Gulsenit provides the most intensive 
blue color due to the high amount of free amino groups, and was used as a binding site for lipoic acid. 
The color intensity decreases gradually with increasing amounts of immobilized lipoic acid. The Kaiser 
test was of limited value for the detection of free amino groups on amino-silanized glass slides or 
glass powder.    
 
Detection of cleaved antibody immobilized onto amino-silanized or amino-
PEGylated carrier using OPA-as a crosslinker and test 
Sulfhydryl groups of ßME were applied for all previously described detections of 
amino groups using OPA (see Chapter 1). This section describes the use of OPA as 
a crosslinker to couple the sulfhydryl of cleaved Ab onto the surface of slides 
containing amino groups.  HRP-IgG was cleaved with immobilized dihydrolipoamide 
to create two Fab` fragments containing free sulfhydryl groups in the hinge region. 
OPA was used as a crosslinker for these Fab` fragments with amino-groups on 
amino-silanized or amino-PEGylated slides (at either pH 5 or 10). Amino-PEGylation 
was carried out using EDC crosslinker or EDC/sulfo-NHS (see Chapter 1). Figure 4 
shows that the EDC/sulfo-NHS activation apparently increases the efficiency of bis-
amino-PEG coating. Due to the high cost of sulfo-NHS this method might not be 
suitable for an up-scaled industrial process, but for proof of principle as was required 
for this thesis it was the method used for all immobilization steps. 
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Figure 
Immobilization of  cleaved 
HRP-Ab (via immobilized dihydrolipoamide) onto slides with: 
4 A Organic amino-silanization 
4 B 
Binding of succinic anhydride at pH 4.8, EDC-crosslinking at pH 10, coupling of bis-
amino-PEG in carbonate-bicarbonate buffer at pH 10 
4 C 
Binding of succinic anhydride at pH 4.8, EDC/sulfo-NHS crosslinking at pH 10, 
coupling of bis-amino-PEG in  carbonate-bicarbonate buffer pH 10 
4 D 
Binding of succinic anhydride at pH 4.8, EDC crosslinking at pH 10, coupling of bis-
amino-PEG in citric acid-sodium citrate buffer pH 5 
4 E 
Binding of succinic anhydride at pH 4.8, EDC/sulfo-NHS crosslinking at pH 10, 
coupling of bis-amino-PEG in citric acid-sodium citrate buffer pH 5 
4 F Binding of succinic anhydride at pH 4.8, EDC crosslinking at pH 10 
4 G Binding of succinic anhydride at pH 4.8, EDC/sulfo-NHS crosslinking at pH 10 
 
Table 1. Set up conditions of carrier (glass slides) before immobilization of HRP- Fab`fragments by 
means of OPA. Figure 4 shows the fluorescence microscope images of each carrier. 
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Figure 4. HRP-IgG Fab fragments immobilized by means of OPA onto following carriers (glass slides) 
A: organic amino-silanized, B: activated with  EDC and amino-PEGylated at pH 10, C: activated with  
EDC/sulfo-NHS and amino-PEGylated at pH 10, D: activated with  EDC and amino-PEGylated at pH 
5, E: activated with  EDC/sulfo-NHS and amino-PEGylated at pH 5, F: activated with  EDC (negative 
control), G: activated with EDC/sulfo-NHS (negative control). Table 1 shows the details for set up 
conditions of each carrier. 
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Part 2  
Development of new analytical tools for demonstration of 
protein binding to solid surfaces and binding of PLGA-
nanoparticles to the receptor on the implant surface 
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A dot-blot test using gold colloid cluster technology as a 
miniaturizable alternative to ELISA and hapten inhibition tests 
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determination of IgEs in patient sera 
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The third aim of this thesis focuses on our effort to search and develop a 
biorecognitive and reloadable binding system [antibody or enzyme e.g. LDH 
(lactat dehydrogenase)] for the drug delivery system (e.g. PLGA-nanoparticles).  
For this purpose pc anti PLGA antibodies were produced in rabbits (no. 52 und 53). 
The determination of PLGA Abs in rabbit‟s immune sera was rather difficult as PLGA 
easily hydrolyzes and a completely new system for detection (CLISA – Cluster 
Linked Immunosorbent Assay) had to be established as is described in this Chapter. 
This method was first optimized using several antigen/antibody interactions and then 
used for determination of PLGA-Abs in rabbit‟s immune sera (Chapter 5). During the 
course of this development, we realized the potential of applying it for detection of 
allergens and also for antibodies in sera of allergic patients (Chapter 4). The binding 
specifity of LDH to PLGA is described in more details in Chapter 5. 
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A dot-blot test using gold colloid cluster technology as a 
miniaturizable alternative to ELISA and hapten inhibition tests 
 
Haifa Al-Dubai*, Gisela Pittner, Fritz Pittner 
 
Max F. Perutz Laboratories, Department of Biochemistry, University of Vienna, 1030 
Vienna, Austria 
 
Abstract  
A novel miniaturizable method to quantify antigens is described in form of a Cluster 
Linked Immunosorbent Assay (CLISA), using inexpensive nitrocellulose (NC) 
membranes as a support for dot-blotting the antigens. Antibodies for detection are 
labeled with gold-colloid clusters (GCC). After blocking of the membrane with non 
reacting protein and application of the GCC labeled antibodies the signal is 
detectable by visual colorimetry and can be compared to a color scale prepared from 
a dilution series of known sample concentrations. The color reaction product is stable 
for a very long time and does not fade. The sensitivity of the method is comparable to 
that of ELISA if not better and furthermore needs only small amounts of antibody for 
detection or for GCC labeling. This method provides an alternative to the use of 
expensive enzyme-conjugated antibodies for a number of applications, such as 
tracking of antibodies during purification or hapten inhibition tests. 
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Introduction 
Immunoassays are based on specific antibody-antigen reactions (Wild D. 2001) and 
quantification of the antigen is generally achieved by measuring the amount of a label 
molecule bound covalently to the antibody, which can then be detected due to its 
radioactivity, enzyme reaction, fluorescence, chemiluminescence, bioluminescence, 
or electrical conductivity (Wild D. 2001; Rossier J.S. et al. 2001; Santandrew M. et al. 
1999). However, these labels share a common drawback, as they are not suitable for 
long-term preservation (Wild D. 2001). While some isotopes have half-lives that 
would allow long-term applications, the use of radioactivity has in general become 
less desirable, because of issues concerning waste disposal and potential harm to 
human health. Furthermore, most fluorescence based assays suffer from fading 
signal intensity due to photo-bleaching (Longin A. et al. 1993). Recently, 
nanoparticles, in particular gold and silver particles, were used successfully for 
labeling, as their size can be controlled easily, they are stable over long periods of 
time, and they are compatible with biological macromolecules, including proteins and 
nucleic acids (Daniel M.C. et al. 2004; Jain KK. 2003). Quantification by visual 
inspection with the naked eye may help reduce costs and makes the test also 
applicable for field studies, as most other available techniques require specialized 
detection equipment, software, and specific sample preparation before the detection 
step.  
 
The procedure for preparing gold colloid clusters (GCC) is well established. Colloidal 
gold has an orange, red or red-violet color, depending on the size of the particles 
which can be adjusted by the modifying the method of preparation. Colloidal gold is 
prepared by reducing gold salts with different reagents, the most common one being 
used in this research is tri-sodium-citrate and others are include tannic acid, ascorbic 
acid, and phosphorus. Depending on the method used, GCC preparations vary in 
particle size (expressed as the average particle diameter) and size variability 
[expressed as the coefficient of variation (CV) of the gold particle diameter in a sol]. 
Such a sol is called monodisperse when the CV is less than 15% (Schalkhammer T. 
2003). The GCC preparation used in this research is carried out according to the 
method described by Frens 1973. This method provides monodisperse colloidal gold 
with a size range from 14 to 50 nm. The size of the clusters can be adjusted by 
adding different amounts of reducing agent (tri-sodium- citrate).  
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GCC with an average diameter of 17 nm can be prepared by reduction of HAuCl4 
with tri-sodium-citrate. Immediately after adding the reducing agent, aggregation of 
gold atoms forms central icosahedral gold cores of eleven atoms at nucleation sites. 
The formation of nucleation sites proceeds very rapidly. The remaining gold atoms in 
solution bind to the nucleation sites, until all atoms are removed from the solution. As 
a larger number of nucleation sites for a given amount of gold chloride in solution 
results in smaller final size of each gold particle, the size of the particles is 
determined by the amount of reducing agent. To obtain stable gold colloids, they 
have to be surrounded by a charged layer preferably negative, formed by the residual 
negative ions in the solution. This negatively charged layer, forming the so called 
zeta potential, causes the gold particles to repel each other and to stay suspended. 
Proteins such as antibodies (Abs) bind very stably to the surfaces of these gold 
particles.  
 
 
 
Figure 1. Setup of the dot blot test compared to experimental results using BSA (or HSA) as an 
antigen and GCC labeled polyclonal-BSA-antibodies (or monoclonal-HSA- antibodies) for detection. 
 
This phenomenon is utilized to quantify antigens dotted onto the NC membrane in 
form of a Cluster Linked Immunosorbent Assay (CLISA, see Figure 1). Here we 
demonstrate some examples of successful applications of this principle: Firstly, the 
detection of bovine serum albumin (BSA) samples dotted onto NC membrane with 
polyclonal BSA-antibodies tagged with GCC. Secondly, the interaction between 
human serum albumin (HSA) samples dotted on NC membrane and monoclonal 
HSA-antibodies tagged with GCC. Thirdly, using an inverse setup, peroxidase-Ab 
dotted onto NC membrane and peroxidase tagged to GCC.  
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The sensitivity of the method makes it comparable to ELISA and allows for a rapid 
quantification of antigens at least semi quantitatively. This approach opens a wide 
field for applications such as testing for antibody-antigen binding specificity or tracing 
the purification of antibodies. 
 
Results and Discussion 
The dot-blot tests presented here can be used for various purposes; e.g. semi 
quantitative estimation of antigens by binding to GCC conjugated antibodies or 
testing specificity of antibodies. In order to achieve specific binding of the GCC 
conjugates to the respective samples on the NC membrane, either the antigen or the 
antibody is coupled to the GCC. Antibodies bind with their Fc-domain to the clusters 
and with the Fab-domain to the antigen on the NC membrane. In this study, 1% 
aqueous fish gelatin containing 0.1% Tween 20 is used as a stabilizing and blocking 
reagent for GCC as it lacks HS-groups. 
 
Semi quantitative determination of antigens - BSA and HSA dot blot tests 
To test for applicability of our approach in a broader field, BSA as well as HSA and 
their respective GCC labeled antibodies were used as test substances for semi 
quantitative estimations (Figure 2). A signal between BSA or HSA samples on the 
membrane and GCC labeled polyclonal BSA or monoclonal HSA-AB respectively is 
observed. The color of the reaction signal depends on sample concentration.  
For BSA as an antigen the weakest color is observed at 0.025µg/ml and almost no 
signal can be detected at 0.001µg/ml. The lower limit of detection in this test is 
considered to be at 0.025µg/ml (Figure 2a). With increasing concentrations the color 
gradually shifts towards a dark red. At higher concentrations adding even more 
sample does not lead to a further increase in color as stacking of protein on the dot 
will occur. In case of HSA decreased color intensity is observed at 0.1µg/ml and no 
signal can be detected at 0.05µg/ml (Figure 2c). 
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Figure 2. Semi quantitative dot blot test for BSA and HSA samples: 
a) BSA samples (concentrations in the range between 200mg/ml to 0.001µg/ml) dotted onto NC-
membrane without dotting of additional buffer onto the same spot. 
b) BSA samples dotted onto NC-membrane and dotting additional buffer onto the same spot, to 
minimize multilayers of protein. 
c) HSA samples (concentrations in the range between 200mg/ml to 0.025µg/ml) dotted onto NC-
membrane without dotting of additional buffer onto the same spot. 
d) HSA samples dotted onto NC-membrane and dotting additional buffer onto the same spot, to 
minimize multilayers of protein. 
 
The test can be improved substantially by dotting a certain amount of buffer onto the 
spot immediately afterwards, resulting in much bigger spots (Figure 2b and 2d). As 
the affinity of NC membrane and protein is very high, only protein not already bound 
directly to NC can be dissolved by the buffer solution migrating to free NC surface 
areas, where it is immediately bound thus resulting in quite even covering of the NC 
on much bigger spots. As shown in Figure 3, the amount of bound antigen can then 
be calculated from the diameter or more precisely from the surface area of the 
detected spots. In the lower range of sensitivity the diameters of the spots are the 
same as they are determined by the diameter of the tips used for dotting. Here the 
amount of antigen may be estimated by color intensity of the spot. 
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Figure 3. Calculation of antigen concentration from surface area of spot after addition of 5 µl buffer: 
The developed dot blot membranes were scanned, the pictures transferred to a graphics program 
(Corel Draw 11) and the diameter of the spots then measured (using the zoom tool for small spots). 
Accuracy of the values on y-axis is dependent on the quality of the scanner. 
a) BSA samples in various concentrations (left: 5 µg/ml to 10mg/ml and right: 0.05 to 1 µg/ml) 
b) HSA samples in various concentrations (left: 5 µg/ml to 10mg/ml and right: 10mg/ml-200mg/ml 
 
For negative controls, BSA and HSA samples in the same concentrations as 
described above were incubated for 2 hours in the same solutions omitting the 
antibodies and resulting in no detectable signals. As a second negative control, 
antigen samples were incubated in GCC labeled with non binding antibodies 
(monoclonal HSA-antibody for BSA samples and β-galactosidase-antibody for HSA 
samples) also resulting in no color reaction (see Figure 4 b, c).  
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Figure 4. Semi quantitative dot blot test for BSA, HSA and peroxidase including negative controls and 
cross reactivity  
a) BSA samples reacted with GCC labeled polyclonal BSA antibodies 
b) BSA samples reacted with GCC labeled monoclonal HSA antibodies (negative control) 
c) HSA samples reacted with GCC labeled β-galactosidase antibody (negative control) 
d) HSA samples reacted with GCC labeled polyclonal BSA antibodies (cross-reactivity) 
e) HSA samples reacted with GCC labeled monoclonal HSA antibodies  
f) Peroxidase antibody reacted with labeled Peroxidase but not with negative control (ß-galactosidase 
antibody) 
 
Testing for specificity of antibodies 
Incubation of HSA samples with GCC labeled polyclonal anti BSA-antibodies showed 
a certain degree of cross-reactivity due to some degree of homology between human 
and bovine serum albumins as can be seen from Figure 4d. This shows that the test 
presented here could serve as substitute for the more time consuming and 
inconvenient hapten inhibition tests. Various antigens can be dotted onto the same 
NC membrane and incubated with the GCC labeled antibody to be tested for 
specificity. This setup can also be used for microarrays and automatisation. 
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Inverse dot blot setups 
In some cases GCC tend to aggregate after addition of certain antibodies, which are 
positively charged at the test conditions as is the case for e.g. peroxidase antibody. 
In this case an inverse setup is recommended. 
Peroxidase antibody dot blot: Peroxidase antibody (1µl 41 mg/ml, Sigma Aldrich) and 
also monoclonal ß-galactosidase antibody (1µl 2-2.5 mg/ml, Promega) as a negative 
control are dotted onto the NC membrane. Blocking and washing procedures and 
also incubation with the antigen GCC labeled peroxidase (40µg peroxidase used for 
labeling, Fluka) was done according to the previously mentioned protocol and 
showed only specific binding to the peroxidase antibody on the membrane (see 
Figure 4 f). As an additional negative control, GCC without peroxidase were reacted 
with a peroxidase antibody dotted membrane as above, showing no color, indicating 
no unspecific binding. 
 
Experimental Methods 
Synthesis of 17 nm gold colloid clusters (GCC) according to Frens 
Frens et al. described procedures for producing mono-disperse colloidal gold with a 
size range from 14 to 50 nm. Preparation of 17 nm gold clusters: In a very clean 
Erlenmeyer flask rinsed several times with doubly distilled water (dd. H2O) and 
covered with aluminum foil, 10 mg HAuCl4.3H2O (Sigma Aldrich) is added to 100 ml 
dd. H2O. The solution is heated to boiling under vigorous stirring. Then 4 ml of sterile 
filtered 1% (w/v) tri-sodium-citrate (Riedel-de Haen) is added very quickly (the 
solution is blown out of a 5-ml glass pipette). The initiation of nucleation can be seen 
after approximately 25 sec when the slightly yellowish solution will turn into a faint 
blue color. After approximately 4 min, the blue color changes into cherry-red, 
indicating the formation of monodisperse spherical particles. The solution is boiled for 
an additional 10 min to complete the reduction of the gold chloride under constant 
stirring. Spectrophotometric analysis at excitation wavelengths from 300 to 800 nm 
shows the plasmonic absorption as a single peak with a maximum at 520 nm. The 
GCC solution can be stored at 4°C for prolonged period and used until a color 
change is observable. 
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Preparation of GCC-labeled antibodies 
In order to achieve specific binding of the labeled GCC to the samples dotted on NC 
membrane, either the antigen or the antibody has to be bound or adsorbed to the 
GCC. Stock solution (10 ml) of GCC (17 nm) is mixed with 1 µl antibody under gentle 
stirring for 30 min at room temperature (rt) to generate the labeled GCC-antibody 
conjugate. Polyclonal anti-rabbit bovine serum albumin (BSA) antibody (Sigma 
Aldrich, 3.6 mg/ml), and monoclonal anti-human serum albumin (HAS) antibody 
(Sigma Aldrich, 7.8 mg/ml) were used in this study. Then 1 ml aqueous 1% fish 
gelatin (Sigma Aldrich) including 0.1% Tween 20 (Sigma Aldrich) is added under 
stirring for 30 min. Fish gelatin stabilizes GCCs during the following incubation steps 
and blocks free binding sites of GCCs avoiding their direct binding to detected 
antigen on the NC membrane. The concentration of fish gelatin was assessed using 
a salt flocculation test for GCC. 10 µl of 1% fish gelatin dissolved in dd. H2O 
stabilizes 100 µl 17nm GCC. 
 
Preparation of GCC-labeled antigen 
The protocol for labeling antigens used in this study is carried out according to the 
protocol for the preparation of GCC labeled antibodiesPeroxidase-GCC conjugate 10 
ml of 17 nm synthesized GCC stock solution is mixed with 40 µg peroxidase (Fluka, 
502U/mg) to generate the conjugate. The following incubation step of peroxidase-
GCC conjugate in fish gelatin and Tween 20 is carried out as described above. 
 
Dot blotting of test- samples 
A test sample (1µl, antigen or antibody) is dotted onto the surface of a NC membrane 
(pore size 0.45 µm, Protran BA 85, Schleicher & Schuell). For semi quantitative tests 
5 µl Tris-HCl buffer (50 mM Tris-HCl, 0.15 NaCl pH 7.3) is then dotted onto the same 
sample spot to increase the diameter of the protein monolayer avoiding multilayers of 
protein on the sample spot (Figure 1a). This step can be omitted if only testing for 
antigen- specificity is desired. The spots are dried for 1h at rt. Then the membrane is 
immersed in blocking solution containing 2% fish gelatin (Sigma Aldrich), 0.1% 
Tween 20 (polyethylene glycol sorbitan monolaurate, Sigma Aldrich) and Tris-HCl 
buffer for 20 min at rt under gentle shaking. Fish gelatin is used for eliminating 
unspecific background staining as it does not contain free reactive HS–groups that 
would form a tight chemical bond with the GCC. Therefore, blocking with HS-group 
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containing reagents, such as BSA or milk, is not recommended. Blocking is further 
enhanced by the addition of the non-ionic detergent Tween 20. After blocking, the 
membrane is treated 2x5 min in excess washing solution (Tris-HCl buffer containing 
0.5% Tween 20) and 3x1 min in dd H2O to remove residual NaCl, which otherwise 
causes flocculation of GCCs. Flocculation occurs immediately if the gold sol is 
unstable and the red color of GCC turns to violet and blue. The washed membrane is 
then incubated for 2 hours in the GCC-labeled antibody or antigen solution (inverse 
setup) at rt under gentle shaking, followed by washing for 3x10 min under gentle 
shaking at rt in the above mentioned solution.  
 
Dilution series of antigen samples 
BSA dilution series in Tris/HCl buffer pH 7.3 were made in a concentration range 
between 20 mg/ml and 0.001 µg/ml, HSA dilution series in Tris/HCl buffer pH 7.3 in 
the range from 20 mg/ml and 0.025 µg/ml. 
 
Salt flocculation test 
Gold particles in a gold colloid are surrounded by a layer of negative charges, 
deriving from negatively charged ions present in the reaction mixture (tri-sodium 
citrate) during synthesis. Due to this charged layer the gold particles repel each other 
and stay dispersed. During labeling with GCC the colloidal gold sols become 
unstable in the presence of electrolytes. Addition of electrolytes turns the red color of 
GCC into violet or blue, and clusters flocculate. However, when poly-electrolytes are 
added under appropriate conditions, these adsorb spontaneously to the gold 
particles, and sols are rendered hydrophilic and stable in the presence of added salt. 
The binding of poly-electrolytes to gold is irreversible in most cases (Walter H. 1999). 
In this study the GCC is stabilized using fish gelatin. The salt flocculation test is 
carried out according to Walter and Bauer (Walter H. and Bauer G. 2000)
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The demand for rapid, sensitive and low-cost alternatives immunoassay-tests 
for a wide variety of applications in several fields (such as allergies, tumor marker 
and serological tests) will likely increase. For this purpose a novel immunoassay-
method for detection of antibody or antigen in form of a dot-blot test on microtiterplate 
or nitrocellose (NC) membrane using gold nanoparticles was developed in this study. 
This Chapter describes our efforts to develop this method using several interactions 
between different antigen/antibody and solutions for GCC-flocculation (e.g. using 
Protein G) and application of CLISA for other analytic purposes such as detection of 
allergens in patient sera. 
The gold colloid cluster technology - developed for determination of successful 
binding of antibodies to the implant surface and also for use in long term tests 
concerning degradation of bound nanoparticles to these surfaces as well as possible 
reloading - proved successful also as a general immunochemical test tool. Therefore 
–as a byproduct to the main goal of this thesis – this technology was also used for 
testing sera of allergic patients and compared to conventional ELISA tests. The 
stability of GCC-labeled allergens makes them potentially applicable in a kit format. A 
GCC based allergy test could promise more simplification and patient comfort 
compared to the currently available allergy tests (such as skin-prick tests). The 
advantages of this rapid method are; 1) the procedure is not time consuming (the 
whole procedure takes four hours) and economic; 2) the GCC detection method is 
very sensitive and therefore requires only very low amounts of Abs; 3) there is no 
need of enzyme conjugated secondary antibodies and their substrates; 4) the signal 
detection of the cherry red color of GCCs can be observed by the naked eye and 
does not require any instruments, which makes it useful also for analytic field studies, 
e.g.  profiling patient‟s potential allergies.  
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Abstract 
A sensitive and simple immunosorbent assay using gold colloidal cluster labeling is 
developed for determination of proteins such as antigen or antibody. This method is 
can be carried out on nitrocellose membrane or on microtiterplate as a dot blot 
support. The positive interaction between proteins can be detectable by naked eye 
and produced colored reaction product is stable for prolonged periods. In this study is 
shown that the CLISA-method (Cluster Linked Immunosorbent Assay) is an 
alternative to ELISA. Several interactions between different antigen/antibody and 
solutions for GCC-flocculation (e.g. using Protein G) are studied. CLISA was also 
applied for other analytic purposes such as detection of allergens in patient sera. 
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Introduction 
The demand for rapid, sensitive and low-cost alternatives immunoassay-tests for a 
wide variety of applications in several fields (such as allergies, tumor marker and 
serological tests) will likely increase. For this purpose a novel immunoassay-method 
for detection of antibody or antigen in form of a dot-blot test on microtiter plate or 
nitrocellose (NC) membrane using gold nanoparticles was developed in this study. 
Antibodies (Abs) for detection are labeled with gold-colloid clusters (GCCs). Abs bind 
with their Fc-domain to the clusters and with the Fab-domain to the antigen on the 
NC membrane or microtiter plate as a support for dot-blotting (Figure 1). The signal 
of positive interaction between GCC-labeled Abs and its dotted antigen (Ag) is 
detectable by naked eye and can be compared to a color scale prepared from a 
dilution series of known sample concentrations. The color intensity of the signal is 
proportional to the sample concentration. The colored reaction product is stable for 
prolonged periods and does not fade, thus making this method a simple, fast and 
convenient means for detection of antigen/antibody biorecognitions. 
 
 
 
Figure 1. Principle of a Cluster Linked Immunosorbent Assay (CLISA) in form of a dot-blot test using 
GCC-labeled Abs which bind with their Fc-domain to the clusters and with the Fab-domain to the 
antigen on the NC membrane or microtiter plate as a support for dot-blotting. 
 
Proteins such as antibodies can bind very stably to the surfaces of these gold 
particles via intercalation of their sulfur atoms with the gold lattice. A “good” 
conjugate of gold particles and protein is one where the protein is adsorbed passively 
onto the surface of the gold (Chandler J. et al. 2000). Antibodies attach firmly to gold 
via the Fc region and leave the Fab region jutting through the double-ionic layer 
surrounding the gold particle and are thus able to bind the analyte (Figure 2). 
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Adsorption of proteins to gold particles occurs within seconds through the following 
mechanisms:  
1. Charge attraction of the negative gold particle to the positively charged amino 
acids within the protein (e.g. lysine).  
2. Hydrophobic adsorption of the protein to the gold particle surface, through 
certain amino acid residues including tryptophan.  
3. Dative binding between the gold particle and sulphur residues on the protein 
(from cysteine residues) 
 
Figure 2. Binding forces between an antibody and a gold particle. 
These binding interactions were utilized in a Cluster Linked Immunosorbent Assay 
(CLISA) to quantify antigens such as, BSA, HSA, ß-lactoglobulin (ß-LG), and IgEs in 
sera that were dotted onto a NC membrane or microtiterplate.  
Some proteins such as pc anti-peroxidase Abs led to the precipitation of GCC as 
observed by its color turning from cherry red to dark violet or black, which indicate 
the formation of larger gold aggregates. To avoid this problem, either Protein G was 
used to stabilize the GCC solution or the Ab preparations were diluted further. 
Another possibility is the use of an inverse setup, where pc anti-peroxidase Abs are 
dotted onto the NC membrane and peroxidase is tagged to GCC (Al-Dubai H. et al. 
2008). Protein G binds to the surface of gold particles and protects them from 
precipitation after addition of proteins. In this case, the additional proteins (Abs) bind 
to Protein G (Figure 3). The sensitivity of the method is comparable with ELISA. 
Furthermore this GCC-labeling method may also be applicable for other analytic 
applications, such as the detection of allergens in patient sera. 
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Figure 3. Scheme of stabilization of GCC using Protein G. 
 
The GCC preparation in this research was carried out according to the protocol 
reported by Frens G. (1973). This method generates monodisperse colloidal gold 
with a size range from 14 to 50 nm. The size of the clusters can be adjusted by the 
regulating the amount of reducing agent (tri-sodium- citrate) used. GCC with an 
average diameter of 17 nm were prepared by reduction of gold tetrachloric acid 
(HAuCl4) with tri-sodium citrate. Immediately after adding the reducing agent, 
aggregation of gold atoms leads to the formation of central icosahedral gold cores of 
eleven atoms that serve as nucleation sites (Figure 4). The formation of nucleation 
sites proceeds very quickly. The remaining gold atoms in solution bind to the 
nucleation sites, until all atoms are deposited. As a larger number of nucleation sites 
for a given amount of gold chloride in solution results in smaller final size of each 
gold particle, the size of the particles is determined by the amount of reducing agent. 
Gold tetrachloric acid + reducing agent → gold colloid  
(HAuCl4 + 3 e
– → Au0 + H+ + 4 Cl-) 
 Chapter 4  
119 
 
Figure 4. Reduction of gold ions to form gold particles. 
 
Results and Discussion 
In order to achieve specific binding of the GCC conjugates to the respective samples 
on the NC membrane, either the Ag (antigen) or the Ab (antibody) is coupled to the 
GCC. Abs bind with their free –SH groups on the Fc-domain to the GCCs, and with 
the Fab-domain to the antigen on either the NC membrane or microtiterplate.  
 
Imaging of GCC particles 
The 17 nm synthesized GCC particles were visualized by transmitted light 
microscopy (Leitz-Reichert Univar) magnification 40 x (Figure 5).  
 
 
 
Figure 5. Images of sole 17 nm GCC particles taken on a Univar microscope with a binary video 
camera and 40 x magnification.  
 
The color of synthesized GCCs is cherry red (Figure 6 a) and the intensity of the 
color increases after addition of protein (Figure 6 b, c). However, the concentration of 
added protein is critical due to the tendency of GCCs to flocculate immediately above 
a certain protein concentration (Figure 6 d, e).  
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Figure 6. a) Color of GCC solution; b) after adding 1µl pc anti-BSA Ab to 10 ml GCC solution; c) after 
adding 10 µl pc anti-BSA Ab to 10 ml GCC solution; d) GCC flocculates after adding 1 µl pc anti-
peroxidase Ab to 10 ml GCC-solution and its red color turns into violet then blue; e) black by total 
precipitation of GCC solution.  
 
Transmitted light microcopy images in Figure 7 show that individual GCC particles 
bind to Abs, and form dark, cherry red aggregates. The color and size of the 
aggregates depend on the concentration of added Abs (Figure 7 a, c). The change in 
color intensity of GCC-labeled Ab solutions was shown with either 10 µl or 1 µl pc 
anti-HSA Ab by detection of 1 µl HSA sample (200 mg/ml) dotted onto the NC 
membrane (Figure 7 b, d). This phenomenon illustrates that the detection of protein 
depends on the color, size and type of aggregate. However, the GCCs tolerate only a 
certain amount of protein added, which needs to be tested for each protein 
separately. Adding too much of a protein turns the red color of GCCs into violet, blue, 
and finally black due to flocculation of GCCs (Figure 6 d, e). 
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Figure 7. Detection of 1µl HSA (200 mg/ml) dotted onto NC membrane after incubation in GCCs 
(10ml) including different amounts (b; 10 µl, d; 1 µl) of labeled mc anti-HSA Ab and images of these 
GCC-labeled Ab solution (a; 10 µl, c; 1 µl) at 40x magnification.  
 
Antigen detection using GCC labeled Abs and ELISA – a comparison 
For evaluation of the here presented GCC-labeling method, it was compared to 
ELISA for the HAS protein, as standard ELISA tests are available for this protein. 
Detection of HSA antigens by means of GCC-labeling was carried out in a 
microtiterplate format and compared to detection by ELISA.  
The GCC-labeling method provides the following advantages: 
 The procedure is not time consuming (the whole procedure takes four hours) 
and economic.  
 The GCC detection method is very sensitive and therefore requires only very 
low amounts of Abs.  
 There is no need of enzyme conjugated secondary antibodies and their 
substrates.  
 The signal detection of the cherry red color of GCCs can be observed by the 
naked eye and does not require any instruments.  
 This makes it useful also for analytic field studies  
The detection of HSA samples using CLISA (GCCs labeled with mc anti-HSA Ab) 
was similar to ELISA and the lower limit of detection was observed at 25 ng/ml 
(Figure 8a, row A). After incubation of coated HSA-samples on the microtiterplate 
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with GCC including only blocking solution no signal was observed (Figure 8a, row B 
negative control). No color reaction was observed for the negative controls after 
incubation of coated samples in GCC labeled with non binding Ab (mc anti-β-
galactosidase Ab, Figure 8a, row C) and after incubation of GCC-labeled Ab in 
blocked and washed wells without coated HSA-samples (Figure 8a, row D). A certain 
degree of cross-reactivity was observed after incubation of coated HSA-samples in 
GCC-labeled with pc anti-BSA Ab due to some degree of homology between human 
and bovine serum albumins as can be seen in Figure 8a, row E. This cross-reactivity 
was also detected with ELISA. The importance of blocking GCC particles using fish 
gelatine is illustrated in Figure 8a, row F. A positive unspecific signal was observed 
after incubation of coated HSA samples (see materials and methods) in GCC 
solution due to the high affinity of GCC to bind albumins.  
 
 
 
Figure 8.  a) CLISA Test: Wells of microtiterplates were coated with HSA- samples and incubated in: 
A: GCC- labeled with mc anti-HSA Ab including GCC blocking solution. 
B: GCC solution including GCC blocking solution (negative control). 
C: GCC-labeled with mc anti-ß-galactosidase Ab including GCC blocking solution (negative control). 
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D: GCC-labeled with mc anti-HAS Ab including GCC blocking solution incubated in blocked, washed 
and without coated HSA-sample wells (negative control). 
E: GCC-labeled with pc anti-BSA Ab including GCC blocking solution (for testing the specificity of Ab). 
F: Incubation of GCC solution (without GCC blocking solution) in wells coated with samples (to show 
the importance of blocking GCC particles using GCC blocking solution). 
b)  ELISA Test: incubated in: 
A: Wells of microtiterplates were coated with Tris/HCl puffer and incubated in mc anti-HSA Ab solution 
(negative control). 
B: Wells of microtiterplates were coated with HSA- samples and incubated in mc anti-HSA Ab. 
 
Avoiding of GCC flocculation during reaction with certain proteins 
GCCs tend to flocculate after addition of certain proteins. To avoid the GCC 
flocculation appearing immediately after addition of some proteins such as anti-
peroxidase Ab, either Protein G is added to GCC solution or its amount was 
increased. Figure 9 A and B illustrate the positive signal after incubation of GCC- 
labeled Ab (pc peroxidase- Ab) with dotted peroxidase after increasing the amount of 
GCC solution (20 ml incubated in 1 µl peroxidase Ab) and additional use of Protein 
G. Protein G was  incubated with GCC solution and bound to the surface of gold 
particles. This prevented premature precipitation of gold particles after addition of 
proteins.  
 
 
Figure 9. Incubation of dotted peroxidase with GCC-labeled with peroxidase Ab. GCC flocculation ater 
addiding of peroxidase Ab can be avoided by; A) increasing the amount of GCC solution, which was 
incubated with Ab to produce GCC-labeled Ab or by; B) addition of Protein G to the GCC solution 
before incubation with the Ab. No color reaction was observed by dotted ß-LG protein (negative 
control).  
 
This effect is shown in Figure 10 and illustrated again by detection of beta-
lactoglobulin (ß-LG), the major allergen in milk. The detected signal of ß-LG using 
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GCC-labeling is still quite intense at 0.001 mg/ml. No signal was observed after the 
incubation of NC membrane containing dotted ß-LG samples in GCC solution 
including Protein G and GCC blocking solution in the absence of Ab (negative 
control).   
 
 
Figure 10. Positive signal of detected ß-LG using the GCC labeling method.  
 
Application of GCC-labeling for detection of allergens in patients sera 
Microtiterplate wells containing the dotted sera of allergic patients were incubated 
with GCC-labeled allergen solutions over night at 4°C. Positive color reactions were 
obtained (Figure 11) by specific interactions of specific IgE in allergic patients serum 
to the suspected allergen labeled with GCC. Table 1 gives an overview of the results. 
The allergy of patient A was suspected to be against grasses, rye, birch tree, ash 
tree and ragweed. The GCC-labeling test indicates specific IgEs against 
grasses/cereals, Dermatophagoides farinae, Dermatophagoides pteronyssinus and 
ash tree in his serum. The quality of used ragweed allergen seemed to be not 
sensitive as no color signal was observed for patient A who has been tested allergic 
against ragweed before.  
Patient B was previously tested positive for allergy against grasses and trees. The 
GCC-test procedure gave corresponding positive allergy results for grasses and ash 
tree. Patient C suffered from allergy against different pollen, foodstuff and different 
animals. GCC-labeled tests demonstrated a positive color reaction for 
grasses/cereals, ash tree, Dermatophagoides farinae and Dermatophagoides 
pteronyssinus. Allergen cross-reactivity occurs when IgE antibodies originally raised 
against one allergen recognizes or binds a similar protein from another source 
(Aalberse RC. et al. 2001; Aalberse RC. et al. 2000; Weber RW. 2003). A cross 
reactivity between Dermatophagoides farinae and Dermatophagoides pteronyssinus 
allergens to crustaceans and sea food is known (Ayuso R. et al. 2002; Sidenius KE. 
et al. 2001; Jeong KY. et al. 2006). This could be the reason for higher color intensity 
of the detected signal in patient C compared to patients A and B. The signal intensity 
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for grasses/cereals allergens was low in patient B, due to allergy against only 
grasses, however patient A had allergy against grasses and rye and patient C 
against food and different pollen and therefore the signal intensity was higher. These 
findings show that cross reactivity with other antigens could increase the total signal 
in one sample.   
It is remarkable that the sera of patients A and B gave a positive color reaction with 
Dermatophagoides farinae and Dermatophagoides pteronyssinus allergen, although 
this was not indicated for those patients. It might be derived from an immune 
response of patients developed against both allergens and the respective IgGs were 
detected in their serum. To increase the specificity of this test for the detection of 
allergens, purification of sera is necessary for the isolation of IgEs. No signal was 
observed with the other supplied allergens against which the patient sera did not 
contain specific IgEs, such as fungi I, mugworth (Artemisia vulgaris). Moreover the 
specificity of the GCC based test is highly dependent on the allergen concentration 
and purification.   
As is shown in Figure 11 and 12 (well 9) positive color reaction was obtained by 
incubation of the dotted patient sera in GCC-solution including GCC blocking 
solution. An explanation might be that the concentration of added GCC blocking 
solution was too low for blocking in the presence of high concentrations of albumins.  
HSA is the most abundant protein in human blood plasma and albumin reacts with 
GCC with high affinity. HSA contains free reactive SH–groups that form a tight 
chemical bond with the GCC. However, adding of allergens and GCC blocking 
solution was sufficient to block the whole surface of GCC particles, therefore not all 
the used GCC labeled with allergens show a signal with dotted serum. These 
aggregates were then able to bind specifically to the IgEs in serum and gave a 
positive signal on the surface of the microtiterplate and no color reaction in the 
absence of suspected allergens. The negative control (Figure11 row D) shows no 
color reaction after incubation of blocked and washed wells with the different 
prepared GCC-labeled allergens.   
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Figure 11. Detection of IgE in patient sera shows cherry red color signals. Columns: Allergens: 1: 044 
fungi I (380 µg protein/ml); 2: 106 mugwort (standardised concerning biological activity); 3: 154 short 
ragweed (320 µg/ml); 4: 015 grasses/cereals (630 µg/ml); 5: 708 Dermatophagoides farinae (130 
µg/ml) (dust mite, Ed.); 6: 725 Dermatophagoides pteronyssinus (standardised concerning biological 
activity) (house dust mite, Ed.); 7: 108 birch tree (standardised concerning biological activity); 8: 116 
ash tree (320 µg/ml); 9: GCCs-solution including GCC blocking solution as a negative control – see 
Section Results and Discussion. Wells of rows A, B, C were incubated with patients-serum. Wells of 
row D were blocked, washed and used as negative control. See Table 1 for overview of the results.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Overview of positive color reaction (+) of allergic patient sera to the suspected allergen by 
means of GCC-labeling method (Figure 11, 12) 
 
 
Patient: 
allergy 
4 
GCC& 
grasses/cereals 
5 
GCC& 
Dermatophagoides 
farinae 
6 
GCC& 
Dermatophagoides 
pteronyssinus 
 
8 
GCC& 
ash 
tree 
A:Grasses, 
ragweed, 
birch-&ash-
tree, rye  
 
+ 
 
+ 
 
+ 
 
+ 
 
B: Grasses 
& Trees 
 
 
+ 
 
+ 
 
+ 
 
+ 
C: Pollen-& 
animal mix, 
foodstuff  
 
+ 
 
+ 
 
+ 
 
+ 
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Furthermore the same GCC based detection was carried out with 21 days old GCC-
labeled allergen to test the stability of labeled allergens after storage. Figure 12 
presents the same allergens as were tested in Figure 11, but using GCC-labeled 
allergen that has been stored for 21 days before use by 4°C. The stability of GCC-
labeled allergens makes them potentially applicable in a kit format, as long time 
storage of components is a prerequisite for kit development. A GCC based allergy 
test could promise more simplification and patient comfort compared to the currently 
available allergy tests (such as skin-prick tests).  
 
 
  
Figure 12. Test for stability of GCC-allergen conjugates: Repetition of the same experiment as 
illustrated in Figure 11 but here using 21 days old GCC-labeled allergens (stored at 4°C).  
 
Experimental Methods 
Synthesis of 17 nm gold colloid clusters (GCC) according to Frens: 
The production of mono-disperse colloidal gold with a size range from 14 to 50 nm 
was prepared according to the method developed by Frens G. (1973). A detailed 
protocol for the preparation is described by Al-Dubai H. et al. 2008. 
  
Preparation of GCC-labeled antibodies  
For a specific test on the NC membrane or the microtiterplate, either the antigen (Ag) 
or the antibody (Ab) has to be bound or adsorbed to the GCC and the aggregate then 
stabilized with fish gelatine. Fish gelatine stabilizes gold clusters during the following 
incubation steps and blocks free binding sites of GCCs avoiding their direct binding 
to detected antigen on the NC membrane. 10 ml stock solution of GCC was mixed 
with 1µl pc anti-BSA Ab 3.6 mg/ml (Sigma Aldrich) or mc anti-HSA Ab 7.8 mg/ml 
(Sigma Aldrich) under gentle stirring for 30 min at room temperature to generate the 
GCC–Ab conjugate. 1ml GCC-blocking solution (1% (w/v) fish gelatine (Sigma 
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Aldrich) dissolved in dd. H2O including 0.1% (v/v) Tween 20, Sigma Aldrich) was 
added under further stirring for 30 min 10 µl of 1% (v/v) fish gelatine dissolved in dd. 
H2O stabilizes 100 µl 17nm GCC (Al-Dubai H. et al. 2008; Walter H. and Bauer G. 
2000). As a negative control 10 ml stock solution of GCC was mixed with 1 ml GCC-
blocking solution under stirring for 30 min. The GCC labeled Abs solution is checked 
by microscopy (Olympus and Leica-Reichert Univar respectively) concerning their 
aggregation status.  
 
Qualitative determination of antigens on NC membranes 
For antigen-sample preparation a dilution series in Tris/HCl buffer (50 mM Tris/HCl 
pH 7.3) were made in a concentration range between 10 mg/ml and 1 µg/ml ß-LG 
(Sigma Adrich) and 100 mg/ml peroxides-sample (502 U/ mg, Fluka). A test sample 
(1µl antigen) was dotted onto the surface of a NC membrane (pore size 0.45 µm, 
Protran BA 85, Schleicher & Schuell). The dotted sample was dried for 1 hour at 
room temperature. The membrane was then immersed in blocking solution 
containing 2% (w/v) fish gelatine, 0.1% (v/v) Tween 20 and Tris-HCl buffer for 20 min 
at room temperature under gentle shaking. Fish gelatine was used for eliminating 
unspecific background staining as it is free of reactive –SH groups that would form a 
tight chemical bond with the gold cluster. Therefore, blocking with -SHgroup 
containing reagents, such as BSA or milk, is not recommended. Blocking is further 
enhanced by addition of the non-ionic detergent Tween 20. The membrane was 
treated 2 times for 5 min in excess washing solution [Tris-HCl buffer containing 0.5% 
(v/v) Tween 20] and 3 times rinsed in dd. H2O to remove residual NaCl, which 
otherwise causes flocculation of GCCs. Flocculation occurs immediately if the gold 
sol is unstable and the red color of gold clusters turns into violet and blue. The 
washed membrane was then incubated for 2 hours in the GCC-labeled Ab solution at 
room temperature under gentle shaking. For preparation of GCC-labeled Ab solution 
GCC stock solution was mixed with Protein G (1mg/ml, Fluka, dissolved in 50 mM 
Tris/HCl buffer pH 7.3) under gentle stirring for 20 min at room temperature. Then Ab 
solution [either pc anti-ß-LG (1mg/ml, Bethyl) or pc-anti peroxidase (41 mg/ml, Sigma 
Aldrich)] was added and stirred for further 30 min. Finally GCC-blocking solution was 
added under further stirring for 30 min. Table 2 shows quantities and concentrations 
of the solutions used.   
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The NC membrane was washed 3 times for 10 min under gentle shaking at room 
temperature in the washing solution. The detection of a positive signal (red color of 
gold clusters) was observed with the naked eye and does not require any 
instruments.  
 
GCC solution Protein G (1mg/ml) Antibody GCC-blocking solution 
5 ml 5 µl 5µl pc anti-ß-LG (1mg/ml) 0.5 ml 
20 ml 10 µl 1µl anti peroxidase (41 mg/ml) 2 ml 
 
Table 2. The solutions used to produce labeled-GCC Ab including Protein G.   
 
Detection of HSA-antigen using GCC-labeling (CLISA) 
The selection of the microtiterplates used is important to reduce the background of 
negative controls and enhance the color reaction of positive control. The DYNATECH 
MicrotiterTM 2 plates, DYNATECH LABORATORIES, INC (U.S.A), exhibit these 
desired properties and were used in our studies. They are arranged in a standard 96 
well format, have a flat bottom made of polystyrene and additional materials and are 
also treated to remove electrostatic charge at the end of the manufacturing process. 
For antigen-sample preparation a dilution series in Tris/HCl buffer (50 mM Tris/HCl 
pH 7.3) were made in a concentration range between 200 mg/ml and 1 µg/ml HSA 
(Sigma Aldrich). The wells of the microtiterplate (MicrolitetiterTM 2, DYNATECH) were 
filled with sample (60 µl per well of HSA-dilutions in 50 mM Tris/HCl pH 7.3) for one 
hour at room temperature. The microtiterplate was emptied by shake off and blocking 
solution was added to the wells for 20 min then washed 3 times for 5 min in washing 
solution under shaking, followed by rinsing 2 times in dd. H2O. The samples on the 
microtiterplate were incubated in 350 µl GCC-labeled Ab solution per well for 2 hours 
at room temperature under shaking. The GCC-labeled Ab solutions were prepared by 
adding of 1 µl Ab [mc anti-HSA Ab (7.8 mg/ml, Sigma Aldrich) or mc-anti ß-
galactosidase Ab (2.5 mg/ml, Promega) or pc anti-BSA Ab (3.6 mg/ml, Sigma 
Aldrich) separately] to 10 ml GCC stock solution under stirring for 30 min at room 
temperature followed by the addition of 1ml GCC-blocking solution under continued 
stirring for additional 30 min. The samples were washed 3 times in washing solution 
and then 3 times rinsed in dd. H2O. The detection of a positive signal (red color of 
gold clusters) was observed with the naked eye. 
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Detection of HSA-antigen using ELISA 
The wells of the microtiterplate (Maxisorp, NUNC) were coated with 60 µl of samples 
per well over night at 4°C (wells of negative control were coated only with Tris/HCl 
buffer). The samples were blocked and washed as described before. The dotted 
samples were incubated in 100 µl Ab solution per well (1:5000 diluted in 0.01M PBS 
pH 7.4) for 2 hours at room temperature under shaking. The samples were washed 3 
times with washing solution for 5 min. The microtiterplates were incubated for 1 hour 
with 100 µl per well of the conjugated HRP secondary Ab (anti-mouse IgG, Sigma 
Aldrich) solution (diluted 1:10.000 in 0.01M PBS pH 7.4) at room temperature under 
shaking. The microtiterplate was washed 3 times with washing solution for 5 min 
100 µl TMB-substrate (Sciotec, Austria) was added per well and incubated for 10 min 
at room temperature. The color of TMB-substrate changes to blue in presence of 
antigen. The color intensity is proportional to the amount of detected protein. The 
reaction was stopped with 50 µl 1M H2SO4. The color intensity of individual wells was 
quantified at 450 nm with a Microplate Reader Model 450, Bio-Rad. The coated wells 
were also incubated with pc-anti-BSA-Ab solution (prepared in analogy to mc-anti-
HSA-Ab solution described above) for testing of antibody specifity. 
 
Detection of allergens in patient sera using gold cluster labeling  
GCC solutions were labeled with several allergens (allergy-causing substance) from 
Prick-/Scratch testing solutions. The scratch test or skin prick test is one of the most 
commonly used methods of allergy testing on the skin. It is performed by placing a 
small amount of the suspected allergen on the skin. The allergic skin shows a 
physiological reaction as swelling or redness at the scratch/prick site. The prepared 
GCC-labeled allergen solutions were incubated in the dotted allergic patient sera on 
the microtiterplate. The specific interaction of the IgE in the allergic patient serum and 
the suspected allergen, labeled with GCC, shows a positive color signal on the 
surface of microtiterplate. 2 µl serum of each allergic patient was dotted onto one row 
(A-C) of a microtiterplate (MicroliteTM 2, DYNATECH) from well 1 to 9 and incubated 
overnight at 4°C. Wells of row D on the microtiterplate were blocked, washed and 
used as negative control.   
The patients were allergic to: 
Patient A: Grasses, rye, birch tree, ash tree, ragweed 
Patient B: Grasses and trees 
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Patient C: Pollen mix, foodstuff and animal mix 
All wells of the microtiterplate were blocked and washed in 100 µl per well washing 
solution (Tris-HCl buffer containing 0.5% (v/v) Tween 20) under stirring for 5 min 
under shaking. Each washed well (1-8 of rows A-D) was incubated in 350 µl of 
GCCs-labeled allergen solutions, each row including one of the following allergens 
(1-8 see below), overnight at 4°C. The ninth well was incubated in GCCs-solution 
including GCC blocking solution as a negative control. Eight different GCC-labeled 
allergen solutions were separately prepared by stirring 10 ml GCC stock solution with 
500 µl of the following allergen solutions (fungi I 300µl) for 30 min at room 
temperature. 1 ml GCC-blocking solution was added to each GCCs- labeled allergen 
solutions under stirring for 30 min. The GCCs-solution including GCC blocking 
solution as negative control was prepared analogues to GCC-labeled solution 
omitting allergen.  
Allergens: 
1) 044 fungi I (380 µg protein/ml) 
2) 106 mugwort (standardised concerning biological activity) 
3) 154 short ragweed (320 µg/ml)  
4) 015 grasses/cereals (630 µg/ml) 
5) 708 Dermatophagoides farinae (130 µg/ml) (dust mite, Ed.) 
6) 725 Dermatophagoides pteronyssinus (standardised concerning biological 
activity) (house dust mite, Ed.) 
7) 108 birch tree (standardised concerning biological activity) 
8) 116 ash tree (320 µg/ml) 
 
The wells were rinsed with dd. H2O and a positive signal was observed with the 
naked eye. For testing the stability of the GCC labeled antigen solutions the same 
experiment was repeated after 21 days using the same solutions of GCC-labeled 
allergens that had been stored at 4°C. The GCC-labeled allergens were stable and 
showed the same results as freshly prepared GCC-labeled allergens (Figure 11, 12). 
These preliminary results show that CLISA could be a useful test principle to develop 
further into a kit format allergy test 
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Part 3 
Proof of binding of nanoparticles serving as drug carriers 
to receptors onto the biocompatible-coated implant 
surfaces and long term test showing degradation of 
nanoparticles and reloadability 
 
Chapter 5 
CLISA as a tool for detection of successful immunization of rabbit’s 
in order to produce PLGA Abs and testing binding of PLGA NPs to 
the coated implant surface for reloadability studies. 
 
Chapter 6 
Production of polyclonal antibodies against the biocompatible 
polymer PLGA using silica amino microspheres as a carrier 
 
Chapter 7 
Production of polyclonal antibodies against the biocompatible 
polymer PLGA using silica amino microspheres as a carrier 
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in order to produce PLGA Abs and testing binding of PLGA NPs to 
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An important aim of the thesis was to search and develop a biorecognitive and 
reloadable binding system [antibody or enzyme e.g. LDH (Lactate Dehydrogenase)] 
for PLGA nanoparticles as a drug delivery system. For this purpose pc anti PLGA 
antibodies were produced in rabbits. The determination of PLGA Abs in rabbit‟s 
immune sera was detected by means of CLISA that was established using several 
antigen/antibody interactions as is described in Chapters 3 and 4. The search for 
biorecognitive and reloadable binding system for PLGA-nanoparticles was 
investigated also for other proteins such as LDH. The binding specificity of PLGA to 
LDH is discussed in this Chapter and also a degradation time assay of PLGA-NPs 
after their specific binding to their immobilized recognitive site (PLGA-Abs) on the 
surface of the carrier using CLISA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5 
136 
Abstract 
The degradation time assay of PLGA-NPs was carried out with immobilized, non 
purified immune sera of rabbit 52 and 53. The carriers were loaded with PLGA NPs. 
A positive interaction between immobilized immune sera and PLGA NPs was then 
detected visually by means of a CLISA assay. To assess degradation of PLGA NPs 
over time, the carriers were then incubated in Ringer´s solution at 37°C. During two 
months of incubation the color of the carriers faded. Then the carriers were incubated 
with fresh PLGA NPs, and reloading was detected again using the CLISA method. 
The carriers showed a marked increase in color but the color intensity was lower than 
after the initial loading. After one year incubation of carriers in Ringer‟s solution, the 
reloading procedure with PLGA NPs and detection using CLISA were repeated. But 
this time color intensity could not be enhanced. This shows that the immobilized 
immune sera after one year incubation did not bind specifically to PLGA NPs.  
The purified proteins from immune-sera by means of affinity chromatography using 
PLGA loaded columns showed no characteristics of PLGA-Abs. These proteins were 
analyzed by tryptic digestion and peptide mapping using mass spectrometry and 
rather revealed sequences for proteins that bear strong homology to albumins. This 
means that the immunisation of rabbit 52 and 53 was not efficient and a more 
stringent immunization strategy had to be carried out (Chapter 6). Due to this 
unspecific interaction between albumin and PLGA a new targeting system using 
another biocompatible polymer (chitosan, Chapter 7) was developed. 
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Introduction 
To produce PLGA antibodies, two rabbits (number 52 and 53) were immunized with 
PLGA nanoparticles suspended in an adjuvant. The immunization procedure was 
performed in collaboration with a certified laboratory. Nanoparticles (NPs) were 
produced using the water-in-oil-in-water (w/o/w) solvent–evaporation technique 
(Weissenböck A. et al. 2004) in the presence of Pluronic F-68. Pluronics are a class 
of nonionic copolymers called Poloxamers that contain a central hydrophobic 
polyoxypropylene chain and two hydrophilic polyoxyethylene chains. Depending on 
the length of the side chains their surface activities can be modulated and used to 
tune the hydrophilicity-lipophilicity balance of solutions and reaction mixtures. The 
success of pc PLGA-Ab production was proven using GCC-labeling as well as ELISA 
for the sera of rabbits 52 and 53 (see Chapter 6). The CLISA method developed in 
this thesis for the detection of PLGA Abs produced in immune sera of immunized 
rabbits (rabbit number 52 and 53) was also previously optimized for other Abs to 
show the versatility of this assay and are described in Chapter 3 and 4.  
 
Determination of PLGA Abs in rabbit’s immune sera (no. 52 und 53) using 
CLISA  
As described in Chapter 3 and 4, flocculation occurs immediately after addition of 
some proteins such as anti-peroxidase Ab. To avoid this problem, several methods 
were established in addition to the described inverse dot blot method described in 
Chapter 3. The gold sol of labeled GCC was stabilized either by using Protein G or 
by increasing the amount of labeled GCC (Chapter 4). Protein G binds to the surface 
of gold particles and protects them from precipitation when the protein analytes are 
added (see Chapter 4, Figure 4). The success of labeled GCC stabilization by means 
of Protein G has been demonstrated in several examples such as labeling of GCC 
with pc anti-peroxidase Ab, pc anti-ß-LG Ab (Chapter 4).  In this part of work Protein 
G was used for stabilization of GCC-solution before addition of either LDH (Lactate 
Dehydrogenase) or sera of rabbit‟s number 52 and 53 to avoid flocculation.  
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Degradation time assay for the degradation and reloading of PLGA 
nanoparticles 
The same CLISA method was also used for a visual long term assay for the 
verification of degradation of PLGA nanoparticles bound to the receptor on the 
biocompatibly coated implant surface and a successful reloading with fresh 
nanoparticles. The principle of the degradation time assay is based on the coupling 
of PLGA-Ab in non purified immune sera (of rabbit 52 and 53) onto amino-silanized 
or amino-PEGylated carriers. The disulfides in the hinge region of the Abs in immune 
sera, which connect the heavy chains, were selectively reduced with the reducing 
agent 2-MEA (2-mercaptoethanolamine) to create two Fab` fragments, each of which 
contains one antigen binding site (Palmer J.L. and Nissmoff A. 1963; Sun M C. et al. 
2005). The generated free sulfhydryl groups can be used for immobilization by 
means of thiol-reactive probes or crosslinkers such as Sulfo-SMCC. As conjugation 
takes place via -SH groups in the hinge region of the Ab, the antigen binding regions 
retain their activity. The antibody fragments were immobilized onto amino-silanized or 
amino-PEGylated carriers using sulfo-SMCC crosslinker. Sulfo-SMCC 
(Sulfosuccinimidyl-4-(N-maleimidomethyl)-cyclohexane-1-carboxylate) is a water 
soluble heterobifunctional crosslinker whereas SMCC [Succinimidyl-4-(N-
maleimidomethyl)-cyclohexane-1-carboxylate] is soluble only in organic solvents. 
Both can be used to immobilize either the whole antibody molecule or an Ab-
fragment (Fab´) by reacting with primary amines (Figure 1). The NHS-ester as part of 
the cross linker reacts with primary amines, whereas the maleimide group reacts with 
the sulfhydryls of the cleaved Ab fragments.  
 
 
Figure 1.  Immobilization of antibody fragments onto carriers containing amino groups via sulfo-SMCC 
activation. 
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These carriers bind specifically to PLGA NPs. The binding between immobilized 
PLGA-Ab on the carrier and PLGA NPs was detected using CLISA. For this 
procedure, gold colloid cluster (GCC) conjugate was used to label PLGA-Abs in the 
immune sera. Subsequently, the carriers that were loaded with PLGA NPs were 
incubated with GCC-PLGA-Abs. The binding of PLGA NPs to the carriers could then 
be detected visually as the GCC-labeled PLGA-Abs bound onto PLGA NPs on the 
carrier.  
 
 
 
Figure 2. Schematic representation of the principle for testing of reloadability of coated implant 
materials.  
 
To assess degradation of PLGA NPs over time, the carriers were then incubated in 
Ringer´s solution at 37°C mimicking the chemical composition of body fluids 
surrounding a putative implant. After complete degradation of PLGA NPs, the binding 
site (immobilized Abs on the carrier surface) becomes free again to bind PLGA NPs 
(Figure 2). Consistent with this mechanism is the decrease of the intensity of red 
color that results from GCC labeled PLGA-Abs, which can be directly visualized. 
After complete degradation of PLGA-NPs, the GCC labeled PLGA Abs dissociated 
from the carrier as the binding partner (PLGA-NPs) was missing, resulting in a 
colorless carrier. After repeated incubation of the carrier with PLGA NPs the color 
intensity then increased again, as GCC labeled Abs were able to bind again. 
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Purification of IgGs from rabbit 52 and 53 immune serum using Dynabeads® M-
280 Sheep anti-Rabbit IgG or Protein A 
 To produce PLGA-Abs that may serve as a biorecognitive binding site for PLGA NPs 
on implant surface material, rabbit‟s no. 52 and 53 were immunized. As mentioned 
earlier, the immunization procedure was performed by a certified laboratory and was 
not a part of this thesis. However, several purification methods for serum to isolate 
PLGA-Abs had to be developed in this thesis. Immunoglobulins G (IgGs) in sera of 
rabbit no. 52 and 53 were isolated using  Dynabeads®  M-280 Sheep anti-Rabbit, or 
Protein A Antibody Purification Kit. Affinity chromatography was carried out to purify 
PLGA-Abs from isolated IgGs with either Dynabeads® M-450, Epoxy containing 
immobilized PLGA, or in a different approach by Gulsenit conjugated with PLGA as a 
column material. Moreover, the effect of direct isolation of PLGA-Ab using affinity 
chromatography was investigated.  
 
     
 
Figure 3.  Schematic principle of purification of IgGs using Dynabeads
®
 M-280 Sheep anti-Rabbit.   
 
Dynabeads® M-280 Sheep anti-Rabbit IgG 
 Dynabeads are uniform superparamagnetic polystyrene beads with a surface 
suitable for physical and chemical binding of antibodies (Abs), Antigens (Ags) or 
other biomolecules. Dynabeads provide a versatile tool for isolation of both cells and 
non-cellular targets (such as proteins and other biomolecules). Using a magnet 
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(Dynal® MPCTM, Magnetic Particle Concentrator), the beads can be easily separated 
and the target molecules can then be handled in a highly specific manner. The beads 
can be added directly to the sample containing the target Ab/Ag. Dynabeads® M-280 
Sheep anti-Rabbit (2.8 µm) are designed as a solid support for simple and efficient 
binding of all rabbit IgGs via a rabbit primary Ab (Figure 3). All IgGs in sera of rabbit 
no. 52 and 53 were isolated via Dynabeads® M-280 Sheep anti-Rabbit. 
 
 
Affinity chromatography of purified IgGs of rabbit 52 and 53 to isolate PLGA-
Abs 
 PLGA IgGs were isolated from the purified IgG fraction of rabbit sera via 
Dynabeads® M-280 Sheep anti-Rabbit or a protein A column. The carriers for affinity 
chromatography (either Dynabeads® M-450Epoxy or Gulsenit) were immobilized with 
PLGA. In a second approach the PLGA-Abs were isolated directly from immune sera 
(rabbits no. 52, 53) without previous purification of IgGs by means of PLGA 
immobilized to Gulsenit. As a control, this affinity chromatography was also carried 
out with pre-immune serum of rabbit and human serum. Dynabeads® M-450 Epoxy 
(4.5 µm diameter) are hydrophobic and covered with surface epoxy groups, these 
may be used for immobilization of ligands containing amino, thiol or hydroxyl groups. 
No further activation is necessary and irreversible binding of the ligands to the epoxy 
groups is achieved over a wide temperature range and at a neutral to alkaline pH. 
PLGA (Resomer RG 502 H) was coupled onto Dynabeads® M-450 Epoxy (Figure 4) 
and used as a material for affinity chromatography to bind PLGA-Abs from previously 
isolated IgGs of sera (rabbit‟s no. 52, 53).  
 
 
 
Figure 4. Immobilization of PLGA onto Dynabeads
®
 M-450 Epoxy 
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Results and Discussion 
Detection of PLGA Ab in sera of rabbit 52 and 53 
The immunization of rabbits 52 and 53 was carried out by injection of PLGA-NPs, 
which contained a small amount of Pluronic. Therefore, the immune sera were tested 
for PLGA and Pluronic Abs. Several dilution series of PLGA and Pluronic were 
incubated in GCC solution including Protein G and labeled with immune serum of 
rabbit 52 or 53 respectively. Both immune sera of Rabbit 52 and 53 gave similar 
results, whereas the negative controls (Pluronic and PLGA samples) showed no 
signal when incubated in GCC solution containing Protein G and GCC blocking 
solution (Figure 5). PLGA samples incubated in GCC-labeled solution showed a faint 
color signal at an immune serum dilution of 4:10.000 and at PLGA concentrations in 
the range between 10 mg/ ml and 1 mg/ml. At PLGA concentrations from 0.5 to 
0.005 mg/ml, the faintest color signal was seen at 5:10.000 immune serum dilution. 
The color intensity of PLGA in the concentration range between 10 to 1 mg/ml and 
between 0.5 to 0.005 mg/ml was identical (Figure 5). This shift of color intensity 
between the two different ranges (10 to 1 mg/ml and 0.5 to 0.005 mg/ml) by either 
low concentrations of PLGA or immune sera is indicative of a protein (possibly a 
PLGA Ab) present in the immune sera that binds specifically to PLGA.  
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Figure 5. Detection of PLGA Ab in immune serum of rabbit 52 using GCC-labeling. A positive color 
signal was observed when incubating different PLGA concentrations in different dilutions of GCC-
labeled with immune serum. The color intensity was depending on the concentration of both, PLGA 
and dilution of immune serum. No signal was detected by incubation with Pluronic in different dilutions 
of GCC-labeled with immune serum (negative control). In the negative control for PLGA Abs PLGA 
samples were incubated in GCC solution without Abs, but with Protein G and GCC blocking solutio; no 
signal was detected. 
 
Degradation time assay for the degradation and reloading of PLGA 
nanoparticles 
The degradation time assay was carried out with immune sera of rabbit 52 and 53, 
omitting purification to test the avidity of whole immune sera and benefit from the 
total amount of PLGA Ab in the immune serum of rabbit 52 and 53. A positive 
interaction between immobilized immune sera on amino-silanized glass carriers and 
PLGA NPs was visualized directly by color reaction (Figure 6 A; 1, 2) using CLISA 
(GCC-labeled with immune serum of rabbit 52 or 53 separately). The carrier for the 
negative control was prepared by omitting the immobilization of immune sera and 
showed a less intensive color reaction (Figure 6; A 3) due to some unspecific 
interaction between labeled GCC sera and amino-silanized carrier. All carriers were 
incubated in Ringer‟s solution, which was exchanged repeatedly, at 37°C under 
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gentle shaking for one month. The unspecific background of the negative control 
disappears after incubation for one day in Ringer‟s solution. However, the color of 
carriers containing immobilized immune sera faded slower during two months 
incubation (Figure 6 B; 1, 2, 3). After the two months of incubation, the carriers were 
reloaded with fresh PLGA NPs, and reloading was detected again using the CLISA 
method as described previously. The carriers with immobilized immune sera showed 
a marked increase in color (Figure 6 C; 1, 2). However, color intensity was lower than 
that observed after the initial loading (Figure 6 A). Carriers were also incubated in 
Ringer‟s solution for a period of one year, and the reloading with PLGA NPs and 
detection using CLISA were repeated. This time the color intensity remained constant 
as that observed prior to reloading with PLGA (Figure 6 D; 1, 2). This means that the 
immobilized immune sera, after incubation for one year, did not bind specifically to 
PLGA NPs. Therefore, PLGA-Abs were purified from immune rabbit sera in order to 
immobilize a high amount of PLGA Abs. 
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Figure 6. Long time testing for reloadability of carriers using CLISA for the detection of the 
biorecognitive interaction between immobilized immune sera 1: rabbit 52, 2: rabbit 53, 3: negative 
control) on carriers containing bound PLGA-NPs (A). B: After 2 months of incubation in Ringers 
solution at 37°C. C: After reloading of PLGA NPs. D: After one year of incubation the color remained 
constant even after repeated loading with PLGA NPs. Negative control (3) omitting immobilization of 
immune serum showed a faint color signal (A) and this color disappears after one day incubation.  
 
Moreover, the degradation time assay was carried out using different amino-
PEGylated materials [stainless-steel L316 and ceramics (ZrO2)] and compared with 
glass. The color intensity for ceramics and glass was similar and therefore only glass 
carriers were incubated in Ringer solution for one year as described before. The 
amino-PEGylation was carried out at pH 5 and 10. Both pH conditions showed 
positive signals (Figure 7). The negative controls showed a faint color reaction as 
was already discussed before. 
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Figure 7. CLISA on different amino-PEGylated carriers loaded with PLGA NPs shows a positive signal 
and negative controls without PLGA NPs show a much fainter color. 
 
Purification of immune serum  
In this section, some of the issues that proved difficult to resolve and impacted on the 
proof of principle for using PLGA Abs as capture molecules for PLGA NPs will be 
discussed. CLISA showed a positive interaction between PLGA and GCC-labeled 
with immune sera of rabbits 52 and 53. In this section CLISA was carried out using 
GCC labeled with preimmune serum of rabbits that should have served as a negative 
control to compare with immune sera. Surprisingly, even the preimmune serum either 
fresh, or old (stored for one year at -20°C) showed a positive interaction with PLGA 
dotted onto a microtiter plate (Figure 8). Thus, the question arose as to which protein 
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is present regularly in the serum of rabbits and binds to PLGA. One of the possible 
candidates was L-Lactate dehydrogenase (LDH). LDH is an ubiquitous enzyme in all 
vertebrate species and catalyzes the final reaction step of glycolysis, the formation of 
L-(+)-lactic acid. The enzyme activity that is found in serum or plasma usually 
originates from the liver, the heart, and skeletal muscle, and erythrocytes as well as 
from tumors (Kopperschläger G. et al. 1996). Haemolysis may increase lactate 
dehydrogenase-1 in the serum (Leung F. et al. 1981). Therefore, to assess whether 
LDH could be a possible, ubiquitous unspecific binding protein, LDH from different 
species (pork, cow and rabbit) was also labeled with GCC solution and incubated in 
microtiterplates dotted with PLGA. CLISA tests showed no interaction between PLGA 
and LDH (Figure 8). Therefore, LDH can be ruled out as the protein binding 
unspecifically to PLGA.  
 
 
 
Figure 8. CLISA of preimmune sera (fresh, old) and immune-sera of rabbit (r.) 52 and 53. All sera 
showed a positive interaction between sera and PLGA dotted onto the microtiterplate. The highest 
color intensity was observed in fresh preimmune sera. No color signal was observed in LDH of 
different species and in the 1st and 2nd negative control (-). Negative control 1 shows the incubation 
of GCC solution containing Protein G and GCC blocking solution in the wells coated with different 
concentrations of PLGA. In negative control 2 the wells were blocked and washed then incubated with 
GCC-labeled with sera or LDH.  
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On the basis of these results, preimmune serum and immune-serum was purified by 
means of affinity chromatography using PLGA loaded columns to identify which 
protein in serum interacts with PLGA. This protein could then be used as a specific 
binding site for PLGA-NPs instead of PLGA-Abs. For this purpose, PLGA was 
immobilized onto amino-silanized Gulsenit. The efficiency of immobilization was 
determined with the Kaiser-test (Figure 9) described in Chapter 1. 
 
 
 
Figure 9. Kaiser test of amino-silanized Gulsenit before and after immobilization of PLGA. The lighter 
blue colour indicates the lower amount of free amino groups in amino-silanized Gulsenit after coupling 
of PLGA. 
 
Table 1 shows that the concentration of purified protein using Gulsenit coupled with 
PLGA (affinity chromatography columns material) from preimmune serum is lower 
than that of immune serum of rabbit 52 and 53 measured by Qubit™ Fluorometer. 
These proteins were analyzed by native gel electrophoresis (Figure 10) and western 
blot (Figure 11).  
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 Sample Method 
Protein concentration 
µg/ml 
Rabbit‟s preimmune 
serum  
Affinity chromatography  
Gulsenit 
15.1 
Immune serum of rabbit 
52 
Affinity chromatography  
Gulsenit 
18.5 
Immune serum of rabbit 
53 
Affinity chromatography  
Gulsenit  
17.2 
Rabbit‟s preimmune 
serum  
Dynabeads
®
 M-280 
Sheep anti-Rabbit  
16.88 
Immune serum of rabbit 
52 
Dynabeads
®
 M-280 
Sheep anti-Rabbit 
17.3 
Immune serum of rabbit 
53 
Dynabeads
®
 M-280 
Sheep anti-Rabbit 
16.5 
Preimmune serum of 
rabbit 
Protein A  13.6 
Immune serum of rabbit 
52 
Protein A  15.6 
Immune serum of rabbit 
53 
Protein A 14.5 
 
Table 1. Concentration of proteins isolated from preimmune serum and immune serum using different 
methods and measured by means of a Qubit™ Fluorometer. 
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Figure 10. Native gel after CBB-stain of purified sera using affinity chromatography. 1: protein ladder 
Rage Ruler TM, 2: human serum, 3: immune serum of rabbit 53, 4: rabbit preimmune serum 5; 
immune serum of rabbit 52.  
 
Even the isolation of pure IgGs from immune sera, either using Dynabeads® M-280 
Sheep anti-Rabbit, or Protein A columns, confirmed that the preimmune serum 
contained a lower concentration of IgGs than the immune sera. After affinity 
chromatography of the pure IgGs, no more protein could be detected using Qubit™ 
Fluorometer measurement. These results were also confirmed by analysis of isolated 
IgGs from all sera after native gel electrophoresis using ELISA and AP detection; a 
black smear was observed (Figure 11: lanes 1, 2, 5) which referees to the presence 
of different kinds of IgGs in the sample. However no signals were observed after 
affinity chromatography (using Dynabeads® M-450 Epoxy with coupled PLGA) of the 
isolated IgGs (Figure 11). These experiments confirm that the immune sera of rabbits 
52 and 53 do not contain PLGA IgGs.  
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1 purified IgGs from preimmune serum isolated with  Dynabeads
®
 M-280 Sheep anti-
Rabbit 
2 purified IgGs of preimmune serum isolated via protein A followed by affinity 
chromatography using Gulsenit with PLGA isolated via Dynabeads
®
 M-280 Sheep 
anti-Rabbit 
3 1 after affinity chromatography using Dynabeads® M-450 Epoxy with coupled PLGA 
4 2 after affinity chromatography using Dynabeads® M-450 Epoxy with coupled PLGA 
5 purified IgGs of rabbit 52 of serum  immune isolated with Dynabeads
®
 M-280 Sheep 
anti-Rabbit 
6 protein ladder Page Ruler TM 
7 5 after affinity chromatography using Dynabeads® M-450 Epoxy with coupled PLGA 
8 purified IgGs of preimmune serum isolated via protein A and after affinity 
chromatography using Gulsenit with PLGA 
9 purified IgGs of rabbit 53 isolated via protein A and after affinity chromatography using 
Gulsenit with PLGA 
10 purified IgGs of rabbit 52 isolated via protein A and after affinity chromatography using 
Gulsenit with PLGA 
 
Figure 11. Detection of purified proteins from preimmune and immune serum after native gel 
electrophoresis by means of ELISA and AP. The black smear in lanes 1 and 2 shows the presence of 
different kinds of IgGs in the sample and empty lanes demonstrate that the immune serum of rabbit 52 
and 53 do not contain PLGA IgGs.  
 
The purified proteins from preimmune- and immune-sera, by means of affinity 
chromatography using PLGA loaded columns, were analyzed by native gel 
electrophoresis. As shown in Figure 10, a single band is obtained. This band was 
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analyzed by means of tryptic digestion and peptide mapping using mass 
spectrometry, revealing a sequence that bears strong homology to albumins 
(Appendix section 2.1, Figure 3), indicating that albumins in rabbit serum interact with 
PLGA. To show whether this interaction is specific to rabbit albumins or also occurs 
in human albumins, human serum was purified analogous to rabbit serum and then 
analyzed by native gel electrophoresis. The results demonstrated that human serum 
albumin interacts as well with PLGA (Figure 10).   
 
Considering the results from CLISA, affinity chromatography, native gel and finally 
mass spectrometry, it is very likely that the color reaction observed in the degradation 
time assay may also be caused by an unspecific interaction between rabbit albumin 
immobilized to the implant surface and PLGA NPs. Due to this unspecific interaction, 
it is recommended for purification of PLGA Abs from immune serum that IgGs should 
be isolated first and afterwards affinity chromatography can be carried out as 
described previously. These results show the problems that may arise in principle 
when PLGA NPs are intended for use as a drug targeting system: Serum albumins 
will bind to the PLGA surface thus lowering the chance of site specific targeting! 
Futhermore, this finding suggests that the surface of PLGA-NPs needs to be coated 
adequately to prevent binding of serum albumin onto PLGA before injecting the 
particles into the human body. The coating of PLGA-NPs could be achieved by using 
biocompatible “non fouling” biodegradable polymers to prevent accumulation of the 
coating material in the body if frequent injections are necessary and also to allow for 
reloading. The results presented thus far in this Chapter, as well as the results 
obtained by ELISA (Chapter 6), demonstratethat the immunisation of rabbit 52 and 
53 was not efficient. This led us to change the immunization strategy (see Chapter 6) 
and search for other targeting systems using biocompatible polymers, such as 
chitosan (see Chapter 7). 
 
Experimental Methods 
Preparation of PLGA-nanoparticles 
Nanoparticles (NPs) were produced using the water-in-oil-in-water (w/o/w) solvent–
evaporation technique according to Weissenböck et al., 2004. PLGA (Resomer RG 
503H, 400 mg, Boehringer Ingelheim) was dissolved in 2 g ethyl acetate under 
stirring at 4°C. This PLGA solution was emulsified with 400 µl dd. H2O (or solutions of 
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drugs, enzymes, etc.) by sonication for 60 sec (Sonifier Bandelin electronic UW 
70/HD 70; tip, MS 72/D, Berlin, Germany) under cooling in a water bath. 6 ml of 10% 
Pluronic F-68 solution was added rapidly and the emulsion was sonicated again for 
50 sec under cooling to yield the (w/o)/w emulsion. The (w/o)/w emulsion was rapidly 
poured into 1% Pluronic F-68 (Sigma Aldrich) solution. After stirring (600 rpm) for 1 
hour at room temperature the residual ethyl acetate was removed under reduced 
pressure (100 mbar) and rotation (170 rpm) for 30 min and finally for further 30 min 
under high vacuum. The resulting NPs were filtered (Prefilter 1µm glass fiber, 
Millipore) to eliminate aggregates. The mean particle size and distribution were 
determined by dynamic light scattering (DLS; Zetasizer Nano ZS, Malvern 
Instruments Ltd, U.K.) in triplicate at 20°C. The NPs suspension was stored at -80°C 
until use. To measure PLGA concentration in a NP suspension and for other 
applications, as much Pluronic as possible should be removed from the NP 
suspension using diafiltration as following. Therefore, 20 ml of the PLGA NP 
suspension was carefully washed (7 times) with 40 ml dd. H2O on a tangential flow 
filtration system, using an ultrafiltration membrane (Vivaflow 50; 100000 MWCO 
PES, Sartorius Vivascience G.m.b.H). The tangential flow was generated by a 
peristaltic pump (MV-CA 8, Ismatec, Glattbrugg) at a system pressure of 2.5 bar. As 
the washed NP suspension is less stable when most of Pluronic is removed, it was 
used immediately. The concentration of PLGA in NPs suspension was determined 
after lyophilisation of 1 ml washed NPs yielding 2.86 mg/ml. 
The average size of the used PLGA-NPs was 130 nm and PdI was 0.162 and the 
concentration of PLGA used was determined by the weight after lyophilisation and 
found to be 2.86 mg/ml. 
 
Detection of PLGA antibodies in sera of rabbit 52 and 53 
Success of pc PLGA-Ab production was quantified using GCC-labeling as well as 
ELISA for the sera of rabbits 52 and 53 (see Chapter 6). For this purpose several 
dilution series of PLGA (RG 503 H) in DMSO were made in a concentration range 
between 10 to 0.005 mg/ml. In contrast to other organic solvents for PLGA, DMSO 
doesn‟t damage the polystyrene surface material of the microtiterplate. The dotted 
PLGA samples were incubated with GCC-labeled sera, either serum after 
immunization (immune-serum) of rabbit no. 52 or 53. Different amounts (from 10 to 
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0.5 µl) of the sera were added to 10 ml GCC solution. Each dilution of GCC, labeled 
with immune-serum was incubated in the serial dotted dilutions of either PLGA or 
Pluronic respectively to test also for the formation of antibodies against Pluronic.  
During the synthesis of PLGA nanoparticles, Pluronic is added to stabilize 
nanoparticles. Therefore, it had to be determined whether the immune sera of rabbits 
52 and 53 included Pluronic Abs. Pluronic samples were treated analogous to PLGA 
samples.  
The wells of the microtiterplate (MicroliteTM 2, DYNATECH) were filled  with 60 µl  
sample per well [either PLGA dissolved in DMSO containing 1% (v/v) glycerol, to 
keep PLGA samples hydrated during drying at room temperature, or Pluronic diluted 
in dd. H2O] for one hour at room temperature. The serial dilutions of either PLGA or 
Pluronic were dotted separately into the wells for incubation in each GCC-labeled 
solution with either immune-serum of rabbit 52 or rabbit 53. As a negative control, 
one serial dilution was incubated in 350 µl per well GCC solution including Protein G, 
GCC-blocking solution and omitting immune sera of rabbit 52 or 53 [10 ml GCC 
solution containing 10 µl (1mg/ml) Protein G and 1 ml GCC-blocking solution]. The 
microtiterplate was emptied by shake off and blocking solution [50 mM Tris/HCl pH 
7.3 containing 2% (w/v) fish gelatine, 0.1% (v/v) Tween 20] was added to the wells 
for 20 min then washed 3 times for 5 min in washing solution [50 mM Tris/HCl pH 7.3 
containing 0.5% (v/v) Tween 20] under shaking, followed by rinsing 2 times in dd. 
H2O. Then eleven GCC-labeled solutions with immune-serum were prepared 
identically, however each solution included a different amount of immune serum 
(from 10 µl to 0.5 µl). 10 ml GCC solution was stirred with 10 µl Protein G (1 mg/ml) 
for 20 min at room temperature. Thereafter, 10 µl of either immune-serum of rabbits 
52 or 53 was added respectively under stirring for further 30 min at room 
temperature, followed by adding of 1ml GCC-blocking solution under continuous 
stirring for another 30 min. The samples on the microtiterplate were incubated in 350 
µl per well of either GCC-labeled immune-serum solution of rabbit 52 or 53, GCC-
labeled preimmune serum, or in GCC-labeled LDH solution (see below) separately 
for 2 hours at room temperature under shaking. The samples on the microtiterplate 
were washed 3 times in washing solution and then 3 times rinsed in dd. H2O. The 
detection of a positive signal (red color of gold clusters) was observed with the naked 
eye. 
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Preparation of GCC-labeled LDH (Lactate Dehydrogenase) solution  
Three portions of GCC solution (10 ml each) were stirred with 10 µl Protein G 
(1 mg/ml) for 20 min at room temperature. Thereafter to each solution 5 µl of a 
solution of 2.5 mg/ml LDH of pork or cow or rabbit respectively diluted in dd. H2O 
were added at room temperature under stirring for another 30 min followed by 
addition of 1ml GCC-blocking solution under continuous stirring for another 30 min.  
 
Preparation of GCC-labeled preimmune serum 
10 ml GCC solution was stirred with 10 µl Protein G (1 mg/ml) for 20 min at room 
temperature. Thereafter, 10 µl of either preimmune serum or immune-serum of 
rabbits 52 or 53 was added respectively under stirring for further 30 min at room 
temperature, followed by adding of 1ml GCC-blocking solution under continuous 
stirring for another 30 min.  
 
Degradation time assay for the degradation of PLGA-nanoparticles and 
reloading 
Antibodies (Abs) in immune sera (of rabbit 52 and 53) were cleaved by means of 2- 
MEA and then immobilized onto the surfaces of amino-silanized or amino-PEGylated 
materials (glass, stainless steel 316 L and ceramic). These carriers were then 
blocked, washed, and incubated in a solution of washed PLGA-NPs. The carriers 
were washed and then incubated in GCC-labeled immune serum of rabbit 52 or 53.  
 
Procedure: 
Organic amino-silanization and amino-PEGylation by means of EDC/Sulfo-NHS of 
carriers are described in Chapter 1. Abs in immune-sera of rabbit 52 or 53 were 
cleaved by means of 2-MEA (see below). These cleaved Abs were immobilized onto 
carriers, activated with sulfo-SMCC (see below). This step was omitted for negative 
control carriers. PLGA-NPs were preparated (with a size of 151 nm) and washed as 
described in Chapter 6. The carriers were incubated in PLGA NP suspension (2ml/ 
carrier) overnight at 4°C on an orbital shaker under gentle shaking. GCC-labeled 
immune serum of rabbit 52 or 53 was preparated by stirring of 10 ml GCC-stock 
solution with 10 µl immune-serum of either rabbits 52 or 53 for 30 min at room 
temperature respectively, then 1 ml of GCC-block solution was added under 
continuous stirring for another 30 min). The carriers were rinsed in dd. H2O, then 
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blocked and washed as mentioned by immobilization of cleaved antibody fragments 
onto carrier activated with sulfo-SMCC (see below). The carriers were incubated in 
GCC-labeled immune serum (2 ml/ carrier) for two days at 4°C under gentle shaking 
on an orbital shaker, then washed as mentioned before. For the degradation time test 
carriers (amino-silanized glass) were incubated for one year in Ringer‟s solution (2ml/ 
carrier) under gentle shaking at 37°C in a water bath. Ringer‟s solution was replaced 
repeatedly. These carriers were loaded again with washed PLGA NPs and binding 
was detected with the GCC labeling method, as described above, after two months 
incubation in Ringer‟s solution and again after one year.  
 
Cleavage of disulfide bonds in the hinge region of the antibodies with 2-
mercaptoethanolamine 
2-mercaptoethanolamine can be used to cleave disulfide in the hinge region of IgG 
(Yoshitake S. et al. 1979). The most critical aspects are the concentrations of 2-
mercaptoethanolamine (2-MEA) and EDTA in the reaction mixture. An optimal 
reduction of IgG takes place in 50-100 mM 2-MEA and 1-100 mM EDTA. The pH of 
the reaction may vary from pH 6 to 9, with an optimum of pH 8. The concentration of 
Ab can vary too. This method was used to cleave IgG in immune sera of rabbits 52 or 
53.  
 
Procedure: 
6 µl immune serum was diluted in 0.1M PBS with 0.15 M NaCl, pH 7.2 containing 3 µl 
10 mM EDTA and 3 µl 1.5 NaCl. 5 mg of 2-MEA was dissolved in 10 µl H2O, 3 µl was 
added to immune serum solution and incubated for 90 min at 37°C. The cleaved IgG 
in serum was separated from the reducing agent by means of gel filtration using 
Sephadex G-25. Use 0.1M PB, 0.15 M NaCl, pH 7.2 containing 10 mM EDTA as 
chromatography buffer. 300 µl fractions were collected and selected for free –SH 
groups of the Fab´ fragments with the Ellman's test. The fractions with positive 
Ellman's test containing reduced Ab were pooled and immediately used for 
immobilization onto sulfo-SMCC activated amino-silanized or amino-PEGylated 
carriers (see below). 
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Activation of amino-silanized or amino-PEGylated carriers with sulfo-SMCC to 
immobilize cleaved Abs  
The amino-PEGylated (NH2-PEG-NH2) or amino-silanized carriers (4x 12 mm glass 
slides) were washed with buffer (0.1 M PBS with 0.15 M NaCl, pH 7.2). 4 mg sulfo-
SMCC was dissolved in 1 ml dd. H2O and then filled to 11 ml with washing buffer. 
The carriers were incubated for 30 min in this solution under gentle shaking. The 
carriers were washed 3 times with buffer for 5 min under gentle shaking. The 
activated carriers can be stored freeze-dried for at least one year without losing 
maleimide activity. 
 
Immobilization of cleaved antibody fragments onto carrier activated with sulfo-
SMCC  
400 µl of cleaved Abs in immune sera of rabbit 52 or 53 using 2-MEA was pipetted 
onto the carriers activated with sulfo-SMCC. The carriers were incubated for 2 days 
under gentle shaking at 4°C in a humid chamber. The carriers were washed 3 times 
for 5 min with washing solution under gentle shaking. Washing solution contained 
0.5% (v/v) Tween 20 and 0.1 M PB, 0.15 M NaCl, pH 7.3. The carriers were blocked 
for 30 min with blocking solution [2% (w/v) gelatine from cold water fish skin 
dissolved in 0.1 M PB, 0.15 M NaCl, pH 7.4 and 0.1% (v/v) Tween 20] under gentle 
shaking. The carrier was washed 2 times for 5 min in washing solution under gentle 
shaking. Now the carriers were for incubation with PLGA-NPs. 
 
Purification of IgGs from rabbit 52 and 53 serum using Dynabeads® M-280 
Sheep anti-Rabbit IgG 
All IgGs in sera of rabbit no. 52 and 53 were isolated as described in the following. 
 
Washing procedure of Dynabeads® M-280 Sheep anti-Rabbit 
The Dynabeads® M-280 Sheep anti-Rabbit were resuspended thoroughly in the vial 
by vortexing and shaking. 1 ml of resuspended beads was transferred into a 2 ml 
Eppendorf vial. The vial was placed onto the magnet for 2 min and the supernatant 
removed by pipetting, carefully avoiding to touch the inside wall of the tube (where 
the beads attract to the magnet) with the pipette tip. The vial was removed from the 
magnet and the pellet was resuspended in 1 ml wash buffer (PBS buffer pH 7.4 
(washing buffer) containing 0.16 g NaH2PO4.H2O, 0.98 g Na2HPO4.2H2O, 8.10 g 
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NaCl was filled with dd. H2O to 1L). The vial was placed onto the magnet for 2 min 
and the pellet again resuspended in 1 ml wash buffer. 
 
Separation procedure of target IgG 
The pellet of washed beads was resuspended in 1 ml diluted serum of rabbit no. 52 
or 53 respectively (300 µl of serum was made up to 1 ml with PBS pH 7.4 and  
centrifuged briefly at 14.000 rpm) and incubated under slow tilted rotation mixing over 
night at 4°C. The Eppendorf vial was placed for 2 min on the magnet and the 
supernatant pipetted off. The Eppendorf vial was removed from the magnet and the 
pellet resuspended in 1 ml washing buffer. This wash step of the pellet in 1 ml 
washing buffer was repeated twice. The bound and purified IgGs were now ready to 
be eluted off the beads. 
 
Elution procedure of isolated IgGs 
300 µl 0.1 M citrate buffer pH 2.5 (elution buffer) was added to the beads with 
immobilized IgGs and mixed well by tilting and rotation for 2 min At pH 3.1 most of 
the IgGs are expected to be eluted. 3 times consecutively, the Eppendorf vial was 
placed on the magnet and the supernatant containing purified IgGs transferred to a 
clean and autoclaved Eppendorf. The pH was immediately neutralised with saturated 
sodium phosphate (Na3PO4) buffer pH 12.7. The pellet was resuspended again in 
300 µl 0.1 M citrate buffer pH 2.5 to elute any remaining IgGs and mixed well by 
tilting and rotation for 2 min.  
For a qualitative determination of the protein content Bradford protein assay 
chemistry was used. 20 µl Bradford reagent (Bio-Rad Protein Assay) diluted 1:5 with 
dd. H2O were added to 2 µl of supernatant and the color changed to blue. Then the 
supernatants of the first and second eluate containing pure IgGs were pooled. The 
protein concentration was measured using a Qubit Fluorometer (Invitrogen). 
Subsequently PLGA-Abs were isolated from the pure IgGs via affinity 
chromatography, using immobilized PLGA onto either Dynabeads® M-450 Epoxy or 
Gulsenit. The concentration of pure IgGs was determined with the Quant-iT™ Protein 
Assay Kit (for use with the Qubit™ fluorometer, Invitrogen as described below). 
For reuse of the beads their pH was immediately neutralized using a Na-phosphate 
buffer. For storage, the beads were re-suspended in PBS/BSA buffer (isotonic PBS 
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buffer pH 7.4 containing 0.1 % BSA and 0.02% sodium azide (NaN3) as preservative 
for storage).  
 
Purification of serum from rabbit 52 and 53 using Protein A Antibody 
Purification Kit 
The Protein A Antibody Purification kit provides all reagents necessary for the 
isolation of IgGs. According to the product information, the Protein A cartridge can 
bind approximately 5 mg/ml IgG content from 2 ml of human serum.  
 
Serum purification 
1 ml binding buffer was added to 500 µl of serum (serum-Binding buffer) and mixed 
well. A 10 ml syringe was filled with 10 ml HEPES buffer and connected to the top 
(male connector) of the desalting cartridge. The cartridge was regenerated by 
passing the buffer through the cartridge at an approximate flow rate of 1 ml/min. A 5 
ml syringe was filled with 5 ml Regeneration buffer and connected to the top (male 
connector) of the Protein A cartridge. The Cartridge was regenerated by passing the 
buffer though the cartridge at an approximate flow rate of 1 ml/min. A 10 ml syringe 
was filled with 4 ml Binding buffer. The Protein A cartridge was equilibrated by 
passing the buffer through the cartridge at an approximate flow rate of 1 ml/min. A 10 
ml syringe was filled with serum-Binding buffer mixture. The Protein A cartridge was 
loaded by passing the serum-Binding buffer mixture through the cartridge at an 
approximate flow rate of 0.5 ml/min. After the sample was loaded onto the Protein A 
cartridge, the 10 ml syringe was rinsed with 1 ml H2O and refilled it with 6 ml Binding 
buffer and the Protein A cartridge washed by passing the buffer through the cartridge 
at an approximate flow rate of 1 ml/min. The female end of the Protein A cartridge 
was attached to the male Luer lock fitting to the Desalting cartridge. The 5 ml syringe 
was filled with 1.5 ml Elution buffer and attached to the Protein A cartridge. The 
cartridge was eluted by passing the Elution buffer through the cartridge at an 
approximate flow rat of 0.5 ml/min. The purified IgGs in the eluate show a neutral pH. 
For a qualitative determination of the proteins by means of the Bradford protein 
assay 20 µl Bradford reagent (Bio-Rad Protein Assay) were diluted 1:5 with dd. H2O 
and added to 2 µl of elute and the color changed to blue. The concentration of eluate 
was determined with the Quant-iT™ Protein Assay Kit (for use with the Qubit™ 
fluorometer, Invitrogen, as described below). The two cartridges (Protein A cartridge 
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and Desalting cartridge were detached and regenerated by passing 5 ml 
Regeneration buffer through the Protein A cartridge and 10 ml HEPES buffer through 
the Desalting cartridge. Regeneration was proven by a negative Bradford protein 
assay.  
 
Immobilization of PLGA onto Dynabeads® M-450 Epoxy for affinity 
chromatography 
Washing procedure 
The Dynabeads® M-450 Epoxy were resuspended thoroughly by vortexing and 
shaking. 1 ml of resuspended beads was transferred into a glass tube. The tube was 
placed on the magnet for 2 min and the supernatant discarded. The vial was 
removed from the magnet and the pellet resuspended in 1 ml dd. H2O. Step 3 was 
repeated and the pellet resuspended again in 1 ml dd. H2O. 
 
PLGA coupling procedure to Dynabeads® M-450 Epoxy 
The pellet of washed beads was resuspended in 5 ml of 500 mg PLGA (Resomer RG 
502H) dissolved in 2 ml DMSO. The incubation was carried out over night at room 
temperature under slow rotation. The tube was placed in the magnet and the 
supernatant was discarded. The pellet was mixed and incubated with 1 ml DMSO for 
5 min under rotation to remove uncoupled PLGA. The tube was placed in the magnet 
and the supernatant was discarded. 3 times consecutively, the pellet was washed 
again with 1 ml isotonic PBS buffer pH 7.4 and incubated for 5 min under rotation. 
The tube was placed in the magnet and the supernatant was discarded. The third 
time the beads were rotated with isotonic PBS buffer pH 7.4 for 10 min.  
 
Affinity chromatography using Dynabeads® M-450 Epoxy with coupled PLGA 
Separation procedure of PLGA-Ab  
PLGA-Abs were isolated from the pure IgGs of immune sera (rabbit 52, 53) purified 
with either the Dynabeads® M-280 Sheep anti-Rabbit kit or the Protein A Antibody 
Purification Kit by means of PLGA coupled to Dynabeads® M-450 Epoxy. 
The pellet of washed beads was resuspended in 600 µl of pure IgGs of immune sera 
(rabbit no. 52 or 53 respectively) and incubated under slow tilt rotation mixing over 
night at 4°C. The remaining protocol was carried out analogous to the protocol 
described before in separation procedure of target IgG. 
Chapter 5 
161 
Elution procedure of PLGA-Ab 
The elution was carried out analogous to the protocol for the elution of isolated IgGs 
as described before.  
 
Immobilization of PLGA onto Gulsenit  
1 g PLGA (Resomer RG 502H) was dissolved in 20 ml ethyl acetate. NHS (575 µg) 
was dissolved in 40 ml ethyl acetate. N,N‟-Diisopropylcarbodiimide (DIC, 310 µl) was 
added to the dissolved NHS and this solution immediately pipetted into the dissolved 
PLGA. Mixing and reaction for one hour was performed at room temperature. The 
activated PLGA solution was incubated in 20 g amino-silanized Gulsenit (Chapter 1) 
overnight at room temperature under stirring. The Gulsenit was rinsed 3 times with 
ethyl acetate to remove unreacted PLGA followed by 3 times with dd. H2O; using a 
suction funnel, pore size 4, to remove solvent from carrier after each rinse. The 
Gulsenit can then be used as a column material for the purification of PLGA-Ab by 
means of affinity chromatography. The efficiency of immobilization was determined 
with the Kaiser-test (Chapter 1). 
 
Affinity chromatography using Gulsenit with coupled PLGA 
A 2.5 ml chromatography column  with a 10 µm pore filter at the bottom (Mo Bi Tec) 
was filled with PLGA conjugated Gulsenit and washed with 5 column volumes of 
binding buffer (5 mM PBS, 0.15 M NaCl, pH 7.2). The diluted serum (1:5 with binding 
buffer) was centrifuged shortly at 14000 rpm and then loaded onto the PLGA 
conjugated Gulsenit column at a flow rate of 0.15 ml/min. The column was washed 
with binding buffer until no proteins were detected by Bradford protein assay. 20 µl 
Bradford reagent (Bio-Rad Protein Assay) diluted 1:5 with dd. H2O were added to 10 
µl of each fraction and blue color indicated the presence of proteins. The PLGA-Abs 
were eluted with elution buffer (0.1 M acetic acid/ 0.1 M NaOAc, pH 3) at a flow rate 
of 1.7 ml/min. Every eluted fraction (two drops) was collected in a well of a 
microtiterplate containing about 10 µl neutralization buffer (0.5 M NaHCO3) to 
neutralize the purified Abs immediately. The fractions containing protein (detected by 
Bradford protein assay) were pooled and the pH was adjusted to a physiological pH. 
For a qualitative determination of the proteins by means of the Bradford protein 
assay, 20 µl Bradford reagent (Bio-Rad Protein Assay) diluted 1:5 with dd. H2O were 
added to 10 µl of each fraction and the color changed to blue. These fractions were 
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pooled. The sample was concentrated for 5 min by 4000 rpm at 4°C using an Amicon 
ultra centrifuge filter. The concentration of the eluate was determined using the 
Quant-iT™ Protein Assay Kit (for use with the Qubit™ fluorometer, Invitrogen as 
described below). 
 
Quant-iT™ Protein Assay Kit (Invitrogen) 
Three BSA standards (0 ng/µl, 200 ng/µl and 400 ng/µl in TE buffer with 2 mM 
sodium azide) were used for calibration of the Qubit™ Fluorometer. 10 µl of each 
standard was diluted in 190 µl Quant-iT™ working solution, prepared by diluting the 
Quant-iT™ protein reagent 1:200 in Quant-iT™ protein buffer and measured after 15 
min incubation at room temperature.1-20 µl (dependent on the concentration of the 
sample) of sample were diluted in Quant-iT™ protein buffer to obtain finally 200 µl 
solution. The diluted samples were mixed well (avoiding air bubbles) and the protein 
concentration measured after 15 min incubation at room temperature with the 
Qubit™ Fluorometer. The concentration of the sample was calculated using the 
following equation: 
x
valueQFsampleyourofionConcentrat
200
  
 
QF value = the value given by the Qubit™ fluorometer and 
x = microlitres of sample added to the assay tube. 
 
Native gel and Western blot 
Buffers and solutions  
Stacking gel 
The stacking gel solution contained 1 ml 30% acrylamide/ 0.8% Bisacrylamide ; 4.8 
ml dd. H2O; 2 ml 0.5 M Tris/ HCl pH 6.8; 80 µl 10% (w/v) APS and 8 µl TEMED. 
 
Separating gel 
The separating gel solution contained 6 ml 30% acrylamide/ 0.8% Bisacrylamide; 
11.8 ml dd. H2O; 6 ml 1.5 M Tris/ HCl pH 8.8 ; 200 µl 10% (w/v) APS and 20 µl 
TEMED. 
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Running buffer (pH 8.4) 
The running buffer contained 3.0 g Tris; 14.4 g glycine and was filled to 1 L with dd. 
H2O. 
 
Sample preparation and electrophoresis 
1 µl serum was diluted 1:40 in 50 mM Tris-HCl (pH 7.4) or running buffer and then 40 
µl sample buffer pH 6.7 [2.5 ml 125 mM Tris/ HCl pH 8.4; 20% (v/v) glycerin (2 ml)]; 1 
mg bromophenol blue and was made up to 10 ml with dd. H2O was added. The gel 
slots were loaded with 20 µl of sample.  
The separation of proteins was performed at 150 V and 60 mA for approximately 1 to 
1.5 hours. After separation of the proteins by electrophoresis, they have to be either 
fixed in the gel with methanol/ acetic acid / water-solution resulting in denaturation 
and precipitation of the proteins or they can be blotted onto a nitrocellulose 
membrane (NC) by Western Blotting. Gel, NC-membrane and Whatman paper for 
blotting were treated with transfer buffer [Tris (5.8 g); glycine (2.9 g); dd. H2O to 1 L, 
pH 6.5]. By semidry-blotting (NovaBlot, Pharmacia, Multiphor II SemiDry) separated 
proteins can be transferred from the gel to the NC-membrane at 10 V and 150 mA 
within 1.5 hours. The proteins adhere to the nitrocellulose membrane by hydrophobic 
interactions and can be detected on the membrane by AP (alkaline phosphatase) 
according to manufacturer‟s instructions.  
 
Visualization of proteins after gel electrophoresis: CBB-staining 
The separated proteins can be detected directly in the gel after PAGE by staining 
with Coomassie-Brilliant-Blue-R250 (CBB-R250). In acidic solution, CBB binds 
unspecifically to basic amino acids, primarily arginines, showing an absorbance shift 
from 465 nm to 595 nm. Gels were incubated in staining solution (1.25 g CBB-R250; 
5 ml acetic acid; 15 ml methanol and 30 ml dd. H2O) under shaking for 30 min and 
then in de-staining solution (25 ml acetic acid; 60 ml methanol filled to 200 ml with 
dd. H2O) over night. 
 
 
 
 
 
Chapter 5 
164 
References 
 Kopperschläger G., Kirchberger J., Methods for the separation of lactate 
dehydrogenases and clinical significance of the enzyme. Journal of 
Chromatography B: Biomedical Applications (1996) 684: 25-49. 
 Leung F., Henderson A., Influence of hemolysis on the serum lactate 
dehydrogenase-1/lactate dehydrogenase-2 ratio as determined by an accurate 
thin-layer agarose electrophoresis procedure Clinical Chemistry (1981) 27: 
1708-1711.  
 Palmer J.L. and Nissmoff A., Reduction and reoxidation of a critical disulfide 
bond in the rabbit antibody molecule. J. Biol. Chem. (1963) 238: 2393-2398. 
 Sun M C., Beam K S., Cerveny C G., Hamblett K J., Blackmore R S., Torgov 
M Y., Handley F G. M., Ihle N C., Senter P D., Alley S C., Reduction-alkylation 
strategies for the modification of specific monoclonal antibody disulfides. 
Bioconjugate Chem. (2005) 16: 1282-1290. 
 Weissenböck A., Wirth M., Gabor F., WGA-grafted PLGA-nanospheres: 
preparation and association with Caco-2 single cells. J. Controlled Release 
(2004) 99: 383-392. 
 Yoshitake S. Yamada Y., Ishikawa E., Masseyeff R., Conjugation of glucose 
oxidase from Aspergillus niger and rabbit antibodies using N-
hydroxysuccinimide ester of N-(4-carboxycyclohexylmethyl)maleimide. Eur. J. 
Biochem. (1979) 101: 395-399.  
 
 165 
 
 
 
 
 
 
Chapter 6 
Production of polyclonal antibodies against the biocompatible 
polymer PLGA using silica amino microspheres as a carrier 
 
 
 
 
                        
 
 
 
 
 
                                                    
 
 
 
 
Chapter 6 
166 
 One of the specific aims in this thesis was to search and develop a 
biorecognitive reloadable binding system for drug delivery system e.g. 
nanoparticles. 
The first chosen drug delivery system was based on functionalized PLGA 
nanoparticles. These particles should be capable of binding to antibodies as 
molecular receptors embedded on the applied biocompatible coated implant material. 
In this Chapter the production of polyclonal antibodies against the biocompatible and 
biodegradable PLGA polymer under very stringent immunisation protocol is 
described.  
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Abstract 
A very stringent immunisation protocol was developed in rabbits for the production of 
polyclonal antibodies against a biocompatible and biodegradable polymer, such as 
PLGA. To achieve this goal a number of technical problems regarding the purification 
of the antibodies and titer determination had to be solved. By direct purification of 
PLGA antibodies from sera of immunized rabbits, using affinity chromatography, a 
protein which interacts with PLGA was isolated. Analysis of this protein by means of 
native gel electrophoresis and mass spectrometry revealed that this protein has a 
homology to albumins. Therefore, we investigated the effect of human serum albumin 
on PLGA, and could prove its binding to PLGA nanoparticles. Together our results 
suggest that coating PLGA-NPs as a drug targeting system with biocompatible and 
biodegradable polymer before injecting them into the human body eliminates  
unspecific coating with serum albumin, which could  lowering the chance of site 
specific targeting in our design.  
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Introduction 
PLGA (poly (D,L-lactide-co-glycolide) is a random copolymer of glycolic acid and 
lactic acid and is widely used for bioabsorbable sutures or drug delivery systems. 
The ratio of glycolic acid to lactic acid determines the rate of degradation, mostly by 
hydrolysis. Degradation of PLGA yields lactic acid and glycolic acid, both also 
products of the endogenous metabolism. A large number of in vivo and in vitro 
studies have shown the full biocompatibility and biodegradability of PLGA 
nanoparticles and their degradation product (Athanasiou K. et al. 1996; Anderson J. 
et al. 1997; Tracy MA. et al. 1999). 
PLGA‟s versatile degradation kinetics, established safety and biocompatibility, makes 
it an ideal material for drug delivery applications. Moreover, PLGA nanoparticles not 
only modify the pharmacokinetics of encapsulated drugs, but they also protect the 
occluded drugs from enzymatic attack. 
Currently, a number of FDA-approved products on the market utilize PLGA as 
excipients to achieve sustained release of the active ingredient, such as e.g. 
Neutropin Depot, Sandostatin LAR or Trelstar Depot. PLGA nanoparticles are 
used also as a carrier for AI-700 that is used for stress echo cardiological evaluation. 
The efficiency of PLGA nanoparticles as a local drug delivery system (for example 
dexamethasone) to decrease neointimal proliferation, without having significant 
systemic effects was already shown in the rat carotid injury model after ballon injury 
(Anderson J. et al. 1997). 
Production of PLGA antibodies can have a benefit in clinical and research imaging. 
For example targeting of drugs or drug-delivery system to the site of interest drug 
containing nano-particles can be conjugated with specific antibodies against certain 
characteristic components of the tissue of interest. An example of such a passive 
targeting is the preferential accumulation of chemotherapeutic agents in solid 
tumours as a result of the enhanced vascular permeability of tumour tissues, 
compared with healthy tissue. For various therapeutic and diagnostic targeting 
purposes to PLGA-nanoparticles PLGA-antibodies are needed: A spacer molecule 
might be coupled on one end with ligands that are selectively recognized by 
receptors on the surface of the cells of interest and the other end of the spacer 
molecule then bound to PLGA antibodies which interact specifically with PLGA 
nanoparticles containing drugs for therapeutical purposes or visualisation dyes for 
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diagnostic purposes or, e.g. gadolinium for MRI (magnetic resonance imaging) or 
PET (positron emission tomography) live imaging. This could allow for a more 
precise targeting to the site of interest (for example in solid tumors) since ligand–
receptor interactions can be highly selective. 
The production of polyclonal antibodies (pAb) against a biocompatible and 
biodegradable polymer, such as PLGA (poly (D, L-lactide-co-glycolide), is still a 
challenge. Here, an approach using PLGA (a short chain polymer Resomer RG 
502H) coupled to amino group containing SAM (silica-amino- microspheres, diameter 
0.50-0.99 µm) as an antigen carrier for immunization is taken. These 100% solid 
microspheres do not contain latex, which has been shown to induce allergic reactions 
(Nutter AF. et al. 1979; Gelfand DW. et al. 1991). 
 
Results and Discussion 
Conjugation of PLGA to SAM 
Conjugation of PLGA to amino group containing SAM was achieved using DIC 
chemistry. Prior to the conjugation reaction, the terminal carboxylate groups of PLGA 
were chemically activated by the addition of DIC (diisopropylcarbodiimide), a non-
allergenic, N-substituted carbodiimide cross-linker to PLGA in ethyl acetate (Figure 
1). N-substituted carbodiimides react with carboxylate groups to form highly reactive 
O-acylisourea intermediates. To enhance the coupling efficiency to the attacking 
amine, N-hydroxysuccinimide (NHS) was added (Williams A. and Ibrahim I.A. 1981) 
and the efficiency of PLGA immobilization to SAM was assessed by determining the 
amount of unreacted free amines using the Kaiser-Test (1970).  
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Figure 1. PLGA (poly (D, L-lactide-co-glycolide) binding to the amino groups of silica microbeads 
(SAM). The conjugated complex of PLGA and SAM is used as an antigen for immunization. 
 
The injection sample contained SAM conjugated with PLGA polymer. The efficiency 
of PLGA immobilization to SAM was assessed by the Kaiser-Test (Chapter 1). Figure 
2 shows the color reaction of free amino groups in sample that contains SAM before 
PLGA conjugation with ninhydrin inducing a pink color in contrast to SAM after PLGA 
conjugation. 
 
 
Figure 2. The Kaiser-Test shows a purple color after reaction with the free amino groups of SAM. After 
binding of PLGA onto SAM, no color reaction is observed.  
 
Immunization and titer determination 
Two rabbits (numbers 95 and 96) were immunized. The injection sample contained 
SAM conjugated with PLGA polymer. The conjugated complex of PLGA and SAM is 
used as an antigen for immunization. To enhance production of specific PLGA-pAbs, 
the amount of PLGA was increased with each immunization (Table 1 in experimental 
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methods). The injection of conjugated silica microspheres into New Zealand white 
rabbits (age 3 weeks) was carried out according to Mihee K. et al, 2007. Eight 
successive, sub-cutaneous immunization injections were carried out in total, with the 
exception of the 7th injection that was administered intravenously (Table 1 see 
experimental methods). Anti-PLGA antibody titer was determined by ELISA for each 
stage after the third immunization. The highest titer found was observed after the 
fourth immunization (Figure 3). No signal was detected with pre-immune serum 
(before immunization). Only injections with immune serum yielded a positive signal. 
Both rabbits no. 95 and 96 were immunized identically; however rabbit no. 96 
showed higher PLGA-antibody titers than rabbit no. 95 (Figure 3, 4). This indicates 
successful immunization compared to the previous immunizations of rabbits 52 and 
53 (see Appendix, section 3.1, Table 1 and Figure 5 F, G).  
By determination of Anti-PLGA antibody titer using ELISA the concentrations of 25 
and 12.5 µg /ml PLGA were too high for the small well size of the microtiterplate, 
because of multilayer formation. These layers bind the specific PLGA-antibodies, but 
each washing step peels off one layer. The signal intensity of positive interaction 
between antigen and captured antibody decreased dramatically after several 
washing steps. Therefore a concentration of 5 µg/ml was chosen to show specificity 
of the binding between antigen and PLGA antibody. The dotted 100 µl of sample 
contain 500 ng of PLGA completely covering the surface of a single well in the 
microtiterplate with a monolayer. The absorbance values and curves of serial diluted 
sera as a relative measure for the amount of captured antibodies are presented in 
Figure 4. The titer of the fourth immunization of rabbit 96 showed an endpoint titer at 
a dilution of 1:8000 of serum and an absorbance (ABS) of 0.07 (Figure 4 B). The 
dilutions of sera after the fifth immunization showed an ABS of 0.05 at 1:8000, and 
after the seventh and eighth immunization at 1:5000 (Appendix, section 3.1, Table 1, 
2).  Rabbit 95 produced a low titer after  the fourth immunization with an ABS value of 
0.01 at a  1:8000 dilution (Figure 4 G, Appendix, section 3.1, Table 3) and no titer at 
subsequent  immunizations (Appendix, section 3.1, Table 1 and 3, Figure 5 B, C).  
These results show that four immunizations are sufficient for the production of PLGA-
Ab. We observed that the addition of PLGA powder to immobilized silica amino 
microspheres (SAM) and PLGA-NPs during the third and fourth immunization was 
essential for PLGA-Ab production, despite the difficulties that occurred when injecting 
the sample (see experimental methods for more details). To minimize these 
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problems during immunization in the future, the amount of PLGA powder can be 
reduced. However, intravenous injection of PLGA-NPs alone during the seventh 
immunization, and also the subcutaneous injection of PLGA conjugated to SAM only, 
did not increase the production of PLGA-Ab.  
The analysis of pre-immune serum and immune serum of rabbit 96 are shown on 
silver stained native gels in the next section. 
 
 
 
Figure 3. Titer determination of rabbit (R.) number (no.) 95, no. 96, no. 52 and no. 53 by ELISA. The 
highest titer is observed after the fourth immunization (imm.) of rabbit 96. Rabbit 96 showed higher 
PLGA-antibody titers after immunizations than rabbit 95 with a negative signal except after the 3rd and 
4th Immunization, when a low positive signal was detected. Pre-immune sera of rabbit 95 and 96, 
immune sera of rabbit 52 and 53 and the negative control show no signal. 
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Figure 4. Absorbance curves of different dilutions of immune and pre-immune serum from rabbit no. 
96. (Appendix section 3.1, Tables 1 and 2). The 4th immunization shows the highest endpoint titer at 
1:8000 dilution and an ABS value of 0.07. The 5th immunization shows an ABS value of 0.05 at 
1:8000 dilution and the same ABS value after the 7th and 8th immunization at a dilution of 1:5000  
This summarizes that four immunization steps are sufficient for PLGA-Ab production. 
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Analysis of gel electrophoresis, western blot and AP detection 
To show PLGA-Ab production in sera after the third immunization SDS- and native-
PAGE were performed. The gels were stained with a Coomassie Brilliant Blue (CBB) 
stain. Neither SDS- nor native- gels showed a difference between immune sera (after 
immunization) and preimmune sera of both Rabbits (no. 95, 96, Figure 5 A). To 
determine the zone of IgGs in the native gel a Western blot and ELISA-AP (alkaline 
phosphates) was carried out. The NC-membrane after blotting was incubated with 
anti rabbit IgG conjugated with AP and stained with AP substrate. The purified IgGs 
(using Dynabeads M-208 sheep anti-rabbit IgG see Chapter 5) from immune serum 
after the third immunization of rabbit 95 & 96 did not show any bands in the native gel 
with CBB-staining (Figure 5 B no. 6, 7) but a positive signal was observed using AP 
staining (Figure 5 C no. 6,7). However, the PLGA-Abs isolated with Epoxy beads 
coupled with PLGA (see Chapter 5) from the previously purified IgGs did not show a 
signal due to low titer concentration after the third immunization (Figure 5 C no. 8, 9).  
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Figure 5. Preimmune serum and immune serum after third immunization of both rabbits 95 and 96 
(R=rabbit) seem similar in the SDS gel (A) and native-gel (B) after CBB-stain. Rabbit IgGs are isolated 
from immune serum using Dynabead purification. PLGA-antibodies are isolated from the whole IgGs 
via Epoxy beads. No bands are observed with isolated IgGs and purified PLGA-Ab after the third 
immunization. The isolated IgGs show a positive signal when detected using AP-staining (C: 6, 7) and 
no signal of purified PLGA-Ab after third immunization (C: 8, 9).  
 
1 Preimmune serum R. no. 95 
2 Preimmune serum R. no. 96 
3 Protein-ladder 
4 Immune serum R. no. 95 after 3rd 
immunization 
5 Immune serum R. no. 96 after 3rd 
immunization 
1 Protein-ladder 
2 Preimmune serum R. no. 95 
3 Preimmune serum R. no. 96 
4 Immune serum R. no. 95 after 3rd 
immunization    
5 Immune serum R. no. 96 after 3rd 
immunization    
6 Purified IgGs from immune serum 
of R. no. 95 after 3rd 
immunization 
7 Purified IgGs from immune serum 
of R. no. 96 after 3rd 
immunization 
8 Isolated PLGA-Ab from purified 
IgGs of R. no. 95 after 3rd 
immunization 
9 Isolated PLGA-Ab from purified 
IgGs of R. no. 96 after 3rd 
immunization 
10 Protein-ladder 
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The visualization of proteins in native gels is enhanced by silver stain, which is 
generally accepted to be between 20 and 200 times more sensitive than CBB-stain 
and thus can detect approximately 0.1 ng protein/ band (Merril C. et al. 1987; 
Rabilloud T. et al. 1990). 
As is illustrated in Figure 6, additional bands can be detected in the native gel with 
silver staining after the fifth immunization, in contrast to the preimmune serum (as a 
negative control). These bands may be specific for the production of PLGA-Ab after 
immunization. However, titer determinations using ELISA have shown that the 
highest titer of PLGA-Ab production is observed after the fourth immunization. These 
additional bands were cut and analyzed in mass spectrometry using a protein 
database containing Mammalian proteins (Appendix, section 3.3 Table 1). The bands 
show sequence similarity to components of different proteins (Appendix, section 3.3, 
Tables 2, 3) such as Apolipoprotein A-I, Inter-alpha inhibitor proteins and proteins of 
the complement cascade. Apolipoprotein A-I is the major protein component of HDL 
(high density lipoprotein). HDL carries many protein and lipid species, many of which 
have very low concentrations but are biologically very active. For example, HDL and 
their protein and lipid constituents help to inhibit inflammation, activation of the 
endothelium, coagulation, and platelet aggregation. It has been postulated that the 
concentration of large HDL particles more accurately reflects protective action, as 
opposed to the concentration of total HDL particles (Kwiterovich P.O. et al. 2000). 
Inter-alpha inhibitor proteins (IaIp) are a family of structurally related serine protease 
inhibitors. Recent studies have implicated a role for IaIp in sepsis, and have 
demonstrated their potential as biomarkers in sepsis and cancer (Josic D. et al. 
2006). This would be consistent with a stimulation of the immune system to produce 
biologically active fragments that can either directly attack foreign antigens or 
enhance the functions of certain types of inflammatory leukocytes (Goldman AS. et 
al. 1996). 
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Figure 6. Native gel of preimmune serum und immune serum of rabbit 96 visualized by silver stain. 
Two bands (higher and lower band) appeared after the fifth immunization and were analyzed by mass 
spectrometry.  
 
Experimental Methods 
Injection sample preparation and pre-treatment of SAM 
The PLGA-SAM coupling reaction was carried out immediately before each 
immunization. SAM (100% solid silica amine microspheres, 100 mg) were suspended 
in ethanol (2 ml) and vortexed. The SAM suspension was sonicated in a sonic water 
bath first for 10 min to disperse clumps of unsuspended microspheres, and thereafter 
for another 10 min, until the microspheres were completely dispersed. Aggregates 
have to be avoided as they cause problems after subcutaneous injection. The 
sonicated silica suspension was viewed under a light microscope to confirm complete 
dispersal of microspheres (Figure 7). The microsphere suspension was centrifuged 
at 14000 rpm for 5 min. The supernatant was removed and the microsphere pellet 
was re-suspended in the PLGA-conjugate solution.  
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Figure 7. Individual SAMs (without PLGA) under a transmitted light microscope at 100x magnification. 
 
Preparation of PLGA-conjugate and injection sample 
See Table 1 for the amount of used components for the different immunization steps. 
 PLGA (Resomer RG 502H, 68 mg) was dissolved in 1 ml ethyl acetate. NHS (5 mg) 
was dissolved in 20 µl methanol. DIC (22 µl) was added to the dissolved NHS and 
immediately added to the dissolved PLGA. The reaction mixture was stirred for 30 
minutes at room temperature. Subsequently the activated PLGA solution was added 
to the prepared SAM suspension for conjugation (see above). The reaction mixture 
was kept for 2 days at room temperature. The reaction mixture was centrifuged for 1 
min at 4000 rpm at room temperature. The pellet was washed with ethyl acetate to 
dissolve any unconjugated PLGA. Due to problems (described below) that might 
appear in this step from the fourth immunization onwards the centrifugation time was 
reduced to a short run and washing with ethyl acetate was omitted. After another 
centrifugation step (conditions as above) the pellet was washed with methanol to 
remove any isourea that has formed as a by-product of the cross-linking reaction. For 
separation the suspension was again centrifuged (1 min, 4000 rpm, room 
temperature) and the pellet was used to prepare the injection sample. In this step 
after centrifugation the pellet of the SAM conjugated with PLGA had a gel-like 
consistency and could not be re-suspended completely in ethyl acetate to remove 
unconjugated PLGA. Using shorter centrifugation times also was not successful. 
Even sonication of the conjugate for 5 min did not lead to re-suspension of the gel-
like conjugate in methanol or in washed PLGA-NPs.  
Due to this problem this step was also omitted from the fourth immunization onwards.  
Then the injection sample contained a mixture of the pellet prepared in previous step 
and 1 ml washed PLGA-NPs. For the third and fourth immunization PLGA-powder 
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(Table 1) was added to injection sample. The same problem described before was 
encountered in this step too. Therefore these centrifugation/re-suspension and 
addition of very finely ground PLGA powder to the injection sample steps were 
omitted after the third immunization and the injection samples of the fifth, sixth and 
eighth immunization contained only the PLGA conjugated SAM. 
 
Immunization 
The cumulative injection volume per immunization per rabbit was 0.5 ml and was 
administered subcutaneously into the back skin in five subsequent injections of 100µl 
each, using a 32-gauge syringe. Two Rabbits (No. 95, 96) were immunized. The 
interval for booster injections was two weeks. 
 
Immuni-
zation 
SAM 
(mg) 
PLGA 
(mg) 
EtAc 
(ml) 
DIC 
(µl) 
NHS 
(mg/µl 
MeOH) 
PLGA-NPs 
2.86mg/ml 
PLGA-
powder 
Injection 
type 
1 100 68 1 22 5 /20 µl 1ml None subcutaneous 
2 100 136 2 44 10 /40 µl 1ml None subcutaneous 
3 100 204 3 66 15 /60 µl 1ml 7 mg subcutaneous 
4 200 408 6 132 30 /120 µl 1ml 30 mg subcutaneous 
5 250 816 12 264 60 /240 µl none none subcutaneous 
6 250 816 12 264 60 /240 µl none none subcutaneous 
7 none none none none none 1ml none intravenous 
8 250 816 12 264 60 /240 µl none none subcutaneous 
 
Table 1. Amounts of used components and conditions for the respective immunization steps.  
(SAM = silica-amino- microspheres, PLGA = poly (D,L-lactide-co-glycolide,  EtAC = ethyl acetate, DIC 
= diisopropylcarbodiimide, N-hydroxysuccinimide =NHS, PLGA-NPs= PLGA-nanoparticles,) 
  
Determination of antibody titer using ELISA 
For Abs titer determination blood samples were taken from the ear vein after the third 
immunization. The blood was kept for at least 30 min at room temperature and then 
centrifuged at 4000 rpm, for 10 min at 4°C. The supernatant (serum) was aliquoted 
and stored at -20°C.PLGA-pAb production was tested by ELISA. The sample 
concentration of PLGA dotted onto the well of the sample reader micro-titerplate is 
important for the assay efficiency. Therefore different PLGA concentrations, 25, 5, 
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2.5µg/ml were tested. 5µg/ml gave the best assay readings and therefore, this 
concentration of PLGA was used.  
A 5 µg/ml PLGA (RG 502 H) dilution was prepared in DMSO (Merk). Then 100 µl of 
PLGA dilution was added onto the surface of each well of a microtiterplate (Nunc-
Immuno Plate MaxiSorp, 96-well). For each immunization 14 wells were needed. As 
a negative control 100 µl dilution buffer was used. The uncovered microtiterplates 
were incubated for 1 hour at room temperature, then emptied and the wells were 
filled with blocking solution [2% (w/v) gelatine from cold water fish skin (Sigma 
Aldrich) was dissolved in 50 mM Tris/HCl buffer (50 mM Tris/HCl, 0.15 M NaCl pH 
7.4, and 0.1% (v/v) Tween 20, Sigma Aldrich)] for 30 min under gentle shaking. The 
microtiterplates were washed 2 times with washing buffer [0.5% (v/v) Tween 20 was 
added to 50 mM Tris/HCl buffer] for 5 min under gentle shaking. The sera after 
immunizations were diluted in dilution buffer [50 mM PB, pH 7.2, 30 mM NaCl and 
0.5% (w/v) PEG (polyethylenglycol, Sigma Aldrich)] at 1:100, 1:500, 1:1000, 1:1500, 
1:2000, 1:2500, 1:3000, 1:4000, 1:5000, 1:6000, 1:7000, 1:8000, 1:9000 and 
1:10.000. Then 100 µl of each dilution was added per well of washed microtiterplates.  
The microtiterplates were covered and incubated overnight at 4°C under gentle 
shaking in a humid camber, then washed 3 times with washing solution for 5 min. 
The microtiterplates were incubated for 1 hour with 100µl of anti-rabbit IgG, in dilution 
buffer, conjugated with HRP (Sigma Aldrich) at room temperature under shaking then 
washed 3 times with washing solution for 5 min. For detection, 100 µl TMB-substrate 
(Sciotec) was added to each well. The microtiterplates were incubated for 20 min at 
room temperature and the reaction was stopped with 50 µl 1M H2SO4. The 
microtiterplates were then read out at 450 nm in a Microplate Reader, Model 450, 
Bio-Rad). 
 
Gel Electrophoresis  
The formation of antibodies was examined by SDS and native gel electrophoresis.  
 
SDS-PAGE 
Gel composition and preparation 
For SDS- and native-PAGE the Mini-Protean II Electrophoresis system from Bio-Rad 
was used. According to the molecular weight of the examined proteins, separating 
gels with 7.5% of acrylamide/bisacrylamide were prepared.  
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Buffers and solutions 
Stacking gel (4%) 
The stacking gel solution contained 1.3 ml of 30% acrylamide/ 0.8% bisacrylamide; 
6.1 ml dd. H2O; 2.5 ml 0.5 M Tris/HCl, pH 6.8; 100 µl 10% (w/v) SDS; 50 µl 10% 
(w/v) APS and 10 µl TEMED. 
 
Separating gel (7.5%) 
The separating gel contained 5 ml of 30% acrylamide/ 0.8% bisacrylamide; 9.7 ml dd. 
H2O; 5 ml 1.5 M Tris/HCl, pH 8.8; 200 µl 10% (w/v) SDS; 100 µl 10% (w/v) APS and  
10 µl TEMED.  
 
Running buffer 
The running buffer contained 3.03 g Tris; 14.6 g glycine; 1 g SDS and was filled to 1L 
with dd. H2O.  
 
Sample preparation and electrophoresis 
For SDS PAGE 1 µl serum was diluted 1:40 in 50 mM Tris-HCl (pH 7.4) and then 
40 µl sample buffer [2.5 ml 0.5 M Tris/ HCl pH 6.8; 20% (v/v) glycerol (2 ml); 0.4 g 
SDS; 0.31 g dithiothreitol; 1 mg bromophenol blue and made up  to 20 ml with dd. 
H2O] was added. The sample was heated to 95°C for 5m 95°C. The gel slots were 
loaded with 20 µl of sample. A molecular mass standard mixture (PageRuler 
Fermentas, Protein Ladder, 2 µl) was used for comparison of molecular mass. 
The separation of proteins was performed at 150 V and 60 mA for approximately 1 to 
1.5 hour.  
 
Native PAGE and Western blot 
The protocol is described in Chapter 5. 
 
Visualization of proteins after gel electrophoresis: CBB-staining 
The protocol is described in Chapter 5. 
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Visualization of protein gels after electrophoresis: silver staining 
After running the gel, the separated proteins were visualized with silver staining 
according to Blum (Blum H., 1987). The staining process relies on the reduction of 
Ag+-ions to metallic silver, resulting in staining of the protein bands. 
All steps were carried out on a shaker and all solutions were prepared freshly before 
staining! 
 
Step Reagent Duration 
Fixing 
40% ethanol / 10% acetic acid in 
dd. H2O 
≥ 1 h 
Washing 30% ethanol in dd. H2O 2 x 20 min 
Washing dd. H2O 1 x 20 min 
Sensitizer 
0.02% Sodium thiosulfate in dd. 
H2O 
1 min 
Washing dd. H2O 3 x 20 sec. 
Silver 0.1% Silver nitrate in dd. H2O 20 min at 4 °C 
Washing dd. H2O 3 x 20 sec 
The gel chamber was changed at this step to avoid free silver on the surface of the 
chamber 
Development 
3% sodium carbonate 0.05% 
formaldehyde (37%) in dd. H2O 
3-5 min 
Washing dd. H2O 1 x 20 sec 
Stopping 5 % acetic acid in dd. H2O 5 min 
Washing dd. H2O 3 x 10 min 
Storing 1 %  acetic acid in dd. H2O - 
 
Preparation and washing of PLGA-nanoparticles 
The preparation of PLGA-nanoparticles is described in details in Chapter 5 according 
to Weissenböck et al., 2004. 
 
Organic amino-silanization of Gulsenit: 
 Gulsenit (MAGINDAG, Austria) is an active magnesium silicate mineral having a 
particle size less than 10 µm and a density of about 3.2 kg/l. Gulsenit was covered 
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with freshly prepared 5% (v/v) (3-aminopropyl) triethoxysilane solution (APTS, Sigma 
Aldrich) in 95% EtOH and reacted for one hour under gentle shaking at room 
temperature. Gulsenit was washed with 95% (v/v) EtOH 3 times for 5 min under 
gentle shaking and cured at 110°C over night (Pittner F. 2002).  
 
Immobilization of PLGA onto Gulsenit  
1g PLGA (Resomer RG 502H) was dissolved in 20 ml ethyl acetate. 575 µg NHS 
(Sigma Aldrich) was dissolved in 40 ml ethyl acetate. 310 µl N,N‟-
Diisopropylcarbodiimide (DIC) (Sigma Aldrich) was added to the dissolved NHS and 
this solution was immediately pipetted into the dissolved PLGA.  
The activation reaction was carried out for one hour at room temperature. The 
activated PLGA solution was incubated with 20 g amino-silanized Gulsenit overnight 
at room temperature under stirring. Then the Gulsenit was rinsed 3 times with ethyl 
acetate to remove unreacted PLGA followed by 3 washes with dd. H2O; using a 
suction funnel, pore size 4, to remove solvent from carrier after each rinse. The 
Gulsenit can then be used as a column material for the purification of PLGA Ab by 
means of affinity chromatography. The efficiency of immobilization was determined 
using the Kaiser-test. 
 
Affinity chromatography using Gulsenit with coupled PLGA 
A 2.5 ml chromatography column  with a 10 µm pore filter at the bottom (Mo Bi Tec) 
was filled with PLGA conjugated Gulsenit and washed with 5 column volumes of 
binding buffer (5 mM PBS, 0.15 M NaCl, pH 7.2). The diluted serum (1:5 with binding 
buffer) was centrifuged shortly at 14000 rpm and then loaded onto the PLGA 
conjugated Gulsenit column at a flow rate of 0.15 ml/min. The column was washed 
with binding buffer until no proteins were detected by Bradford protein assay. Briefly, 
20 µl Bradford reagent (Bio-Rad Protein Assay) diluted 1:5 with dd. H2O were added 
to 10 µl of each fraction and changes in the color of the solution to blue indicated the 
presence of proteins. The PLGA-Abs were eluted with elution buffer (0.1 M acetic 
acid/ 0.1 M NaOAc, pH 3) at a flow rate of 1.7 ml/min. Every eluted fraction (two 
drops) was collected in a well of a microtiterplate containing about 10 µl 
neutralization buffer (0.5 M NaHCO3) to neutralize the purified Abs immediately. The 
fractions containing protein (detected by Bradford protein assay) were pooled and the 
pH was adjusted to a physiological pH. For a qualitative determination of the proteins 
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the Bradford protein assay was used. Fractions which showed a positive Bradford 
test were pooled and concentrated for 5 min by 4000 rpm at 4°C using an Amicon 
ultra centrifuge filter. The concentration of the eluate was determined using the 
Quant-iT™ Protein Assay Kit (for use with the Qubit™ fluorometer, Invitrogen). The 
isolated protein was examined by native gel electrophoresis. The gel was stained 
with a Coomassie Brilliant Blue (CBB) stain and the protein bands were then 
subjected to digestion and sequence analysis by mass spectrometry.  
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According to the results illustrated in Chapter 5 concerning deposition of 
human serum albumin onto PLGA another drug delivery system had to be found to 
reach the afforded aims for this thesis:  
 To introduce binding sites for degradable, drug loaded nanoparticles 
into the biocompatible coating and 
 To provide a proof of principle testing of the interaction between the 
nanoparticles and their in biocompatible coating embedded binding site  
To reach this goal another type of nanoparticles had to be looked for, biodegradable 
by enzymes circulating in the bloodstream. Chitosan nanoparticles, degradable by 
lysozyme are known for its biocompatibility, biodegradability, bio-and 
mucoadhesivity, and hydrophilic character. This increases the bioavailability of poorly 
absorbable drugs across various epithelial barriers (Alonso M. J. et al. 2007).  
This Chapter illustrates the successful of introduction of Abs as binding sites for 
chitosan NPs on the amino-silanized, amino-PEGylated and SH-PEGylated implant 
material. Furthermore the binding of CS-NPS labeled with the fluorescent dye 
BODIPY 493/503 to the biocompatibly coated implant surface could be shown. This 
novel developed targeting set up can be used for drug delivery system.  
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Abstract 
Drug delivering implants are becoming increasingly important as tools in the 
treatment of cardiovascular diseases and other diseases. Here we describe the 
development of novel, bio-compatible coatings for medical implant materials with 
antibodies as receptors for bio-degradable and biocompatible chitosan nanoparticles. 
These may serve as drug carriers to mediate local pharmacological activity. After 
biodegradation of the drug containing nanoparticles by lysozyme, an enzyme 
circulating in the bloodstream, the binding sites become free again and can be 
reloaded with fresh drug delivering particles. The design of the receptor is of great 
importance as any bio- or chemorecognitive interaction with other components 
circulating in the blood has to be avoided. Furthermore, the binding between receptor 
and the particles has to be strong enough to keep them tightly bound during their 
lifetime, but on the other hand allow reloading after final degradation of the particles. 
The nanoparticles suggested as a drug delivery system for implant can be loaded 
with different pharmaceuticals such as antibiotics, growth factors or immuno-
suppressives. This concept may enable for changing medication even after 
implantatation of the medical device if afforded by patients needs. 
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Introduction 
Drug delivering implants such as drug eluting stents (DESs) play an important role in 
the treatment of cardiovascular diseases. These stents have been introduced as a 
new and promising technique to reduce restenosis after stent implantation. Several 
substances with immunosuppressive, antiproliferative and cytostatic activities have 
been tested as active stent coatings, and were shown to reduce restenosis in 
humans (Chieffo A. et al. 2000; Grube E. et al. 2004). Despite these advantages, 
restenosis rates still remain substantial in high-risk patients, such as patients with 
long lesions and complex lesion morphologies in bifurcations. The DESs currently in 
use contain only a certain amount of drugs, and restenosis may take place if this 
reservoir is used up. These limitations can be overcome by reloading the stent (or 
other implant material) with drugs. To address this limitation, we and others have 
sought to develop biocompatible drug delivery systems that allow continous 
administration of drugs to meet the clinical need of the patients.  The general design 
of our drug delivery systems (Figure 1) was on the basis of the following: 1) use of 
carrier materials coated with a biocompatible layer covalently bound to the carrier 
backbone. This forms a passive protection layer preventing rejection of the implant 
material; 2) anchoring of antibodies in this protective layer to act as specific bio-
recognitive sites. These were subsequently used to load biodegradable, drug 
containing nanoparticles onto the implant. After implantation of the medical device 
into the patient, such a structure will serve as a re-loadable drug delivery system. 
Biodegradable nanoparticles containing pharmaceutical drugs are injected and while 
circulating in the bloodstream will bind to these specific binding sites. The particles 
are then slowly degraded by enzymes in the surrounding body fluids, thus gradually 
releasing the drugs (Figure 1). At the end of this process, when the polymer of the 
nanoparticle is degraded, the bio-recognitive sites should be free again to be 
reloaded with new drug containing particles.  
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Figure 1. Principle of nanoparticle binding, drug release and reloading.  
 
The possibility of re-loading allows not only patient-adequate dosage of drugs but 
also change of medication after implantation, using different drugs at different stages 
of the treatment process. In case of bone implants nanoparticles can be loaded with 
growth factors that promote replication, differentiation, protein synthesis and/or 
migration of respective cell types. The successful development of this technology will 
provide a better means for controlled drug release from the implant due to the site 
directed binding of the drug carrier nanoparticles to implant surfaces. The more 
efficient and directed drug release at the target site should improve the clinical 
outcome after implantation thus improving the healing process. 
The biocompatible coating in this study is based on polyethyleneglycol (PEG) 
derivatives which are covalently bound to the backbone carrier serving as a passive 
coating. PEG is employed extensively in pharmaceutical and biomedical applications. 
It can be chemically modified for attachment to other molecules and surfaces (Ratner 
B.D. et al. 2004). The drug delivery system in this study is based on chitosan 
nanoparticles. The low toxicity (Aspden T.J. et al. 1995), chemical properties and 
excellent capacity for the entrapment of proteins of chitosan make it a suitable 
candidate for use in gene- and drug-delivery systems (Calvo P. et al. 1997b, De la 
Fuente M. et al. 2008). Chitosan has been a focus of increasing attention in the 
design and engineering of novel nanoparticulate drug delivery systems, due to their 
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desirable properties such as biocompatibility, biodegradability, bio-and 
mucoadhesivity, and hydrophilic character that facilitate the administration and 
increase the bioavailability of poorly absorbable drugs across various epithelial 
barriers, such as corneal, nasal and intestinal mucosa (Alonso M.J. et al. 2007). An 
additional advantage of chitosan nanoparticles is their production under aqueous and 
fairly mild conditions, thus making them especially suitable to preserve the bioactive 
conformation of delicate macromolecules (e.g. proteins, hormones, antigens, pDNA, 
siRNA, growth factors, heparin etc.) that otherwise would be prone to enzymatic 
degradation and hydrolysis (Alonso M. J. et al. 2007). The physicochemical, 
biomedical and pharmaceutical properties of chitosan have been described in detail 
in several articles (Janes K. A. et al. 2001; Csaba N. et al. 2006). Drug delivery 
systems including chitosan-beta-cyclodextrin nanoparticles and nanocore-coated 
type capsules were the focus of a review by Alonso et al. (Alonso M. J. et al. 2007). 
Chitosan has thoroughly been utilized in the development of potentially innovative 
drug delivery, tissue engineering and wound dressing systems over the last decade. 
Over 50% of the total number of filed patents in 2006 (Alonso M.J. and Goycolea F.M 
2008) claim the use of this biopolymer as a substantial part of the invention are 
related to drug delivery, tissue engineering and wound healing (Skaugrud O. et al. 
1999; Agnihotri A. et al. 2004; Ravi Kumar M.N.V. et al. 2004; George M. et al. 2006; 
Rinaudeo M. 2006, 2008).  Chitosan is a linear amino polysaccharide composed of 
approximately 20% 1, 4-linked N-acetyl-D-glucosamine (GlcNAc) and approximately 
80% β1, 4-linked D-glucosamine (GlcN) produced by partial deacetylation of chitin in 
hot alkali. CS is degradable by lysozyme circulating also in the bloodstream, thus 
making it a welcome material for the production of drug containing nanoparticles 
being slowly degraded and thus releasing their content. The interaction between the 
chitosan-fluorescence labeled nanoparticles (containing BODIPY 493/503 as a 
fluorescent tag) and their receptor (antibodies) immobilized onto the carrier surface is 
shown in this study using fluorescence microscopy.   
 
Results and Discussion 
As examples for medical implant materials stainless steel L316 as well as zirconia 
were used. The successful set up procedure of the biocompatible coating was 
already shown for these materials as well as for silicate glass (Al-Dubai H. et al. 
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2010). Because of the uneven surface of zirconia and quenching of optical signals in 
case of metals silicate glass coated under the same conditions was used as a model 
substance when using fluorescence labeling as an analytical tool. 
For immobilization of the biocompatible coating using either the bifunctional bis-
amino PEG (NH2-PEG-NH2; amino-PEGylation) or monofunctional mercapto-PEG 
(SH-PEG; SH-PEGylation) the surface of used carriers needs to be previously 
activated via chemical etching followed by amino-silanization  (Pittner F. 2002). Bi-
functional PEGs or SH-PEG were bound covalently to the previously amino-silanized 
carrier surface to enhance biocompatibility. The choice of PEG-coupling procedure 
depends on the functional groups of the PEG derivative. For amino-PEGylation in a 
first step, succinic anhydride was coupled to the amino-silane followed by EDC/sulfo-
NHS [(1-ethyl-3-(3-dimethylaminopropyl) carbodiimide/ N-hydroxysulfosuccinimide] 
activation (Pittner F. 2002; Hoare D. and Koshland D. 1966). Bis-amino-PEG can 
also be coupled directly to the amino-silanized carrier using p-chloro-anil as a 
crosslinker (Figure 2). p-Chloro-anil linkers reacts with amino groups and thus can be 
coupled to the silane moiety under mild conditions (Pittner F. 2002). In a second 
reaction step the amino groups of a polymer as e.g. NH2-PEG-NH2 can then be 
coupled in para position.  
 
 
 
Figure 2. p-Chloro-anil reacts with amino groups and thus can be coupled to the silane moiety under 
mild conditions. In a second reaction step the amino groups of a polymer such as NH2-PEG-NH2 or 
protein antibodies (e.g. chitosan-Abs) can then be coupled in p-position.  
 
The immobilization of the biorecognitive binding site (antibodies, Abs) for drug 
delivery (chitosan nanoparticles, CS-NPs) onto the PEGylated or amino-silanized 
carrier was carried out by using either the sulfo-SMCC [sulfosuccinimidyl 4-(N-
maleimidomethyl) cyclohexane-1-carboxylat] cross linking method or the p-chloro-anil 
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method (Hashida S. and Ishikawa E. 1985; Pittner F. 2002). In the here presented 
system the used Abs for capture of the CS-NPs was a mouse monoclonal anti-ß-O-
linked acetylglucosamine (O-GlcNAc) IgM isotype that recognizes O-GlcNAc. 
Throughout this paper it is referred to as chitosan-antibody (CS-Ab). CS-Ab 
molecules are immobilized onto the terminal amino groups of the amino-PEGylated 
carrier or directly onto an amino-silanized carrier using either the sulfo-SMCC (Figure 
3) or the p-chloro-anil crosslinking method.  
The SH-PEGylation using monofunctional SH-PEG is carried out on amino-silanized 
slides already containing CS-Ab molecules. The coupling of CS-Ab using sulfo-
SMCC crosslinker is followed by SH-PEGylation. The free maleimide end of sulfo-
SMCC not bound to CS-Abs couples specifically to the sulfhydryl groups of SH-PEG 
(Figure 3). 
 
 
 
Figure 3. Binding of whole Chitosan antibodies onto the carrier via sulfo SMCC followed by reaction 
with PEG-SH for enhancing biocompatibility. Any unreacted sites were finally blocked with ß-
mercaptoethanol (ßME) – not shown here. 
 
The interaction between CS-NPs and their antibodies immobilized onto a carrier was 
demonstrated using CS-fluorescence labeled particles (Figure 4) and fluorescence 
microscopy. 
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Figure 4. Fluorescence microscopy images of CS-NPs including fluorescent marker: A; Nile red, B; 
BODIPY 493/503). 
 
Formation of Chitosan nanoparticles 
The formation of CS-NPs occurs spontaneously under mild gelation conditions with 
no need for sonication, high temperatures, or organic solvents. It has been shown 
earlier that the inter- and intra-molecular linkages created between the positively 
charged amino groups of CS and the negatively charged TPP are responsible for the 
initiation of the gelation process showed in Figure 5A (Bodmeie R. et al. 1989; 
Shiraishi S. et al. 1993; Rajaonarivony M. et at. 1993). The gelation conditions were 
optimised using different dilutions of TPP. A concentration of 1.5 mg TPP/ml dd. H2O 
was found to be the best condition for the formation NPs with a size of 253 nm and a 
PLI of 0.280 (Figure 5B). CS-NPs generated under these conditions were tagged 
with fluorescent marker molecules (BODIPY 493/503). The size of CS-NPs 
conjugated to BODIPY 493/503 was 275.1 nm and its PLI was 0.239.  
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A) 
 
 
B) 
 
 
 
Figure 5. A: Schematic depiction of the strategy for preparation of CS-NPs by inducing the gelation of 
a CS solution with TPP. B: Visualisation of opalescence of the CS-NPs preparation after addition of 
different concentrations of TPP to CS solution 1; TPP-dilution (1:0), 2; TPP dilution (0.667:0.333), 3; 
TPP-dilution (0.5:0.5), 4; TPP- dilution (0.333:0.667). The optimal composition of CS-NPs is observed 
at 0.5:0.5 TPP-dilution.  
 
Immobilization of recognitive binding sites for CS-NPs onto amino-silanized 
carriers 
One of the aims of this study was to develop a process that allows coating of carriers 
with a biocompatible layer that provides free binding sites suitable to load drug 
molecules onto the implant. This was achieved by immobilizing CS-Ab molecules 
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onto a carrier as binding sites for CS-NPs. This approach was demonstrated 
successfully first on amino-silanized carriers (Figure 6). CS-NPs were labeled with 
fluorophores and binding to their binding site (CS-Abs) immobilized on carrier using 
either sulfo-SMCC (Figure 6A) or p-chloro-anil (Figure 6C) was shown by 
fluorescence microscopy. In negative controls where CS-Abs were omitted, no 
fluorescent CS-NPs could be detected in sulfo-SMCC carriers (Figure 6B) and only a 
low background is observed with p-chloro-anil carriers (Figure 6D). 
 
 
 
Figure 6. Fluorescence microscopy images illustrating the binding efficiency of CS-NPS labeled with 
BODIPY 493/503. The immobilization of CS-Ab was carried out by means of sulfo-SMCC (A) or p-
chloro-anil (C) respectively. No signal was observed for the negative control (without immobilized CS-
Ab) using sulfo-SMCC crosslinker (B) and only a low background is observed using p-chloro-anil 
crosslinker (D).  
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SH-PEGylation of carriers containing CS-Abs 
The SH-PEGylation at pH 7.3 was carried out on the amino-silanized carrier after the 
coupling of CS-Ab by means of a sulfo-SMCC cross linker as shown in Figure 7. The 
interaction between immobilized CS-Ab and the labeled CS-NPs is presented in 
Figure 7A. Figure 7B shows that no signal was observed in a negative control, i.e., in 
the absence of immobilized CS-Ab. 
 
 
 
Figure 7. Fluorescence microscopy images of coated silicate glass carriers containing immobilized 
CS-Abs followed by SH-PEGylation (A). No signal was observed for the negative control (B) omitting 
the immobilization of CS-Ab. 
 
Immobilization of recognitive binding site of CS-NPs onto amino-PEGylated 
carrier 
The amino-PEGylation of carriers was carried out by means of EDC/sulfo-NHS or p-
chloro-anil at different pH (5 or 10). Amino-PEGylation at pH 5 results in a higher 
binding affinity of CS-NPs (Figure 8A, C) than at pH 10 (see supplementary materials 
Figure 9). That was consistent with the hypothesis that under acidic conditions amino 
groups on PEG tend to the surface of the molecule because of stronger interactions 
with the hydrophilic surrounding and thus become available for binding of the 
crosslinkers (EDC/sulfo-NHS, Figure 8A, B or p-chloro-anil, Figure 8C, D) necessary 
for further immobilization of CS-Abs using sulfo-SMCC. Figure 8 demonstrates also 
the different crosslinking efficiency of EDC/sulfo-NHS and p-chloro-anil used for 
amino-PEGylation. Coating of NH2-PEG-NH2 using EDC/sulfo-NHS is more time 
consuming than the p-chloro-anil method, but p-chloro-anil gives some low 
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background (Figure 8D) signals, possibly as a result of an incomplete cross-linking 
reaction. 
 
 
 
Figure 8. Fluorescence microscopy images of carriers coated with NH2-PEG-NH2 at pH 5. The 
crosslinkers either EDC/sulfo-NHS (A, B) or p-chloro-anil (C, D) were used to immobilize NH2-PEG-
NH2 onto organic silanized carriers. The immobilization of CS-Ab was applied by means of sulfo-
SMCC. EDC/sulfo-NHS crosslinker shows no signal in the negative control (B) and more captured 
fluorescent CS-NPs than when using p-chloro-anil crosslinker (D).  
 
EDC/sulfo-NHS may be the method of choice for polymer coating of an implant 
surface as the resulting amide bond linkage does not elicit any immunogenic 
response.  
 
Experimental Methods 
Organic silanizaton of inorganic carriers 
Inorganic carriers used here were silicate glass slides (Ø12 mm, Assistant, Austria). 
Silicate glass slides are etched with 1M NaOH for 30 min. The carriers were washed 
several times with dd. H2O and then soaked for at least two days in dd. H2O under 
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gentle shaking. Replacement of dd. H2O is highly recommended several times to 
enhance hydroxyl group formation. The surface of carriers is then modified by amino-
silanization with 3-aminopropyl triethoxysilane in order to immobilize NH2-PEG-NH2 
or SH-PEG. The used carriers were covered with freshly prepared 5% (v/v) (3-
aminopropyl) triethoxysilane solution (APTS, Sigma, Austria) in 95% EtOH and 
reacted for one hour under gentle shaking at room temperature. The carriers were 
washed with 95% (v/v) EtOH 3 times for 5 min under gentle shaking and incubated at 
110°C over night. 
 
Binding of succinic anhydride to the amino-silanized surface 
Succinic anhydride is applied to introduce carboxylate groups onto the surface of 
amino-silanized material: 1 g of succinic anhydride (Merck, Austria) was suspended 
in 25 ml PBS buffer pH 6. The pH was monitored and adjusted to 6 with 1M NaOH to 
prevent severe acidification of the reaction solution, which might damage the 
molecule to be coupled in the further step. This solution was added to the amino-
silanized carrier and reacted at room temperature over night to assure complete 
blocking of all amino groups (control the pH over the first few hours of the reaction). 
The carrier was washed 3 times for 5 min with buffer followed 3 times with dd. H2O. 
 
EDC combined with sulfo-NHS 
0.1mM EDC (Sigma, Austria) and Sulfo-NHS (Pierce, Switzerland) in a final 
concentration of 5 mM were dissolved in 50 ml dd. H2O and the pH adjusted to 10 
with 1M NaOH. The carboxylated carrier prepared with succinic anhydride was 
incubated in this solution for about 1 to 2 h (maximum) at room temperature under 
gentle shaking. The activated carrier was washed several times with dd. H2O. 
 
Coupling of p-chloro-anil as a linker  
As p-Chloro-anil is sensitive to light all reaction steps have to be carried out under 
light protection until NH2-PEG-NH2 or Ab is immobilized. The amino-silanized carrier 
was washed 2 times with toluene (J.T. Baker, Austria) for 5 min under shaking then 
incubated with a 1% (w/v) solution of p-chloro-anil (Fluka, Austria) in toluene for 1 h 
at room temperature under gentle shaking. The carrier was washed 2 times with 
toluene, acetone (J.T. Baker, Austria) and dd. H2O respectively.  
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Amino-PEGylation 
1 g O,O′-bis (3-aminopropyl) polyethylene glycol (NH2-PEG-NH2, MW 1500, Fluka, 
Austria) was dissolved in 50 ml of 0.1M citric acid-sodium citrate buffer pH 5 or 50 ml 
of 0.1M carbonate-bicarbonate buffer pH 10 respectively. The carrier, activated with 
either EDC/Sulfo-NHS or p-chloro-anil, was incubated in the above prepared 
solutions separately at least overnight. Each amino-PEGylated carrier was washed 3 
times for 5 min under shaking with the buffer to remove unreacted PEG and then 
washed several times with dd. H2O.  
 
SH-PEGylation 
SH-PEG (O-[2-(3-Mercaptopropionylamino) ethyl]-O´-methyl-polyethylene glycol, MW 
5000) was provided from Sigma (Austria). Amino-silanized carriers already activated 
with sulfo-SMCC and then coupled with CS-Ab were incubated in 500 µl of a solution 
of 121mg/ ml SH-PEG (dissolved in 50 mM sodium phosphate buffer pH 7.3) per 
carrier (Ø12 mm silicate glass cover slides) under argon in a humid camber over 
night at 4°C under shaking. The carriers were washed 3 times for 5 min with Tween 
20 washing solution [washing solution contains 0.5% (v/v) Tween 20 (Sigma) and 0.1 
M phosphate buffer, 0.15 M NaCl pH 7.3] on an orbital shaker. The washed carriers 
were blocked in 2-mercaptoethanol (ßME, Fluka) blocking solution (35 mM ßME in 
0.1 M sodium phosphate buffer pH 7.3) for 30 min under shaking. The blocked 
carriers were washed as before and incubated with fluorescent chitosan-
nanoparticles (CS-NPs).    
 
Immobilization of antibodies onto the carrier 
The amino-PEGylated or amino-silanized carriers (4x Ø12 mm silicate glass cover 
slides) were washed with buffer (0.1 M PBS with 0.15 M NaCl, pH 7.2). 4 mg sulfo-
SMCC [Sulfosuccinimidyl-4-(N-maleimidomethyl)-cyclohexane-1-carboxylate), 
Pierce] was dissolved in 1 ml dd. H2O and than filled it to 11 ml with the above 
mentioned 0.1 M PBS buffer. The carriers were incubated for 30 min in this solution 
under gentle shaking. The carriers were washed 3 times with buffer for 5 min under 
gentle shaking. Uncleaved CS-Ab (2mg/ ml diluted 1:55 in 50 mM phosphate buffer 
pH 7.5) was pipetted onto the carrier activated with either sulfo-SMCC or p-chloro-
anil and incubated for 1h at 37°C. The carrier was washed 3 times for 5 min with 
Tween 20 washing solution under gentle shaking. Silicate glass carriers with Abs 
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immobilized by means of sulfo-SMCC crosslinker were blocked with 35 mM ßME in 
0.1 M sodium phosphate pH 7.3 for 30 min under shaking. Silicate glass carriers 
containing Abs immobilized via p-chloro-anil crosslinker were blocked using 
ethanolamine (1:10, v/v) in dd. H2O for 30 min on an orbital shaker. Silicate glass 
carriers for negative control were silanized, activated with p-chloro-anil and activated 
with sulfo-SMCC omitting immobilization of CS-Abs. After the blocking step the 
silicate glass surfaces were washed 3 times for 5 min under shaking in Tween 20 
washing solution and subsequently rinsed with dd. H2O. Fluorescent CS-NPs were 
diluted 1:10 with dd. H2O. 100 µl of diluted fluorescent was pipetted onto washed 
carriers. The carriers were then incubated over night at 4°C in a humid chamber. The 
carriers were washed 3 times for 5 min with Tween 20 washing solution under 
shaking. Binding of fluorescent CS-NPs to the silicate glass carriers was visualized 
by fluorescent microscopy (Olympus BX41) using excitation/emission wavelengths of 
493/503 nm for BODIPY 493/503. Images were taken in Color View software (Soft 
Imaging System) at 40x magnification and edited in Cell^D life science 
documentation software (Olympus Soft Imaging Solutions, Münster, Germany). 
 
Preparation of Chitosan-nanoparticles   
A CS solution (2 mg/ml) in 5% stoichiometric excess of acetic acid (HAc) was 
prepared. In our case theoretically 0.063% HAc was needed for CS (Sigma) with a 
deacetylation degree of 75-85% and a MW between 50 000 to 190 000. The resulting 
pH of the solution was adjusted to 4.3 with 5% HAc to obtain a clear solution of CS. A 
TPP stock solution in a concentration of 3mg/ml was prepared in dd. H2O. 5 ml of the 
following dilutions of the TPP stock were prepared (TPP stock: water) 1: stock 
solution, 2: dilution 2:1, 3: dilution 1:1, 4: dilution 1:2. An aliquot of 3 ml CS was 
pipetted into a silicate glass test tube that was placed upright into a 50 ml Erlenmeyer 
flask. 1 ml of the TPP solution (prepared as detailed before) was added under stirring 
into the center of the vortex formed in the CS solution in the test tube. After adding 
TPP the opalescence of the solution increased with TPP concentration. After stirring 
for 10 min the mixture was kept standing for 10 min. Then the solution was visually 
inspected for aggregates. Formation of visible particles is a sign of unwanted 
aggregation. The final pH of the NP suspension is shown in Table 1. With stock 
solution precipitation was observed. Particle size was measured for the formulations 
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that showed no aggregation or precipitation. A 1:1 dilution of TPP was found to give 
best results (Table 1).  
 
TPP-dilution 
(3mg/ml TPP 
stock: water) 
pH of NP 
suspension 
Size of NPs 
(nm) 
PLI 
(polydispersity 
index) 
2:1 5.05 352 0.499 
1:1 4.97 253 0.280 
1:2 4.87 293 0.293 
 
Table 1. The mean CS-NPs size and distribution were determined by dynamic light scattering (DLS; 
Zetasizer Nano ZS, Malvern Instruments Ltd, U.K). All measurements were carried out in triplicate at 
20°C after 5 min of equilibration time. 
After NP formation they were recovered by centrifugation: 1 ml of the NP suspension 
was transferred into 1.5 ml Eppendorf vials with a 20 µl glycerol bed at the bottom of 
the vial (glycerol is used to avoid aggregation and facilitate resuspension of the 
isolated NPs). The vials were centrifuged at 10000 x g for 40 min at 25°C and 
subsequently the supernatant was removed. 100 µl of water was added and the MP-
pellet resuspended with a 100 µl micropipette by vigorous, repeated mixing. The 
preparation of fluorescent CS-nanoparticles tagged with BODIPY 493/503 (4,4-
difluoro-1,3,5,7,8-pentamethyl-4-bora-3a,4a-diaza-s-indacene, Invitrogen) is carried 
out as described above. In this case, 100 µl of BODIPY 493/503 solution (dissolved 
in ethylacetate at a concentration of 1mg/ ml) was added to 3 ml CS solution (2 mg/ 
ml) by stirring vigorously at room temperature for 20 min. The solution was filtered 
through a 5 µm membrane filter (MILLIPORE, sterile MILLEX-SV) and 1 ml of TPP 
solution (1:1) was added analogous to above. The size of NPs tagged with BODIPY 
493/503 was 275.1 nm and their PLI was 0.239. Labeled NPs were centrifuged, 
resuspended in 100 µl dd. H2O as described earlier, and used for detection of 
immobilized CS-Ab on either amino-silanized silicate glass surfaces, or amino-
PEGylated or SH-PEGylated silicate glass surfaces. 
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Supplementary Materials 
We tested the influence of pH during the amino-PEGylation coating with bi-functional 
NH2-PEG-NH2. CS-NPs show a better binding affinity to carriers with NH2-PEG-NH2 
when bound at pH 5 (Figure 8) compared to pH10 (Figure 9).   
 
 
 
Figure 9. Fluorescence microscopy images of carriers coated with NH2-PEG-NH2 at pH 10. The 
crosslinkers either EDC/sulfo-NHS (A, B) or p-chloro-anil (C, D) were used to immobilize NH2-PEG-
NH2 onto organic silanized carriers. The immobilization of CS-Ab was applied by means of sulfo-
SMCC. EDC/sulfo-NHS crosslinker shows signal even in the negative control (B). No captured 
fluorescent CS-NPs than when using p-chloro-anil crosslinker (C, D). 
 
In case of EDC/sulfo-NHS crosslinker the positive carrier and the negative control 
carrier show a signal although no CS-Ab is immobilized. The coating layer of bis-
amino-PEG prepared at pH 10 might have been inhomogeneous and possibly didn‟t 
cover the entire carrier surface. As a consequence the EDC activated surface could 
be still free and active and serve as a binding site for CS-NPs.  
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In case of p-chloro-anil crosslinker in the negative control no signal was observed. 
The blocking with ethanolamine is efficient and protects the free binding site for CS-
NPs.  The positive carrier shows no signal. The immobilized bis amino PEG at pH10 
using p- chloro-anil did not provide free amino groups as a binding site for Ab.  
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Summary  
Although a number of methods were developed earlier to increase 
biocompatibility of implant materials, the design of polymer and implant materials 
poses still challenges for modern biopharmaceutical engineering. Since the 
introduction of drug eluting stents (DES) for clinical cardiology, several studies have 
shown the superiority of drug eluting coronary stent implantation over conventional 
angioplasty. In addition, drug eluting implants that can reduce the local immune 
response at the implant site have proven beneficial in several applications. However, 
currently existing drug eluting materials contain drug volumes sufficient only for 
several weeks after stent implantation and restenosis still remains a major post 
operative risk, even after implanting a DES. Any improved implant material should 
not only have excellent mechanical properties, durability, resistance to corrosion and 
good biocompatibility, but should also allow to increase the time period of drug 
delivery, as well the option to release different drugs.  
In order to develop novel implant materials with such desired characteristics we have 
used stainless-steel and zirconia (ZrO2-TZP-A BiO-HIP) with active and passive 
coating in this study. The passive PEG polymer coating was covalently bound to the 
implant backbone to serve as a barrier with good biocompatibility on the surface of 
the implant materials.  
The active coating, that was designed to release drugs, such as anti-proliferative 
agents, antibiotics, or growth factors, as long as required by the patient. To allow for 
re-loading as well as change of drugs, a drug delivery system was developed based 
on nanoparticles as vehicles which bind to their embedded receptors (antibodies) on 
the passive polymer-coated (PEG) implant materials. For proof of principle studies, 
dyes were successfully embedded into the nanoparticles, which allowed visual 
tracing of the successful setup of the implant coating. While the nanoparticles are 
degraded either by hydrolysis or by enzymes in the surrounding body fluids, the 
drugs are released gradually. At the end of this process the biorecognitive sites 
become free again and able to be reloaded with fresh drug containing nanoparticles. 
Nanoparticles used in this study were made of the well described, biocompatible and 
biodegradable polyester PLGA (Poly (D, L-lactide-co-glycolide)) that is degradable by 
mere hydrolysis, or of chitosan that is degradable by lysozyme circulating in human 
blood. Several studies have already shown the possibility to load and release 
different drugs from PLGA- or chitosan-nanoparticles.  
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In contrast to the currently available drug eluting implant materials, the novel  implant 
materials developed in this study allow drug delivery via nanoparticles throughout the 
entire implant life if necessary, to considerably improve the recovery of the patient 
after implantation. As nanoparticles can be loaded with different drugs, this 
technology allows easy adjustment to patient-specific medication needs as well as 
the administration of compounds that would either degrade quickly, or that are 
difficult to dose, when administered orally or intravenously (e.g. growth factors, 
immuno-suppressants, thrombolytic enzymes made biocompatible by chemical 
engineering). More over, this concept also allows the change of medication after 
implantation by using nanoparticles containing various drugs at different stages of the 
healing process when reloading the implant.   
 
Bi-functional PEGs or SH-PEG were bound covalently to the previously amino-
silanized implant surface to enhance biocompatibility. The choice of PEG-coupling 
procedure depends on the functional groups of the PEG derivative. For 
immobilization of bi-functional NH2-PEG-NH2, in a first step, succinic anhydride was 
coupled to the amino-silane followed by EDC/sulfo-NHS activation. For the 
monofunctional SH-PEG sulfo-SMCC was used as a linker. The immobilization of 
antibodies (Abs) or their Fab´ fragments onto the PEGylated or amino-silanized 
carrier was carried out by using the sulfo-SMCC cross linking method or the p-chloro-
anil method. The Ab molecules were selectively cleaved with a reducing agent such 
as 2-MEA (2-mercaptoethanolamine), or the newly optimized method developed 
during this thesis using dihydrolipoamide immobilized onto amino-silanized Gulsenit 
to create two Fab` fragments. The determination of Fab´ fragments immobilized onto 
amino-silanized or amino-PEGylated glass carriers was shown by OPA–Test (o-
phthaldialdehyde). The OPA-Test was used among other methods, such as the 
Kaiser assay, alkaline phosphatase assay, and finally sulfo-SDTB assay, to 
determine amino groups after amino-silanization and amino-PEGylation of the 
carriers.  
 
The active coating developed in this study is based on the effect of drugs that were 
embedded in nanoparticles. These nanoparticles bind specifically to their immobilized 
recognitive site (antibodies) on the surface of the carrier (implant material). In case of 
PLGA-nanoparticles PLGA antibodies were raised for the first time in this study. The 
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raising of polyclonal antibodies against a biocompatible and biodegradable polymer, 
such as PLGA, requires special efforts under normal conditions. Therefore, a very 
stringent immunisation protocol has been developed for antibody production in 
rabbits. By direct purification of PLGA antibodies from immune rabbit sera, using 
affinity chromatography, a protein was isolated which interacts with PLGA. Analysis 
of this protein by means of native gel electrophoresis and mass spectrometry showed 
that this protein has a homology to albumins. Therefore, we investigated also the 
effect of human serum albumin on PLGA, and could prove its binding to PLGA 
nanoparticles.  
 
According to these results, it is recommended to coat PLGA-NPs before injecting 
them into the human body to avoid unspecific coating with serum albumin. The 
design of such coating of PLGA-NPs has to be carried out carefully, as it needs to be 
biocompatible, rejecting proteins circulating in the body fluids to avoid fouling, and 
also be biodegradable, preferably by the same mechanisms as PLGA. In this case, 
production of antibodies against these biocompatible and biodegradable polymers 
that serve as binding sites for polymer coated PLGA-NPs might be a good solution. 
The raising of antibodies against these polymers can be carried out in analogy to the 
production of PLGA antibodies. 
This deposition of albumins onto PLGA was demonstrated using CLISA (Cluster 
Linked Immunosorbent Assay). This method was utilized for the detection of several 
antigen/ antibody interactions was adapted in this thesis for proving interactions 
between implant coating and nanoparticles in a reloading test. It was further applied 
for other analytical purposes, such as the detection of allergens in patient sera. 
 
Moreover, a drug delivery system based on chitosan nanoparticles was also studied 
in this thesis to show proof of principle for the novel developed implant material. The 
interaction between chitosan nanoparticles and their antibodies immobilized onto a 
carrier was demonstrated on silicate glass material employing CS-fluorescence 
labeled particles using fluorescence microscopy.  However, this method is not finally 
applicable to metals, because of quenching of optical signals, nor to ceramics due to 
its uneven surface characteristics. Therefore, the chemical coating of implant 
materials with PEGs and antibodies as well as antibody fragments was shown with 
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the above mentioned implant materials. To give the final visual proof by fluorescence 
microscopy, the same methods were then carried out using glass cover slips.  
 
Future work 
The principle of implant coating demonstrated in this thesis can be rextended using 
other implant materials such as titanium or glassy carbons. Other biocompatible and 
biodegradable coatings should be also tested for binding of the nanoparticle -
recognition system. Coatings with patient specific surfaces as e.g. endothelial cells of 
the respective patient should be a goal for future developments to achieve even safer 
stents. For coronary artery stents nanoparticles should be loaded with Prostacyclin 
(PGI2) which inhibits platelet aggregation and induces vasodilatation. 
The compatibility of new developed implant materials should then be tested in-vitro 
with endothelial cells e.g. the HUVEC cell line (human venous endothelial cells) and 
finally in animal and clinical studies. 
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Synthesis of amino-methoxy-PEG and carboxy-methoxy-PEG for 
biocompatible coating of implant materials 
 
Introduction 
PEG itself possesses no reactive site moieties due to the repeating ethylene oxide 
units. For binding to other compounds terminal functional groups have to be inserted 
through a series of reactions to more active functional groups (Jing Li et al. 2003) 
e.g. amino groups. To find an efficient way of preparing a hydrophilic polymer bearing 
a positively charged group at one end with economical cost led us to synthesize 
amino-methoxy-PEG. Two different reasonable procedures were tried to synthesize 
mono amino PEG, the first according to Colombo R. (1981) and the second via 
carboxy-methoxy-PEG.  
In this study the implant material has to be coated with biocompatible polymer (PEG). 
A mixture of bis-amino-PEG and amino-methoxy-PEG can be used if the distance 
between the biorecognitive receptors bound to the implant surface turn out to be too 
small and the drug loaded particles too big for adequate fit. This mixture would help 
to regulate the number of immobilized biorecognitive capture sites (Ab) on the 
surface of implant material if necessary, since only the free amino group of bis-
amino-PEG can serve as a binding site for the biorecognition system (Figure 1). 
 
 
Figure 1. Reaction scheme for binding of biorecognitive receptors using a mixture of bis-amino-PEG 
and amino-methoxy-PEG.  
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Synthesis of Amino-methoxy-PEG 2000 
The synthesis of amino-methoxy-PEG was carried out analgous to Colombo R. et al 
1981 as shown in Scheme 1. 
 
 
 
Scheme 1 
 
Synthesis of Carboxy-methoxy-PEG 
The procedure was carried out analogous to a method developed and described in 
Rumplayr K.  2006. 
 
Scheme 2 
 
Results and Discussion  
Detection of the carboxyl group 
The alkali salt of the hydroxamic acid which was obtained under alkaline conditions 
was reacted with FeCl3 after acidification. The Carboxy-methoxy-PEG (c-m-PEG) 
preparation resulted in a red-brownish colouring. As a control the same reaction was 
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performed with methoxy-PEG (m-PEG) where only the color of FeCl3 could be 
obtained. Amino-methoxy-PEG (NH2-m-PEG) reacted immediately and strongly with 
thionyl chloride resulting in a burnt, black substance (Figure 2).  
 
 
 
c-m-PEG  m-PEG           NH2-m-PEG 
 
Figure 2. Test for carboxyl groups in the product of c-m-PEG synthesis.  
 
IR Spectroscopy  
IR spectra of synthesized carboxy-methoxy-PEG are compared to spectra of 
methoxy-PEG (Figure 3 A and B) showing the characteristic absorbance for CO-
groups in the region of 1750 cm-1, absent in methoxy-PEG. 
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Figure 3. IR spectra of synthesized Carboxy – methoxy PEG compared to the starting material 
Methoxy PEG (SIGMA). The absorbance in the region of 1750 cm-1 is characteristic for CO-groups in 
carboxy-methoxy-PEG. 
 
Experimental Methods 
Synthesis of amino-methoxy-PEG 2000 
PEG 2000 (10 g, 5.0 mmol) was dried in vacuum at 60°C over night, dissolved in 150 
ml dry methylene chloride containing 10 ml pyridine. Then 4-toluene sulfonylchloride 
(27 g, 143 mmol) was added to the solution and the mixture stirred under Argon at 
room temperature for 24 hours and then under reflux for 4 hours. The reaction 
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mixture was concentrated to about 50% of the original volume and the polymer 
precipitated from this solution by dropwise addition of 400 ml anhydrous diethylether 
under vigorous stirring. After 30 min the precipitate was filtered and thoroughly 
washed with cold diethylether. The thus obtained tosylate was twice crystallized from 
absolute ethanol, filtered, washed with diethylether and dried under vacuum. The yiel 
was 9.36 g.  
2.8 g of the polymer (3.6 mmol) and 5 g K-phthalimide (26.9 mmol) were dissolved in 
60 ml dry DMF and the mixture stirred over night under Argon and then refluxed for 3 
hours. The precipitate was filtered off, and the product precipitated from the clear 
filtrate by dropwise addition of 300 ml dry anhydrous diethyl ether with stirring, kept 
for 1 hour at – 10°C, the precipitate then filtered and washed several times with 
diethyl ether. The precipitate was dissolved again in the minimal amount of 
chloroform (CHCl3), filtered, concentrated to half the volume and then the polymer 
precipitated again by addition of diethylether, filtered, washed with diethylether and 
dried in vacuum to give the the phthalimide of PEG-monomethlyether. The yield was 
4.11 g 
Phthalimide-PEG-monomethylether (6 g) was dissolved in 80 ml absolute ethanol 
and 6 ml hydrazine-hydrate (6 ml) added and refluxed under Argon for 18 hours. The 
mixture was cooled to 10°C, the product precipitated by dropwise addition of 80 ml 
anhydrous diethyl ether under stirring. The precipitate was filtered, washed with ether 
and dissolved in the minimum amount of dichloromethane (CH2Cl2). After filtering 
again the clear filtrate was concentrated and the polymer precipitated by dropwise 
addition of diethylether. The thus obtained amino PEG monomethylether was filtered, 
washed several times with diethyl ether and dried under vacuum. The yield was 2 g. 
 
Synthesis of carboxy-methoxy-PEG 
Methoxy-PEG 2000 (20 g, 10 mmol) was dissolved in 50 ml dry tetrahydrofurane 
(THF), 2.86 g (30 mmol) chloroacetic acid and 7 ml (50 mmol) triethyl amine were 
then added and the mixture stirred at 40°C for 4 hours. The product was then 
precipitated with 100 ml hexane, filtered, washed with hexane and dried in vacuum. 
The yield was 22.5 g of a white powder. 
This white powder was then dissolved in 120 ml H2O, 10 ml HCl (conc.) added, 
stirred for a few minutes, and then extracted with 3 x 20 ml CHCl3, the extracts 
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combined, dried over Na2SO4 and the solvent then evaporated. The yield was 17.66 
g. 
 
Detection of the carboxyl group in carboxy-methoxy-PEG 
Proof of carboxy content was carried out according to the procedure by Feigl F. 
(1960). Carboxylic acids can be first reacted with thionyl chloride forming the acd 
chloride and it then readily gives the alkali salt of hydroxamic acid on treatment with 
hydroxylamine and alkali (Scheme 3).  
 
 
Scheme 3 
 
All hydroxamic acids give a red or violet color with ferric chloride by formation of 
water soluble inner complex salts (Scheme 4). 
 
 
 
Scheme 4 
 
The conversion into hydroxamic acid and the formation of hydroxamate is used as a 
test for carboxylic acids and their derivates.  
 
Procedure: 
Five drops of thionylchloride were added to 10 mg of synthesized carboxy-methoxy-
PEG. The mixture was then evaporated to dryness on a heating plate to convert the 
carboxylic acid into its chloride. Five drops of saturated alcoholic solution of 
hydroxylamine chloride were then added and a few drops of alcoholic alkali until the 
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liquid reacted basic. The mixture was then acidified with a few drops of 0.5 M HCl. 
Reaction took place during reheating by formation of hydroxamic acid.  
The mixture was treated with five drops of 1% aqueous solution of ferric chloride 
(FeCl3). In presence of carboxyl groups the color changes from brown-red to dark 
violet. 
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Appendix of Chapter 1 
1.1 Calculation of calibration curve for amino group detection using AP enzyme 
assay    
A. 1.12 ng/ml AP-standard  
 
Time 
(sec) 
ABS 
37 0,03 
62 0,044 
103 0,06 
140 0,076 
180 0,096 
219 0,113 
248 0,123 
AP 1.12 ng/ml Standard
y = 0,0004x + 0,0149
R2 = 0,9984
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B. 2.24 ng/ml AP-standard 
 
 
Time 
(sec) 
ABS 
0,035 41 
0,055 70 
0,082 112 
0,111 156 
0,131 187 
0,15 223 
0,164 253 
 
AP 2.24 ng/ml AP Standard
y = 0,0006x + 0,0122
R2 = 0,9969
0
0,05
0,1
0,15
0,2
0,25
0,3
0,35
0 100 200 300
Time (sec)
A
B
S
 
 
C. 4.49 ng/ml AP-standard 
 
 
 
 
 
 
 
Time 
(sec) 
ABS 
37 0,052 
74 0,109 
101 0,143 
131 0,179 
170 0,222 
211 0,267 
248 0,307 
AP 4.49 ng/ml AP Standard
y = 0,0012x + 0,0181
R
2
 = 0,9958
0
0,05
0,1
0,15
0,2
0,25
0,3
0,35
0 100 200 300
Time (sec)
A
B
S
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D. Calibration curve 
 
AP  
concentration 
Slope 
1,12 0,0004 
2,24 0,0006 
4,49 0,0012 
Calibration curve
y = 0,0002x + 0,0001
R
2
 = 0,992
0
0,0002
0,0004
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0,0008
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0,0012
0,0014
0 1 2 3 4 5
AP concentration (ng/ml)
S
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p
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Figure 1. The calibration curve was calculated by measuring the extinction of several concentrations 
of AP over the time separately. The definite concentration of each AP and its slopes (A, B, C) are used 
to give the equation for standard function (y = 0.0002x + 0.0001) of calibration curve (D). The amount 
of immobilized enzymes onto carriers (Figure 2 and 3) was calculated using this standard calibration 
function.  
 
1.2 Quantification of amino groups with glutaraldehyde immobilized AP onto 
amino-silanized carriers 
A. Not etched 316L and amino-silanized 316L 
stainless steel 
 
 
Time 
(sec) 
ABS 
45 0,023 
85 0,023 
125 0,026 
155 0,028 
195 0,036 
240 0,037 
Not etched 316L and amino-silanized
y = 8E-05x + 0,0172
R2 = 0,9003
0
0,05
0,1
0,15
0,2
0,25
0,3
0,35
0 100 200 300
Time (sec)
A
B
S
 
  
B. 316L stainless steel etched with 0.5 M HCl 
and Amino-silanized 
 
 
Time 
(sec) 
ABS 
60 0,023 
100 0,045 
150 0,078 
185 0,096 
240 0,13 
316L etched with 0.5M HCl and amino-
silanized
y = 0,0006x - 0,0133
R2 = 0,9991
0
0,05
0,1
0,15
0,2
0,25
0,3
0,35
0 100 200 300
Time (sec)
A
B
S
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C. 316L stainless steel etched with 3% HNO3 
and amino-silanized 
 
Time 
(sec) 
ABS 
43 0,03 
80 0,05 
121 0,072 
165 0,096 
210 0,118 
247 0,139 
316L etced with 3% HNO3 and amino-
silanized 
y = 0,0005x + 0,0075
R2 = 0,9998
0
0,05
0,1
0,15
0,2
0,25
0,3
0,35
0 100 200 300
Time (sec)
A
B
S
 
D.  Amino-silanized glass  
 
Time 
(sec) 
ABS 
20 0,045 
45 0,064 
70 0,078 
100 0,103 
130 0,122 
160 0,143 
190 0,163 
220 0,18 
250 0,208 
Amino-silanized glass
y = 0,0007x + 0,0316
R2 = 0,9985
0
0,05
0,1
0,15
0,2
0,25
0,3
0,35
0 100 200 300
Time (sec)
A
B
S
 
F. Amino-silanized ceramics  
 
Time 
(sec) ABS 
28 0,02 
64 0,029 
94 0,034 
142 0,044 
183 0,053 
216 0,061 
246 0,067 
Amino-silanized ZrO2
y = 0,0002x + 0,0143
R2 = 0,9988
0
0,01
0,02
0,03
0,04
0,05
0,06
0,07
0,08
0 100 200 300
Time (sec)
A
B
S
 
 
Figure 2. Measurement of AP activation on amino-silanized carriers. The slope of each sample is 
proportional to the concentration of the enzyme, which should be somewhat equal to the number of 
amino groups on the surface of the carrier. Using the standard equation (Figure 1 D) and the slope of 
each sample the amount of immobilized amino groups can be calculated. The highest number of 
detected amino groups was observed for ceramics (F) than glass (D) material. After etching of 316 L 
stainless steel a relative equal AP activation was observed (B, C), however by the silanized non 
etched 316L stainless steel no AP activation was measured (A).  
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1.3 Quantification of amino groups with glutaraldehyde immobilized AP onto 
amino-PEGylated carriers 
A. 316L stainless steel etched with 0.5 M HCl, 
amino-PEGylated (EDC, pH5 
 
 
Time 
(sec) 
ABS 
75 0,031 
108 0,039 
140 0,047 
170 0,055 
206 0,063 
237 0,071 
316Letched with 0,5 M HCl, amino-PEGylated 
(EDC,pH5)
y = 0,0002x + 0,0125
R2 = 0,9996
0
0,05
0,1
0,15
0,2
0,25
0,3
0,35
0 50 100 150 200 250
Time (sec)
A
B
S
 
  
B. 316L stainless steel etched with 3% HNO3, 
amino-PEGylated (EDC, pH5) 
 
 
Time 
(sec) 
ABS 
32 0,015 
71 0,024 
117 0,038 
169 0,049 
209 0,058 
273 0,072 
316L etched with 3% HNO3, amino-PEGylated 
(EDC, pH5)
y = 0,0002x + 0,0082
R2 = 0,9968
0
0,05
0,1
0,15
0,2
0,25
0,3
0,35
0 100 200 300
Time (sec)
A
B
S
 
  
C. 316L stainless steel etched with 0.5 M HCl, 
amino-PEGylated (EDC, pH10) 
 
 
Time 
(sec) ABS 
42 0,025 
75 0,03 
110 0,037 
156 0,048 
193 0,059 
224 0,067 
316L etched with 0.5 M HCl, amino-PEGylated 
(EDC, pH 10)
y = 0,0002x + 0,0129
R2 = 0,9903
0
0,05
0,1
0,15
0,2
0,25
0,3
0,35
0 50 100 150 200 250
Time (sec)
A
B
S
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D. 316L stainless steel etched with 3% HNO3, 
amino-PEGylated (EDC, pH10) 
 
Time 
(sec) 
ABS 
41 0,02 
78 0,03 
119 0,039 
156 0,048 
186 0,054 
218 0,061 
247 0,069 
316L etched with 3% HNO3, amino-PEGylated 
(EDC, pH 10)
y = 0,0002x + 0,0112
R2 = 0,9987
0
0,05
0,1
0,15
0,2
0,25
0,3
0,35
0 100 200 300
Time (sec)
A
B
S
 
  
E. Amino-silanized and amino-PEGylated (pH 
5) glass 
 
 
Time 
(sec) 
ABS 
60 0,099 
120 0,144 
180 0,179 
240 0,23 
Amino-silanized and -PEGylated (pH 5) glass
y = 0,0007x + 0,056
R2 = 0,9953
0
0,05
0,1
0,15
0,2
0,25
0,3
0,35
0 100 200 300
Time (sec)
A
B
S
 
 
F. Amino-silanized and amino-PEGylated (pH 
10) glass 
 
 
Time 
(sec) 
ABS 
60 0,062 
120 0,106 
180 0,137 
240 0,161 
Amino-silanized and -PEGylated (pH 10) 
glass
y = 0,0005x + 0,0345
R2 = 0,9814
0
0,05
0,1
0,15
0,2
0,25
0,3
0,35
0 100 200 300
Time (sec)
A
B
S
 
  
G. Amino-silanized and amino-PEGylated (pH 
5) ceramics 
 
 
Time 
(sec) ABS 
60 0,012 
120 0,032 
180 0,046 
240 0,057 
Amino-PEGylated ZrO2 at pH 5
y = 0,0002x - 0,0005
R2 = 0,9817
0
0,01
0,02
0,03
0,04
0,05
0,06
0,07
0 100 200 300
Time (sec)
A
B
S
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H. Amino-silanized and amino-PEGylated (pH 
10) ceramics 
 
Time 
(sec) ABS 
60 0,013 
120 0,021 
180 0,034 
240 0,046 
Amino-PEGylated ZrO2 pH 10
y = 0,0002x + 0,0005
R2 = 0,9908
0
0,01
0,02
0,03
0,04
0,05
0 100 200 300
Time (sec)
A
B
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Figure 3.  Measurement of AP activation on amino-PEGylated carriers. Using the standard equation 
(Figure 1 D.) and the slope of each sample the amount of immobilized amino groups can be 
calculated. The highest detected amount of amino groups was observed for amino-PEGylated 
ceramics (F, G) than glass at pH 5 (E).  The amino-PEGylated 316L stainless steel samples (A, B, C, 
D) show relatively similar amount of amino groups.  
 
Appendix of Chapter 5 
2.1 Mass spectrometry analysis of purified immune serum of rabbit 52 using 
Gulsenit conjugated with PLGA 
 
 Rabitt 52       
         
         
 gi|126723746    Mass: 70861       Queries matched: 1021      
  
serum albumin precursor [Oryctolagus cuniculus] 
  
         
      1 MKWVTFISLL FLFSSAYSRG VFRREAHKSE IAHRFNDVGE EHFIGLVLIT  
     51 FSQYLQKCPY EEHAKLVKEV TDLAKACVAD ESAANCDKSL HDIFGDKICA  
    101 LPSLRDTYGD VADCCEKKEP ERNECFLHHK DDKPDLPPFA RPEADVLCKA  
    151 FHDDEKAFFG HYLYEVARRH PYFYAPELLY YAQKYKAILT ECCEAADKGA  
    201 CLTPKLDALE GKSLISAAQE RLRCASIQKF GDRAYKAWAL VRLSQRFPKA  
    251 DFTDISKIVT DLTKVHKECC HGDLLECADD RADLAKYMCE HQETISSHLK  
    301 ECCDKPILEK AHCIYGLHND ETPAGLPAVA EEFVEDKDVC KNYEEAKDLF  
    351 LGKFLYEYSR RHPDYSVVLL LRLGKAYEAT LKKCCATDDP HACYAKVLDE  
    401 FQPLVDEPKN LVKQNCELYE QLGDYNFQNA LLVRYTKKVP QVSTPTLVEI  
    451 SRSLGKVGSK CCKHPEAERL PCVEDYLSVV LNRLCVLHEK TPVSEKVTKC  
    501 CSESLVDRRP CFSALGPDET YVPKEFNAET FTFHADICTL PETERKIKKQ  
    551 TALVELVKHK PHATNDQLKT VVGEFTALLD KCCSAEDKEA CFAVEGPKLV  
 
   601 
ESSKATLG       
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 gi|30794280    Mass: 71274    Score: 786    Queries matched: 82   emPAI: 2.21 
  
Albumin[Bostaurus] 
     
         
      1 MKWVTFISLL LLFSSAYSRG VFRRDTHKSE IAHRFKDLGE EHFKGLVLIA  
     51 FSYLQQCPF DEHVKLVNEL TEFAKTCVAD ESHAGCEKSL HTLFGDELCK  
    101 VASLRETYGD MADCCEKQEP ERNECFLSHK DDSPDLPKLK PDPNTLCDEF  
    151 KADEKKFWGK YLYEIARRHP YFYAPELLYY ANKYNGVFQE CCQAEDKGAC  
    201 LLPKIETMRE KVLTSSARQR LRCASIQKFG ERALKAWSVA RLSQKFPKAE  
    251 FVEVTKLVTD LTKVHKECCH GDLLECADDR ADLAKYICDN QDTISSKLKE  
    301 CCDKPLLEKS HCIAEVEKDA IPENLPPLTA DFAEDKDVCK NYQEAKDAFL  
    351 GSFLYEYSRR HPEYAVSVLL RLAKEYEATL EECCAKDDPH ACYSTVFDKL  
    401 KHLVDEPQNL IKQNCDQFEK LGEYGFQNAL IVRYTRKVPQ VSTPTLVEVS  
    451 RSLGKVGTRC CTKPESERMP CTEDYLSLIL NRLCVLHEKT PVSEKVTKCC  
    501 TESLVNRRPC FSALTPDETY VPKAFDEKLF TFHADICTLP DTEKQIKKQT  
    551 ALVELLKHKP KATEEQLKTV MENFVAFVDK CCAADDKEAC FAVEGPKLVV  
    601 STQTALA       
         
Figure 4. Mass spectroscopy analyses of purified immune serum of rabbit 52 using Gulsenit 
conjugated with PLGA showing a homology to albumins.   
 
More Details 
Type of mass spectrometry: Thermo Finnigan LTQ 
Proteins found:  
 Serum albumin precursor [Oryctolagus cuniculus], Queries matched: 1021 (red 
letters)    
 Albumin [Bos taurus], Queries matched: 82   (red letters) 
 Used scoring system: Search algorithm: Mascot: Mascot incorporates a probability based 
implementation of the Mowse algorithm 
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Appendix of Chapter 6 
 3.1 Absorbance of different dilutions of immune and preimmune serum 
Table 1. 
Dilution 
ABS of 
preimmune 
serum from  
R.96 
ABS of 
preimmune 
serum from 
R. 95 
ABS of 
immune 
serum from R. 
95 after 5th 
immunization 
ABS of 
immune 
serum from R. 
95 after 7th 
immunization 
ABS of 
immune 
serum from 
R. 52 
ABS of 
immune 
serum from 
R. 53 
100 0,173 0,116 0,333 0,058 0,05 0,028 
500 0,008 0,015 0,044 0,042 0,004 0,026 
1000 0,007 0,013 0,031 0,026 0,003 0,025 
1500 0,002 0,006 0,025 0,016 0,001 0,021 
2000 0,004 0,007 0,018 0,013 0,003 0,019 
2500 0,003 0,007 0,012 0,015 0,002 0,016 
3000 0,001 0,003 0,01 0,011 0,001 0,012 
4000 0,004 0,006 0,007 0,006 0,002 0,012 
 
Table 2. 
Dilution 
ABS of R.96 
after 3rd 
immunization 
ABS of R. 96 
after 4th 
immunization 
ABS of R. 96 
after 5th 
immunization 
ABS of R. 96 
after 7th 
immunization 
ABS of R. 96 
after 8th 
immunization 
Negative 
control 
100 0,898 0,76 0,581 0,309 0,341 0,061 
500 0,503 0,461 0,264 0,204 0,17 0,061 
1000 0,27 0,398 0,212 0,134 0,117 0,062 
1500 0,161 0,334 0,159 0,124 0,105 0,05 
2000 0,134 0,276 0,11 0,124 0,073 0,051 
2500 0,133 0,163 0,119 0,102 0,072 0,05 
3000 0,081 0,139 0,111 0,091 0,069 0,049 
4000 0,081 0,114 0,089 0,088 0,065 0,052 
5000 0,073 0,125 0,077 0,05 0,051 0,054 
6000 0,063 0,107 0,07 0,055 0,038 0,053 
7000 0,06 0,107 0,048 0,047 0,037 0,058 
8000 0,045 0,076 0,052 0,038 0,038 0,058 
9000 0,055 0,087 0,06 0,035 0,043 0,055 
10000 0,081 0,09 0,048 
 
0,034 0,043 0,055 
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Table 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1, 2, and 3. ABS values of preimmune- and immune- serum of R. 95 and 96 from after the 3rd to 
after the 8th immunization. The negative control is tested with preimmune serum of rabbit 96 after 8th 
immunization and an average value is taken (from all ABS values of the negative control). This 
average value is 0.05 (=blank). All presented ABS values in table 1, 2 and 3 are after subtraction of 
blank. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dilution 
ABS of R.95 
after 3rd 
immunization 
ABS of R. 95 
after 4th 
immunization 
100 0,465 0,134 
500 0,092 0,039 
1000 0,058 0,036 
1500 0,047 0,02 
2000 0,041 0,02 
2500 0,027 0,018 
3000 0,027 0,017 
4000 0,013 0,015 
5000 0,029 0,013 
6000 0,012 0,019 
7000 0,021 0,015 
8000 0,023 0,013 
9000 0,014 0,008 
10000 0,026 0,008 
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3.2 Absorbance curves of different dilutions from preimmune serum and 
immune serum 
   A      B 
Rabbit 95 after 3. immunization
0
0,2
0,4
0,6
0,8
1
0 2000 4000 6000 8000 10000 12000
Dilution
A
B
S
ABS     
Rabbit 95 after 5.immunization
0
0,2
0,4
0,6
0,8
1
0 1000 2000 3000 4000 5000
Dilution
A
B
S
ABS  
   C      D 
Rabbit 95 after 7. immunzation
0
0,2
0,4
0,6
0,8
1
0 1000 2000 3000 4000 5000
Dilution
A
B
S
ABS
    
Preimmune serum of rabbit 95
0
0,2
0,4
0,6
0,8
1
0 1000 2000 3000 4000 5000
Dilution
A
B
S
ABS
 
E      F 
Negative control
0
0,2
0,4
0,6
0,8
1
0 2000 4000 6000 8000 10000 12000
Dilution
A
B
S
ABS
   
Immune serum of rabitt 52
0
0,2
0,4
0,6
0,8
1
0 1000 2000 3000 4000 5000
Dilution
A
B
S
ABS
  
G  
Immune serum of rabbit 53
0
0,2
0,4
0,6
0,8
1
0 1000 2000 3000 4000 5000
Dilution
A
B
S
ABS
 
Figure 5. Absorbance curves of different dilutions from preimmune serum and immune serum of 
Rabbit 95, 52 and 53 and negative control. Preimmune serum of rabbit 95 (D) shows no signal. A very 
low titer was found in rabbit 95 after 3rd, 5th, 7th and 8th (A, B, C) immunization. A negative titer was 
observed in rabbit 52 (F) and rabbit 53 (G). Rabbit 52 and 53 were immunized only with PLGA-NPs. 
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3.4 Mass spectroscopy results for the upper and lower band 
 
Table 1, 2 and 3 summarize results of mass spectrometry for the and lower band of immune sample 
after the fifth immunization on a native gel: 
 
Table 1 
Version: unknown                                           
Charge States Calculated: unknown                                           
Deisotoped: unknown                                           
Textual Annotation: unknown                                           
Database Name: the nr_2009-130.fa database                                           
Version: unknown                                           
Taxonomy: Mammalia                                           
Number of Proteins: 732230                                           
Search Engine: Mascot                                           
Version: Mascot                                           
Samples: All Samples                                           
Fragment Tolerance: 0,80 Da (Monoisotopic)                                           
Parent Tolerance: 2,0 Da (Monoisotopic)                                           
Fixed Modifications: +57 on C (Carbamidomethyl)                                           
Variable Modifications: +16 on M (Oxidation)                                           
Database: the nr_2009-10-30.fa database (selected  
for Mammalia, unknown version, 732230 entries)                                          
Digestion Enzyme: Trypsin                                           
Max Missed Cleavages: 2                                           
Peptide Thresholds: Spectrum Mill: score greater than 11, SPI% greater than 0, Fwd-Rev greater  
than -2147483647, Rank 1-2 greater than -2147483647, and norm Fwd-Rev greater than 0,  
Phenyx: z-Scores of greater than 8,0,OMSSA: -Log (E-Value) scores of greater than 2,0, X! Tandem:  
-Log(Expect Scores) scores of greater than 2,0, Mascot: ion scores must be greater than both the  
associated identity scores and 35, 30, 30 and 40 for singly,doubly, triply and quadruply charged 
 peptides, Sequest: deltaCn scores of greater than 0,10 and XCorr scores of greater than 1,8, 2,5, 3,5  
and 3,5 for singly, doubly, triply and quadruply charged peptides 
Protein Thresholds: 
2 peptides minimum                                           
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Table 2. Identified proteins and accession number of upper and low band of immune serum after fifth 
immunization. 
 
Number Identified Proteins  Accession Number 
1 apolipoprotein A-I (predicted) [Oryctolagus cuniculus] gi|217418328 
2 
inter-alpha (globulin) inhibitor H1 [Oryctolagus cuniculus], 
gi|6579183|dbj|BAA88322.1| inter-alpha-trypsin inhibitor 
heavy chain H1 [Oryctolagus cuniculus] gi|130491439 
3 
inter-alpha-trypsin inhibitor heavy chain2 [Oryctolagus 
cuniculus], gi|11041696|dbj|BAB17301.1| inter-alpha-
trypsin inhibitor heavy chain2 [Oryctolagus cuniculus] gi|130498817 
4 
complement component 3 [Rattus norvegicus], 
gi|149028133|gb|EDL83571.1| rCG45082 [Rattus 
norvegicus] gi|158138561 
5 
serum albumin precursor precursor [Oryctolagus 
cuniculus], gi|44889024|sp|P49065.2|ALBU_RABIT 
RecName: Full=Serum albumin; Flags: Precursor, 
gi|29653363|gb|AAB58347.2| serum albumin precursor 
[Oryctolagus cuniculus] gi|126723746 
6 
liver transferrin [Oryctolagus cuniculus], 
gi|1751|emb|CAA41424.1| liver transferrin [Oryctolagus 
cuniculus] gi|156119356 (+2) 
7 Chain A, Complex Of Bdellastasin With Porcine Trypsin gi|257472074 
8 
paraoxonase 1 [Oryctolagus cuniculus], 
gi|130676|sp|P27170.2|PON1_RABIT RecName: 
Full=Serum paraoxonase/arylesterase 1; Short=PON 1; 
AltName: Full=Serum aryldialkylphosphatase 1; AltName: 
Full=A-esterase 1; AltName: Full=Aromatic esterase 1, 
gi|165660|gb|AAA31452.1| serum paraoxonase, 
gi|7579911|gb|AAB27713.2| paraoxonase; PON 
[Oryctolagus cuniculus] gi|126722853 (+2) 
9 
complement component 3 [Oryctolagus cuniculus], 
gi|116596|sp|P12247.1|CO3_RABIT RecName: 
Full=Complement C3 alpha chain, 
gi|164863|gb|AAA31190.1| complement component C3 
alpha-chain gi|126723309 
10 
hemopexin precursor [Oryctolagus cuniculus], 
gi|1708184|sp|P20058.2|HEMO_RABIT RecName: 
Full=Hemopexin; Flags: Precursor, 
gi|6137344|pdb|1QHU|A Chain A, Mammalian Blood gi|130500366 
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Serum Haemopexin Deglycosylated And In Complex With 
Its Ligand Haem, gi|7245995|pdb|1QJS|A Chain A, 
Mammalian Blood Serum Haemopexin Glycosylated-
Native Protein And In Complex With Its Ligand Haem, 
gi|7245996|pdb|1QJS|B Chain B, Mammalian Blood 
Serum Haemopexin Glycosylated-Native Protein And In 
Complex With Its Ligand Haem, 
gi|433687|emb|CAA34452.1| hemopexin precursor 
[Oryctolagus cuniculus] 
11 
PREDICTED: similar to complement component C5 
[Equus caballus] gi|194225695 
12 
keratin 1 [Homo sapiens], gi|39794653|gb|AAH63697.1| 
Keratin 1 [Homo sapiens] gi|11935049 (+2) 
13 
Chain A, Crystal Structure Of The Rabbit Igg Fc Fragment, 
gi|203282278|pdb|2VUO|B Chain B, Crystal Structure Of 
The Rabbit Igg Fc Fragment gi|203282277 (+2) 
14 cytokeratin 9 [Homo sapiens] gi|435476 (+1) 
15 
PREDICTED: similar to complement component 5 
[Macaca mulatta] gi|109110418 
16 
PREDICTED: similar to keratin 10 isoform 2 [Macaca 
mulatta] gi|109115260 (+11) 
17 
complement component 3 [Mus musculus], 
gi|28175786|gb|AAH43338.1| Complement component 3 
[Mus musculus] gi|126518317 (+3) 
18 
immunoglobulin heavy chain VDJC-alpha 
transrecombinant region [Oryctolagus cuniculus] gi|4063643 
19 Ig kappa chain b4 [Oryctolagus cuniculus] gi|165371 
20 
RecName: Full=Haptoglobin; Contains: RecName: 
Full=Haptoglobin alpha chain; Contains: RecName: 
Full=Haptoglobin beta chain 
gi|123511 (+3) 
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Table 3. Molecular weight, number of unique peptides and percent coverage of Identified Proteins in 
upper and lower band of immune serum after fifth immunization 
 
Number 
 
Upper band Low band 
 
molecular 
 weight 
number of  
unique 
peptides 
percent 
coverage 
number of  
unique 
peptides 
percent 
coverage 
1 31 kDa 12 44% 10 36% 
2 100 kDa 11 12% 12 16% 
3 106 kDa 7 7,60% 9 10% 
4 186 kDa 6 3,80% 4 2,60% 
5 69 kDa 7 14% 6 12% 
6 77 kDa 4 6,80% 12 16% 
7 23 kDa 4 24% 3 20% 
8 40 kDa 2 5,00% 2 5,30% 
9 82 kDa 4 7,40% 2 3,90% 
10 52 kDa 0 0 2 5,20% 
11 192 kDa 5 3,30% 2 1,50% 
12 66 kDa 7 14% 2 3,40% 
13 25 kDa 2 12% 0 0 
14 62 kDa 5 11% 0 0 
15 189 kDa 2 1,40% 0 0 
16 62 kDa 3 5,90% 0 0 
17 186 kDa 2 1,70% 2 1,70% 
18 30 kDa 2 8,60% 0 0 
19 23 kDa 2 11% 0 0 
20 36 kDa 0 0 2 7,00% 
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Materials  
Acetic acid J.T. Baker 
 
Bovine serum albumin (BSA) 
Sigma 
2-Mercaptoethanol Fluka 
3-Aminopropyltriethoxysilane Sigma 
4-Toluene sulfonylchloride J.T. Baker 
Acetone J.T. Baker 
Acrylamide Sigma 
AgNO3 Sigma 
Amicon ultra centrifuge filter Amicon 
Amino-methoxy-PEG Fluka 
Anti rabbit IgG, HRP conjugated Sigma 
Anti-mouse IgG for HSA Sigma 
APS Serva 
Bisacrylamide Sigma 
BODIPY 493/503 (4,4-difluoro-
1,3,5,7,8 pentamethyl, 
4-bora-3a,4a-diaza-5-indacene), 
cat.no. D-3922 
Invitrogen 
Bradford reagent (Protein assay) Bio-Rad 
Bromophenol blue Fluka 
Carboxy-methoxy-PEG Fluka 
CBB-R250 Serva 
Chitosan (MW 50 000-190 
000Dalton,75-85% deacetylation 
degree) 
Sigma 
Chloroacetic acid Sigma 
Chloroform J.T. Baker 
Column (2.5 ml) Mo Bi Tec 
DIC Sigma 
Dichloromethane J.T. Baker 
Diethyl ether J.T. Baker 
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DMF Pierce 
DMSO Merck 
Dynabeads® M-280 Sheep anti-Rabbit Invitrogen 
Dynabeads® M-450 Epoxy Invitrogen 
Dynal® MPCTM, Magnetic Particle 
Concentrator 
Invitrogen 
DYNATECH MicrotiterTM 2 plates 
DYNATECHLABORATORIES, INC 
(U.S.A) 
EDC (N-3-Dimethylaminopropyl-N‟-
ethylcarbodiimide) 
Pierce 
Ellman's reagent (DTNB), MW 396.35 Pierce 
Ethanol J.T.Baker 
Ethyl acetate Merk 
Ethylene diamine Sigma 
FeCl3 Sigma 
Filter (10 µm pore) Mo Bi Tec 
Fish gelatine Sigma 
Formaldehyde J.T.Baker 
Gelatine from cold water fish skin Sigma 
Glass powder Sartorius 
Glass slides (Ø12 mm) Assectent 
Glassfiber Prefilter (1µm) Millipore Filter 
Glycerol Fluka 
Glycine AppliChem 
Gulsenit 
MAGINDAG, FEUERFEST, Leoben, 
Austria 
H2SO4 J.T.Baker 
HAuCl43H2O Sigma-Aldrich 
HCl J.T.Baker 
HNO3 J.T.Baker 
Human serum albumin (HSA) 
 
Sigma 
Hydrazine-hydrate Sigma 
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Isopropanol Fluka 
KCN Sigma 
K-Phthalimide Fluka 
LDH (cow) Sigma 
LDH (pork) Roche 
LDH (rabbit) Sigma 
Lipoic acid Sigma 
Maxisorp microtiterplate NUNC-Immuno 
Methanol J.T.Baker 
Methylene chloride J.T.Baker 
MgCl2 Sigma 
Mk anti Human HSA -Ab (7.8 mg/ml) Sigma 
Mk anti ß-galactosidase -Ab (2.5 
mg/ml) 
Promega 
Na2CO3 Sigma 
Na2HPO4 Sigma 
Na2SO4 Riedel-de Haen 
Na3PO4 Fluka 
N-Acetyl-L-cysteine Sigma 
NaCl Riedel-de Haen 
NaH2PO4 Merck 
NaHCO3 Riedel-de Haen 
NaOAC Fluka 
NaOH Riedel-de Haen 
Natrium azide Sigma 
NC membrane (pore size 0.45 µm) Protran BA 85, Schleicher & Schuell) 
NHS (N-Hydroxysuccinimide) Sigma 
Nile red Sigma 
OPA  (O-phtaldialdehyde) Fluka 
p-Chloro-anil Fluka 
Perchloric acid Sigma 
Peroxidase (502 U/ mg) Fluka 
Peroxidase antibody (41mg /ml) Sigma 
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Phenol Fluka 
Pk anti BSA-Ab (3.6 mg/ml) Sigma 
Pk anti Peroxidase Ab (41 mg/ml) Sigma 
PLGA, 50:50 lactide/glycolide: 
Resomer RG503H 
(acid number min 3 mg KOH/g), 
Resomer RG 502 H 
(acid number min 6 mg KOH/g) 
Boehringer Ingelheim 
Pluronic F-68 Sigma 
p-NPP Fluka 
Prick-/Scratch testing solutions (3 ml) 
Allergopharma Vertriebsges 
 
Protein A, Antibody Purification kit Sigma stock no. PURE-1A 
Protein G Fluka 
Protein Molecular Weight Marker MBI 
(PageRuler Protein Ladder, 
#SM0661) 
Fermentas 
Pyridine Sigma 
Quant-iT™ Protein Assay Kits Invitrogen 
Rabbit anti bovine lactoglobulin Ab Bethyl 
Ringer‟ solution Baxter 
SDS Serva 
SH-PEG, MW 5000 Sigma 
Silica amine microspheres Bangs Laboratories, Inc. 
Silica gel plates gel 60 with 
fluorescence indicator 
MERCK 
Sodium hydrosulfite (Na2S2O4) Sigma 
ß-Lactoglobulin from bovine milk Sigma 
Stainless-steel L 316 (foil) Goodfellow 
Succinic anhydride Merk 
Sulfo-NHS Pierce 
Sulfo-SDTB Pierce 
Sulfo-SMCC Pierce 
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TEMED Bio-Rad 
THF J.T. Baker 
Thionyl chloride (SOCl2) Sigma 
TMB Sciotec 
TNBS Sigma 
Toluene J.T. Baker 
TPP Sigma 
Triethyl amine Sigma 
Tris Base Ultrapure US Biological 
Trisodium citrate Riedel-de Haen 
Tween 20 Sigma 
Vivaflow 50; 100000 MWCO PES Sartorius Vivascience G.m.b.H 
Zirconia (ZrO2-TZP-A BiO-HIP) Z-Systems AG 
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Curriculum Vitae 
239 
 
 
 
 
 
 
 
 
 
Curriculum Vitae 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Curriculum Vitae 
240 
Curriculum Vitae- Mag. Haifa Al-Dubai 
 
 
P E R S O N A L    D E T A I L S 
Date of birth    December 20th, 1968 
Place of birth  Taiz - Yemen 
Citizenship  Austrian 
Social state   Married, two daughters 
Languages  Arabic (mother tongue) 
  German (fluent in speaking and writing) 
  English (good in speaking and writing) 
Address  Simmeringer Hauptstraße16/2/11, Vienna, Austria 
E-mail   haifa.al-dubai@unicvie.ac.at 
 
E D U C A T I O N 
2005-2009  PhD in Biochemistry: University of Vienna, Department of Biochemistry, 
Advisor:  Univ. Prof. Dr. Fritz Pittner Department of Biochemistry 
University of Vienna and MFPL Dr. Bohr Gasse 9 A-1030 Vienna, Austria,  
  Thesis title: Feasibility Studies for Development of Specific Re-loadable 
Binding Sites for Drug Delivery Systems Immobilized onto Implant Surfaces  
 
2004 - 2005    Education for agent to drugs sale, at Pharma Akademie Österreich (PAÖ) and 
the courses took place in Liechtensteinstraße 127/1/9, A-1090 Vienna 
(Austria), The first section of the courses included medical issues of the 
following human tracts or systems and their diseases (histology, locomotor 
system, cardiovascular system, respiratory tract, gastrointestinal tract,  
urogenital tract, blood system, immunology, hormone system, neurology, 
biochemistry, dermatology, pathology, ENT, ophthalmology, psychiatry, 
microbiology, active ingredient) and the second section of the courses 
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included pharmacological issues (chemistry/physic, pharmaceuticals law and 
technology) 
 
Dec.1998 Masters in Microbiology and Biochemistry, University of Vienna, Department 
of medical Biochemistry (Austria) 
  Advisor:  Univ. Prof. Dr. Georg Weitzer 
  Thesis title: Culture and in Vitro Differentiation of Embryonic Stem Cells: 
Analysis of Intermediate Filament Expression in Transgenic Cells with 
different Desmin Alleles 
 
R E S E A R C H    E X P E R I E N C E 
2005-2009  PhD Candidate: Department of Biochemistry University of Vienna and MFPL 
(Austria), The fundamental goal of my thesis research is to realize the 
development of the reloadable drug delivery system for biocompatible coated 
implant materials. To achieve this goal, my thesis project focused on 
achieving three fundament objectives. The first objective focused on the 
production of covalent binding of a biocompatible coating and development of 
analytical tests for proof of a successful set-up. The second objective focused 
on the development of new analytical tools for demonstration of protein 
binding to solid surfaces and binding of PLGA-nanoparticles as a drug 
delivery system to the immobilized receptor on the implant surface. The third 
objective focused on providing a proof of concept of binding of nanoparticles 
serving as drug carriers to immobilized receptors onto the biocompatible-
coated implant surfaces and long term test showing degradation of 
nanoparticles and reloadability.  
 
2005  Research Associate (6 months): Department of Biochemistry University of 
Vienna and MFPL (Austria), in the lab of Prof. Pittner Fritz. As a research 
associated, I worked on the adaptation of gold colloid nanoparticles synthesis 
in different sizes and engineering of lateral-flow test for rapid diagnostic 
application. 
    
1996-1998 Master student: University of Vienna, Department of medical Biochemistry 
(Austria), The overall objective of my master thesis project focused on the 
development regulation of gene expression patterns of the intermediate 
filament proteins desmin, vimentin and cytokeratin 8 during cardiomyocyte 
differentiation in embryoid bodies. A system to optimize the in vitro 
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differentiation system of cardiomycten in early emboryonic differentiation 
events in vitro was adapted using embryoid bodies. Moreover the effect of 
leukaemia inhibitory factor on cardiomyogensis and life duration of 
cardiomyocytes in embryoid bodies was tested in this system. In addition the 
gene expression pattern of previously mentioned intermediate filament 
proteins was compared in emboryoid bodies generated from different 
embroyonic stem cells lines [AB2.2 (wild type), 1B44 (desmin ∆N48  amino 
acid) and knock out (des-/-] .       
 
T E A C H I N G    E X P E R I E N C E 
2006-2009 Instructor and advisor of Masters and Trainees Students, during my 
tenure as a PhD candidate at the MFPL, I supervised several Trainees 
Students (6) and master students (4). Responsibilities included training the 
students on standard laboratory techniques, organic synthesis, protein 
measurement methods and  purification methods, gel electrophoresis, 
Western blot, analytical chemistry (CLISA), ELISA, immobilization of polymers 
onto solid surfaces, design, plan and participate in the execution of their 
experiments.  
 
2009  Teaching assistant, in protein chemistry practical I at the Department of 
Biochemistry supervised experiments to second and third year bachelor 
students in chemistry, molecular biology, genetic and microbiology.  
Responsibilities and taught a class of 8-10 students on the theory and practice 
of protein determination, isolation from eukaryotic cells, purification and 
analysis, technique for homogenisation of plant cells to study photosynthetic 
pigments, enzyme kinetic and regulation, included, exam questions and 
grading of exams.  
 
2006- 2009  Tutor in protein chemistry practical I and II at the Department of 
Biochemistry, Taught and supervised bachelor and master level students in 
chemistry, molecular biology, genetic and microbiology practical courses.  
 
 
F I E L D S    O F    E X P E R T I S E      
Scientific areas and techniques in which I have extensive knowledge experience are listed 
under each category.  
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Immobilization 
 Silanization 
 Immobization of polymers and antibodies molecules or fragments onto solid 
surfaces 
 Determination of immobilized molecules or polymers onto solid surfaces 
 Modification of functional groups on solid surfaces  
Immunization 
 Preparation of sample injection  
 Production of antibodies against biocompatible and biodegradable polymer 
 Titerdetermination 
 Antibodies purification from immune sera 
Drug delivery system 
 PLGA nano- or micro-particle preparation including enzyme, fluorescent dye  
or drug  
 Chitosan nanopatricle preparation including fluorescent dye   
 Degradation of PLGA-nanoparticles 
Protein biochemistry 
 Splitting of antibodies into fragments  
 Protein purification techniques, including all chromatographic techniques 
 SDS-PAGE and western blot 
 Enzyme kinetics 
Analytic chemistry 
 Dot blot 
 Immunoprecipitation 
 ELISA  
 CLISA  
Organic Chemistry 
  Organic synthesis 
  Purification methods (thin layer chromatography, distillation, extraction…) 
 Spectroscopic a analysis of small molecules using IR, HPLC 
Cell biology 
 Cell culture 
 Embryonic stem cell culture adherent and in suspension: AB2.1, AB2.2, D3 
and fibroblast cells (STO, SNL76/7)  
 Embryoid bodies formation and in vitro differentiation  
 Immuncytochemistry and Immunohistochemistry  
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Molecular biology  
 Recombinant DNA techniques (Cloning, PCR) 
 Gel electrophoresis, Western blotting, Northern blotting  
 Isolation and analysis of RNA   
Computer skills 
 Microsoft (Word, Excel, Powerpoint, Corel Draw)  
 
S C I E N T I F I C   TALKS  AND  P O S T E R    P R E S E N T A T I O N S 
 
TALKS in English 
Feb. 1998  Department of medical Biochemistry, University of Vienna (Austria), take 
about differentiation of embryonic stem cells in vitro and expression of 
intermediate filament proteins in transgenic cells.  
 
May 2008 Department for Biomolecular Structural Chemistry, University of Vienna 
(Austria) and MFPL, take at the Symposium of the Computational and 
Structural Biology Programme about Biocompatible coatings of medical 
implants allowing reloadable drug targeting and drug release.  
 
POSTER PRESENTATIONS 
2009  Live Imaging of Nano Gold Particles. Lichtscheidl I., Al-Dubai H., Maier I., 
Reipert S., Pittner F., Super and High Resolution Imaging Conference, Lipica 
– Slovenia  
2008 Gold Cluster Labeling as an Alternative to ELISA. Al-Dubai H., Pittner G., 
Pittner F.  2nd International AllergoOncology Symposium, Vienna – Austria, 
(oral presentation in English) 
2008 A novel dot-blotting method for immunoassays. Al-Dubai H., Hinterwirth H., 
Pittner F., Joint Annual Meeting of Immunology of the Austrian and German 
Societies (ÖGAI, DGFI), Vienna – Austria, (oral presentation in English) 
2005   Resonance Enhanced Fluorescence Biochips – Homogeneity and Corrosion 
Stability of Interlayer Systems in REA Biosensor Devices. Hagelmüller J., Al-
Dubai H., Koelber M., Dragosits M., Gauglhofer C., Mayer C., Bauer G., 
Genov S., Pittner F., Schalkhammer T. Surface Plasmon Photonics 2 (SPP“), 
Graz- Austria 
2005  Resonance Enhanced Cluster Absorption (REA) in Sensoric Applications. 
Hagelmüller J., Dragosits M., Gauglhofer C., Koelber M.,  Al-Dubai H., Maier 
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I., Pittner F., Schalkhammer T. Nanotechnology in Biodiagnostics and 
Analytics (NBDA) Conference, Grenoble - France 
1997  Development regulation of intermediate filament protein expression in 
embryonic   stem cell derived cardiomyocytes. Al-Dubai H., Weizer G. Annual 
meeting of the ÖBG (Österreichische Biochemische Gesellschaft) & ÖGGGT 
(Österreichische Gesellschaft für Genetic und Gentechnik), Vienna – Austria  
 
 
P U B L I C A T I O N S (* CORRESPONDING AUTHOR)  
1. Hinterwirth H. H., Strobl M., Al-Dubai H.*, Analytical methods for detection of small 
amounts of amino groups on solid surfaces – a survey. Chemical Monthly (2009), In 
press, Manuscript Number: MOCHEM-D-09-00441R2. 
 
2. Al-Dubai H.*, Oberhofer G., Kerleta V., Hinterwirth H. H., Strobl M., Gabor F. 
;Cleavage of Antibodies using Dihydrolipoamide and Anchoring of Antibody 
Fragments onto Biocompatible Coated Carriers;  Chemical Monthly (2010),  In press, 
DOI: 10.1007/s00706-010-0284-6. 
 
3. Al-Dubai H.*, Pittner G., Pittner F. A dot-blot test using gold colloid cluster technology 
as a miniaturizable alternative to ELISA and hapten inhibition tests; Chemical Monthly 
(2008) 139: 1531-1536.  
 
4. Al-Dubai H. *, Strobl M., Lichtscheidl I., Pittner G., Pittner F. Immunosorbent assay 
using gold colloid cluster technology for determination of IgEs in patient sera. Journal 
of Biotechnology (2010), to be submitted soon 
 
5. Al-Dubai H. *, Hermann M., Pittner G., Pittner F., Gabor F. Production of Polyclonal 
Antibodies against the Biocompatible Polymer PLGA using Silica Amino 
Microspheres as a Carrier, Biotechnology Letters (2010), to be submitted soon. 
 
6. Al-Dubai H.*, Pittner G., Pittner F., Gabor F. Carrier with Binding Sites for 
Biodegradable Drug Containing Nanoparticles Allowing Reloadability; Open 
Biomedical Engineering Journal (2010) to be submitted soon. 
7. Hölligl A., Puz S., Al-Dubai H, Kim JU, Capetanaki Y, Weitzer G. Amino-
terminally truncated desmin rescues fusion of des(-/-) myoblasts but negatively 
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affects cardiomyogenesis and smooth muscle development; 
Differentiation(2002) 523 (1-3): 229-33. 
 
8. Bader A., Gruss A., Höllrigl A.,  Al-Dubai H., Capetanaki Y., Weitzer G. 
Paracrine promotion of cardiomyogensis in embryoid bodies by LIF modulated 
endoderm; Differentiation (2001) 68:31-43. 
 
9. Bader A, Al-Dubai H., Weitzer G. Leukemia Inhibitory Factor Modulates 
Cardiogenesis in Embryoid Bodies in Opposite Fashions; Circulation 
Research (2000) 86:787-794 
 
PATENT  
Prof. Pittner F., Al-Dubai Haifa, Hinterwirth H., Strobl M., Gold-cluster labelling as a 
simple test system for detection of specific proteins in microtiterplates, U 7117/DB, 
submitted to “Forschungsservice und internationale Beziehungen”, Dipl. Ing. Claudia 
Doubek. 
 
PROFESSIONAL EXPERIENCE 
2006  Delivery of health lectures for Arabic women living in Vienna in cooperation 
with M-17 and FEM-Süd (Health Center) to encourage integration of Arabic  
women into Austrian society 
1999- 2000  Sales representative, Karl Ohrfandl Company/Sigma-Laborzentrifugen 
 
 
R E F E R E NCES 
Univ. Prof. Dr. Fritz Pittner: Department of Biochemistry University of Vienna and MFPL 
Dr. Bohr Gasse 9 A-1030 Vienna, Austria, fritz.pittner@univie.ac.at 
 
Univ. Prof. Dr. Franz Gabor: Department of Pharmaceutical Technology and 
Biopharmaceutics, Faculty of Life Sciences, University of Vienna, Althanstr. 14, A-1090 
Vienna, Austria, franz.gabor@univie.ac.at 
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Univ. Prof. Dr. Marcela Hermann: Max F. Perutz Laboratories, Department of Molecular 
Genetics, Medical University of Vienna, Dr. Bohrgasse 9, A-1030 Vienna, Austria, 
marcela.hermann@univie.ac.at 
 
Univ. Prof. Dr. Irene Lichtscheidl: Institute of Cell Imaging and Ultrastructure Research, 
Althanstrasse 14 A-1091 Vienna, Austria, irene.lichtscheidl@univie.ac.at 
 
 
